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ABSTRACT
Infertility is a worldwide epidemic often treated with in vitro fertilization. The
success of in vitro fertilization is directly dependent upon the quality of oocytes
produced during the controlled stimulation of the patient’s ovaries. There is a need
for improved methods to allow embryologists to select the most viable embryos
with the highest probability of leading to live births since in vitro fertilization success
is far from optimal.
Oocyte and subsequent embryo quality are intimately influenced by the
granulosa cells which surround the oocyte during follicular maturation.

The

oocytes require proper signaling and energy production form the surrounding
granulosa cells for ideal maturation which will allow the oocyte to fertilize and
produce a viable embryo. We hypothesize that mRNA levels of certain genes in
granulosa cells will allow for the identification oocytes that will produce euploid
embryos and the most viable embryos within a cohort. Secondly, we hypothesize
that the rate by which mitochondria from granulosa cells are able to utilize certain
metabolic substrates will be able to identify patients that have increased probability
of producing high quality embryos leading to live births.
This dissertation attempts to identify a group of genes within individual
cumulus cells that show differential mRNA gene expression between oocytes of
euploid embryos and oocytes leading to live birth compared to oocytes that do not.
From these genes we further attempt to create a model using multiple genes to
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identify the most viable oocytes within a cohort. This dissertation also attempts to
identify metabolic substrates differentially utilized by granulosa cell mitochondria
based on patient demographics or embryo development and determine if individual
substrates can be used as mitochondrial biomarkers for assisted reproduction. As
a whole, the work in this dissertation seeks to provide a panel of biomarkers that
can be used by clinicians to better identify embryos that will help improve overall
assisted reproductive success.
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1.1

Significance of Study
In vitro fertilization (IVF) is a common intervention for treating women

struggling with infertility. IVF involves hormonally priming a woman’s ovaries to
mature multiple follicles, retrieving oocytes from the follicles, inseminating the
mature oocytes with the partner’s or donor sperm, and after several days selecting
cultured embryos for transfer to the patient’s uterus. Most IVF cycles fail to lead
to a live birth. Each round of IVF has a tremendous cost to the patient ranging
from $10,000 to $20,000 per fresh oocyte retrieval and around $4,000 for
subsequent frozen embryo transfers (FETs). The low take-home baby rate means
that many patients will incur each of these costs multiple times.
To improve live birth outcomes, the use of preimplantation genetic testing
for aneuploidy (PGT-A) has been employed to identify genetically euploid embryos
before uterine transfer. In some cases, PGT-A has been shown to increase
implantation, ongoing pregnancy, and delivery rates (Chen et al., 2015a,
Schoolcraft et al., 2010, Scott et al., 2013, Yang et al., 2012). However, PGT-A is
also an invasive method that requires the removal of several cells from the
embryo’s trophectoderm layer of the blastocyst. Using euploid embryos for uterine
transfer does not guarantee implantation, however, and some studies have
indicated there is a decreased pregnancy rate following PGT-A (Kushnir et al.,
2016, Chang et al., 2016). One study has shown that only certain age groups
benefit from PGT-A testing (Kang et al., 2016). Additionally, implantation failure
has been positively correlated with the number of cells removed during the biopsy
procedure (Zhang et al., 2016). There is also concern that mosaicism (two distinct
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cells lines within the same embryo) will give rise to erroneous PGT-A results and
that some embryos which would lead to genetically normal live births will not be
transferred because of these misleading results (Kushnir et al., 2018, Gleicher et
al., 2016, Taylor et al., 2014). Therefore, finding a non-invasive and reliable
method to select the most viable oocytes and subsequent embryos for uterine
transfer would be highly desirable in the field of IVF.
The ultimate success of an IVF cycle is determined by ovarian stimulation
protocols and patient characteristics that control the quality of the oocytes retrieved
(Adriaenssens et al., 2010a). These various factors will influence the development
of the somatic cells of the ovarian follicle, specifically, the granulosa cell (GC)
population. In turn, the GCs will impact the developing oocytes they enclose
(Eppig et al., 1996, Gilchrist et al., 2008, Matzuk et al., 2002). In an ideal IVF
stimulation, the interactions of the GCs and oocytes will result in optimal conditions
for oocyte maturation (Tanghe et al., 2002, Uyar et al., 2013). Since the GCs are
readily obtained as a by-product of the IVF process, they are an ideal source of
materials for non-invasive analysis of oocyte potential. Techniques which assess
mRNA biomarker levels and mitochondrial substrate utilization in GCs allow rapid
profiling that could potentially identify the most viable oocytes and subsequent
embryos and still be incorporated into the standard workflow of an IVF laboratory
without much difficulty. mRNA expression analysis and mitochondrial metabolic
assessment of GCs can be performed before embryo transfer (ET) allowing for the
selection of the embryo with the highest implantation potential. Several recent
studies suggest that GC mRNA biomarkers can be used to generate models that
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can identify oocytes/embryos with the highest probabilities of leading to
pregnancies and live births (Borup et al., 2016, Ekart et al., 2013, Iager et al., 2013,
Wathlet et al., 2011, Wathlet et al., 2012, Wathlet et al., 2013). Mitochondrial
function and mitochondria content have also been shown to be related to oocyte
maturation and IVF pregnancies as well (Dalton et al., 2014, Huang and Wells,
2010, Tsai et al., 2010).
The developing ovarian follicle is comprised of an oocyte, follicular fluid, and
distinct somatic cell populations.

The preovulatory follicle, whose cells are

harvested during the IVF procedure, contains two distinct GC types: the cumulus
granulosa cell (CC) and the mural granulosa cell (MGC). The CCs surround and
share gap junctions with their individual oocytes. Cumulus cells remain attached
to their oocytes following oocyte retrieval and must be mechanically and
enzymatically removed before intracytoplasmic sperm injection (ICSI) of
spermatozoa for insemination in male factor and PGT-A cases. Cumulus cells will
remain attached to the oocyte during conventional insemination procedures.
Cumulus cells have bi-directional communication with the oocytes and tend to
reflect the oocyte’s overall health (Huang and Wells, 2010). Biomarkers of GCs
associated with individual oocytes could potentially be used in assisted
reproduction procedures to indicate which embryos have the best chance of
implanting in the uterus and completing gestation.
Successful embryo development relies upon sufficient energy metabolism
generated by adenosine triphosphate (ATP) processed through the mitochondria.
Cumulus cells produce ATP and augment oocyte ATP supply during follicular
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growth. The CCs also provide pyruvate for the oocyte, generated from glycolysis,
via gap junctions. Pyruvate is converted by pyruvate dehydrogenase to acetyl-CoA
which enters the tricarboxylic acid cycle where it is metabolized and ultimately
produces ATP through the process of oxidative phosphorylation (OXPHOS) within
the mitochondria of the oocyte (Su et al., 2009, Sutton-McDowall et al., 2010).
Several studies have evaluated CCs, MGCs, and trophectoderm cells from
blastocysts, and it appears there is a high correlation between the mitochondrial
DNA (mtDNA) content found in oocytes and CCs indicating that CC mtDNA levels
might serve as a biomarker for oocyte competence (Boucret et al., 2015,
Desquiret-Dumas et al., 2017, Diez-Juan et al., 2015, Fragouli and Wells, 2015,
Ogino et al., 2016, Taugourdeau et al., 2019).
We hypothesize that specific biomarkers in GCs can be used to select
individual oocytes and their subsequent embryos that have the best chances of
leading to viable pregnancies and resulting in live births. We propose a series of
studies to determine if (1) a set of CC mRNA biomarkers and (2) GC mitochondrial
metabolic substrate utilization can be used to improve IVF outcomes. Successful
completion of the first study will result in a mRNA biomarker model that can be
used to select the embryos for uterine transfer that have the best chance of
resulting in a live birth. Accomplishment of our second goal will result in
determination if mitochondrial metabolic substrate utilization in pooled MGCs and
CCs can be used as biomarkers relating to patient demographics and embryo
development.

A future goal would be to utilize a small subset of mitochondrial
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substrates as biomarkers to analyze individual CC masses to choose individual
embryos for uterine transfer.
1.2

Ovarian Structure
The female gonad is called the ovary, and it is analogous to the testis in the

male. The ovary’s primary function is oocyte production or oogenesis. It will store
oocytes arrested at the primordial stage of development until they are recruited to
initiate maturation. After puberty and through menopause, the ovary will mature a
cohort of oocytes each reproductive cycle and ovulate one or more oocytes each
cycle. The ovary also acts as an endocrine gland producing hormonal secretions
such as steroids prior to ovulation and from the luteinized cells of the follicle which
remain in the ovary and form the corpus luteum (CL) following ovulation.
A single ovary is located on each side of the uterus and attached with an
ovarian ligament (Figure 1.1). Each ovary lies near the fimbriae of each oviduct or
Fallopian tube. The Fallopian tube acts as a conduit to transport spermatozoa
from the male, oocytes from the female, and the resulting embryo following
fertilization. The Fallopian tubes will also provide a nutrient-rich environment for
the gametes and embryos. A spermatozoon will fertilize the oocyte in the ampulla
of the Fallopian tube and the resulting fertilized oocyte, also known as the zygote,
will be transported to the uterus for implantation. The uterus has an external wall
called the perimetrium, a muscular middle layer called the myometrium, and an
inner layer called the endometrium. Both the myometrium and endometrium are
responsive to hormones of the reproductive cycle. The endometrium has two
layers the stratum functionalis and the stratum basalis. The stratum functionalis
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lines the inside of the uterus and is where the embryo will attach and grow into a
fetus or it will be shed during menstruation if the embryo does not implant.
The ovary (Figure 1.2) is a complex structure containing multiple cell types
with diverse and dynamic functions. The innermost layer is the ovarian medulla
and the outermost layer is the ovarian cortex. The outer cortex, known as the tunica
albuginea, is composed of only dense connective tissues which protect the ovary.
The ovary contains female gametes, termed oogonia or oocytes, and somatic cells
within the ovarian follicles and specialized dense connective tissue, termed
stroma, and blood vessels. Ovarian nerves, as well as blood and lymphatic
vessels, reside within the medulla. The main difference between the medulla and
cortex is that ovarian follicles are only present in the cortex.
The main functional components of the ovary are the ovarian follicles. The
follicles consist of oocytes, GCs, and theca cells (TCs). The GCs and TCs provide
the oocyte they surround with a protected environment in which they grow and
mature, allowing for fertilization by a spermatozoon following ovulation (Buccione
et al., 1990). There is bi-directional communication between the GCs and oocytes,
which promotes oocyte maturation (Tanghe et al., 2002, Uyar et al., 2013). This
close association between the oocytes and their GCs make the GCs good
candidates for research related to oocyte developmental competence.
1.3

Oogenesis
Oogonia are derived from primordial germ cells (PGCs). In humans, PGCs

appear early during the second week of embryonic development from the primary
ectoderm (Larsen, 2001, Wylie, 1999). PGCs can travel to various locations
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throughout the embryo and yolk sac but will finally colonize the gonadal ridges
(Richardson and Lehmann, 2010). Human PGCs migrate from the primary
ectoderm to the extra-embryonic yolk sac after their formation. Around week 5 of
embryonic development, human PGCs travel back to the embryo where they
colonize the epithelial-derived sex cords within the gonadal ridges, which ultimately
form the primordial gonads. Concomitant with cortical sex cords proliferation, the
epithelial cells which surround the PGCs will eventually transform into somatic GCs
within the ovarian follicles and ovarian TCs will derive from the mesenchyme of the
genital ridge.
In humans, PGCs will undergo mitosis until around the seventh month of
fetal development. At that point, they will begin meiosis and give rise to the
oogonia within the ovary. PGCs are unique as they are the only cells that can
initiate and undergo meiosis. The oogonia experience incomplete cytokinesis and
remain linked through cellular bridges and will cluster together into nests
surrounded by a single layer of pre-granulosa cells (Pepling and Spradling, 1998).
It has been suggested that most of the oocytes within an individual nest will not
ultimately undergo folliculogenesis but undergo atresia, so only the most
competent oocytes from each nest will survive (Hernandez-Ochoa et al., 2009).
At birth, female humans will have approximately 1 million oogonia. All the
oogonia will undergo arrest at the diplotene stage of meiotic prophase I (MPI), as
primary oocytes, where they will persist until the onset of sexual maturity
(Whitaker, 1996). The primary oocytes will remain in a quiescent state until a small
cohort of primary oocytes is recruited with each reproductive cycle, due to
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hormonal signals from the pituitary gland, and transform into secondary oocytes
(McGee and Hsueh, 2000). Secondary oocytes will mature and gain meiotic
competence to form a viable metaphase II (MII) oocyte throughout the follicular
stage of the reproductive cycle. In response to the luteinizing hormone (LH) surge,
the oocyte will be expelled from the follicle and ovulated into the oviduct in
preparation for fertilization by a spermatozoon.

The ovary will reabsorb the

remaining oocytes of the cohort that do not gain competence and complete
ovulation. Follicular oocyte quantity dwindles with increasing age and it is widely
accepted that the supply is finite and females will stop ovulating when the stock of
oocytes is depleted (Gosden et al., 1983, te Velde et al., 1998). However, there is
growing evidence that germline stem cells could potentially replenish part of the
ovarian oocyte pool and form new primordial follicles; this is still a topic of debate.
Surface epithelial cells from tunica albuginea in human ovaries have been shown
to differentiate into GCs and oocytes, which combine form new follicles (Bukovsky
et al., 2004, Bukovsky, 2005).
During oogenesis mitochondria, other organelles, RNA, proteins, and
energetic repositories will accumulate in the oocytes in preparation for the early
stages of pre-embryonic development. Mitochondria will proliferate within the
oocyte and a bottleneck appears to exist where the healthiest mitochondria with
minimal mutations are preferentially selected to be passed to the next generation
(Figure 1.3) (May-Panloup et al., 2016, Marlow, 2017). Estimates suggest premigratory PGCs have 10 mitochondria, increasing to 100 when the PGCs migrate
to the gonadal ridges, and nearly 10,000 in the primordial follicle in the human
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(Jansen and de Boer, 1998) with other estimates suggesting up to 250,000
mitochondria or more in the oocyte (Barritt et al., 2002, May-Panloup et al., 2005b,
Reynier et al., 2001, Santos et al., 2006). It has been proposed that the bottleneck
serves to maintain a uniform genome of mtDNA, termed homoplasmy, and reduce
multiple mtDNA genomes, termed heteroplasmy (Cummins, 2001). Mitochondria
are also found within the early flattened GCs which surround the oocyte at this
early stage of development. Regions of concentrated mitochondria and other
organelles, termed Balbiani bodies, are found in the cytoplasm near the nuclei of
primary oocytes humans (Motta et al., 2000). Multiple metabolic pathways are
present during oocyte maturation. Primordial follicles utilize both glucose and
pyruvate as substrates meaning they use both glycolysis and OXPHOS to
generate ATP (Shoubridge and Wai, 2007). Additionally, pyruvate is supplied to
the oocyte from the breakdown of glucose by the CCs through gap junctions
(Jansen and Burton, 2004).
Following a period of dormancy, which can last for several years in humans,
the primary oocyte begins to grow and prepare for fertilization. The nucleus of the
oocyte is termed the germinal vesicle (GV). The GCs and TCs surrounding the
oocyte will transform through varying stages, beginning with a single layer of
flattened squamous pre-GCs into a multilaminar antral follicle containing both GCs
and TCs (Lintern-Moore and Moore, 1979). Germinal vesicle breakdown (GVBD)
is a necessary first step in the resumption of meiosis by the oocytes and the
process is initiated in several animal species by maturation [M-phase] promoting
factor (MPF) following the LH surge (Eppig et al., 1983, Jones, 2004). It has been
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postulated that within the antral follicle that the CCs, MGCs, and TCs all generate
adenosine 3’,5’-cyclic monophosphate (cAMP) which is shuttled into the oocyte. It
has been shown that gap junctions are the gateways by which cAMP is transferred
from the somatic cells to the oocyte leading to the redeployment of the catalytic
subunit of adenylyl cyclase/cAMP/protein kinase A (PKA) (Webb et al., 2002). The
cAMP keeps MPF in its inactive form, maintaining the oocyte in the diplotene
phase of meiosis I (Dekel et al., 1981).
The causal mechanism behind the resumption of meiosis is a marked
decrease of cyclic guanosine monophosphate (cGMP) in GCs following the LH
surge.

There is also a concomitant decrease of cGMP levels in the oocyte

increasing phosphodiesterase 3A enzyme activity which promotes conversion of
cAMP to adenosine 5’-monophosphate (AMP) resulting in lower cAMP levels and
triggers MPF to resume meiotic development (Celik et al., 2015, Jaffe and Egbert,
2017, Mehlmann, 2005). It has been demonstrated that when oocytes from
vertebrates and mammals are removed from antral follicles and cultured in control
media and somatic cell conditioned media, the oocytes in the somatic cell media
exhibit reduced GVBD which suggest CCs and MGCs play a role in maintaining
oocytes in the arrested meiotic state (Liang et al., 2007). When an oocyte is
removed from the follicle, spontaneous maturation will occur because the
communication between the somatic cells and the oocyte ceases (Conti et al.,
2012, Zhang et al., 2010).
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1.4

Folliculogenesis
The pre-antral phase of folliculogenesis is gonadotropin independent, while

the antral phased is governed by the gonadotropins of the reproductive cycle
(Figure 1.4). At any point in time, the ovary contains follicles at many stages of
development. The reproductive cycle begins with the follicular phase when a small
cohort of primary oocytes within small (~2 mm) antral follicles resume growing in
response to follicle stimulating hormone (FSH), the critical regulator of
folliculogenesis, from the anterior pituitary. Follicles will grow for several months
in the primordial, pre-antral, and early antral stages of folliculogenesis prior
reaching the small antral stage. In addition to the oocytes, the somatic cells
surrounding each primary oocyte also grow and transform in response to the
hormones of the reproductive cycle. Throughout the follicular phase, the somatic
cells differentiate into distinct cell types. The cells near the oocyte will become the
GCs (CCs and MGCs) while those most distal from the oocytes will become
internal and external TCs. Both sets of cells will support the oocyte as it matures
and provide nourishment for the oocyte (McGee and Hsueh, 2000, Suh et al.,
2002). The oogonia impact the development of both the GCs and the TCs. The
somatic cells, in turn, also influence the nuclear and cytoplasmic maturation of
oogonia (Eppig, 2001).

This interaction implies that the developmental

competence of the oocyte relies on the complete ultrastructure of the follicle,
indicating that CCs and MGCs are ideal for assessing oocyte and embryo quality.
The various types of follicles exhibited throughout the reproductive cycle
include oocyte nests, primordial follicles, primary unilaminar pre-antral follicles,
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primary multi-laminar pre-antral follicles, antral follicles, and pre-ovulatory or
Graafian follicles (Figure 1.4). The distinguishing property of primordial follicles is
a solitary layer of flattened pre-GCs that surround dormant primary oocytes
(Fortune, 2003). When primary oocytes enter the growth phase, the follicles
become primary unilaminar pre-antral follicles as a single layer of pre-granulosa
cells transforms into cuboidal granulosa cells (Hirshfield, 1989). Granulosa cells
are unlike other somatic cell types, both phenotypically and transcriptionally.
As the follicle continues to develop, cuboidal granulosa cells proliferate into
a primary multi-laminar pre-antral follicle and give rise to primary and secondary
follicles. During this time, each follicle will continue to add GC layers. The somatic
cells at the developing follicle’s periphery, originating from mesodermal embryonic
tissue and exterior to the basement membrane termed the basal lamina, will
transform into TCs (Fortune, 2003). Theca cells produce androgens that diffuse
across the basement membrane to GCs where they are converted into estrogen
(E2).
The pre-antral follicle will contain the oocyte surrounded by multiple distinct
somatic cells layers. The TCs differentiate into both internal and external stratums
at the periphery of the follicle. Within the basement membrane, there are also two
strata of GCs surrounding the oocytes, the MGCs and CCs. The CCs reside
closest to their individual oocyte and they share gap junctions. When the oocyte
is ovulated in a natural reproductive cycle or aspirated during assisted reproductive
technologies (ART) the CC layer, also termed the corona radiata, will remain
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associated with the oocyte. Collectively, the oocyte and the CCs that surround it
are referred to as the cumulus-oocyte complex (COC).
As the follicle continues to increase in size, fluid will collect in the space
between the GCs creating a fluid-filled cavity, or antrum. Oocytes isolated from
smaller antral follicles have been shown to have decreased meiotic competence
and are less likely to undergo final maturation (Hunter et al., 2000). The capacity
for an oocyte to recommence meiosis I is referred to as meiotic competence and
will occur following the LH surge. The antrum will increase in size until it becomes
a pre-ovulatory or Graafian follicle, just before ovulation. The size of Graafian
follicles in human ovaries between 22 to 25 mm. The LH surge will cause the follicle
to rupture releasing the COC and triggering the final maturation of the oocyte from
the GV stage to the MII stage in preparation for fertilization (Stocco et al., 2007).
The MGCs and TCs remaining in the post-ovulatory follicle will become the CL due
to luteinization. In most higher mammals, the TCs transform into small luteal cells
and the GCs will become large luteal cells (Murphy, 2000). The follicular blood
supply of the pre-antral follicles originates from the ovarian stromal cells. During
the antral stage of development, the TCs also develop their own separate blood
supply (Stouffer et al., 2001). When the oocyte ruptures from the follicle, the blood
vessels that surround the follicle will bleed forming a post-ovulatory structure
known as the corpus hemorrhagicum (CH). The CH will quickly transform into the
CL (Niswender et al., 2000). The CL is a temporary endocrine gland that, in
humans, produces both progesterone (P4) and E2. The hormones are produced
for the first few months of the pregnancy, if established, and are needed until the

14

placenta takes over production of the hormones. If pregnancy fails to transpire,
the CL will degenerate into a corpus albicans (CA) which over time will be
reabsorbed into the stroma of the ovary.
Two distinct granulosa cell populations exist in the mature follicle, the MGCs
and the CCs. Cumulus cells surround the oocyte during follicular maturation and
ovulation and remain attached to the oocyte following oocyte retrieval during ART.
Mural granulosa cells and CCs share many similarities but also have individual
transcriptional patterns consistent with their specialized relationship with the
oocyte (Huang and Wells, 2010) and differential responsiveness to pituitary
gonadotropins (Khamsi and Roberge, 2001). Both MGCs and CCs are under the
influence of oocyte secreted factors, most notably growth-differentiation factor 9
(GDF9), bone morphogenetic protein 15 (BMP15) and possibly bone
morphogenetic protein 6 (BMP6). These factors influence CCs and MGCs by
controlling apoptotic activities as well as metabolism and steroidogenesis (Su et
al., 2008). These factors regulate MGC and CC functions by activating the SMAD
and/or mitogen-activated protein kinases (MAPK) intracellular cascade pathways
through Transforming Growth Factor beta (TGF-β) superfamily receptors (Gilchrist
et al., 2008, Liang et al., 2007). Oocyte-secreted factors influence the stem cell
factor (SCF), which binds to the c-KIT receptor (CD117), causing GC proliferation,
inhibiting CC apoptosis and luteinization, and modulating CC metabolism.
Pyruvate metabolism doubles along with a rise in oxygen (O2) utilization in mouse
pre-ovulatory oocytes compared to primary oocytes (Harris et al., 2009). AntiMüllerian hormone (AMH), another member of the TGF-β superfamily, is produced
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by growing follicles and may inhibit primordial follicle activation but the mechanism
by which it acts has not been elucidated.
Three studies utilizing microarray have demonstrated that MGCs and CCs
isolated from the follicles of women undergoing ART exhibit vastly diverse RNA
expression patterns with thousands of genes being differentially expressed. Many
of these differences were confirmed by quantitative real-time polymerase chain
reaction (qRT-PCR). Koks and coworkers (Koks et al., 2010) found that the
mRNAs for fibrinogen gamma chain (FGG), neurotensin (NTS), FosB protooncogene, AP-1 transcription factor subunit

(FOSB), and dual specificity

phosphatase 6 (DUSP6) showed a greater than 2-fold decrease in pooled CCs
compared to pooled MGCs, while tenascin C (TNC), epidermal growth factor like
repeats and discoidin domains 3 (EDIL3), UL16 binding protein 1 (ULBP1), and
ryanodine receptor 2 (RYR2) transcripts showed more than a 2-fold increase in
CCs compared to MGCs.

This study did not consider differences in oocyte

maturational status when pooling cells and may have confounded the data as an
oocyte’s maturity does affect gene expression. A study by Grondahl and colleages
(Grondahl et al., 2012) analyzed paired CCs and MGCs taken from a single large
pre-ovulatory follicle containing a mature oocyte from each patient thereby
controlling for oocyte maturational differences and oocyte yield. When comparing
CCs to MGCs, the mRNAs for growth hormone receptor (GHR), NTS, pepsinogen
3, group I (pepsinogen A) (PGA3), pepsinogen 4, group I (pepsinogen A) (PGA4),
pepsinogen 5, group I (pepsinogen A) (PGA5), progesterone receptor membrane
component 1(PGRMC1), and cytochrome P450 family 11 subfamily A member 1
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(CYP11A1) were significantly increased, while mRNAs for calcium channel,
voltage-dependent, L type, alpha-1C subunit (CACNA1C), interleukin 7 receptor
(IL7R), growth-associated protein 43 (GAP43), AMH, TNC, and RYR2 were
significantly decreased. A third study examined MGCs and CCs samples from
mature oocytes (Burnik et al., 2015b). These authors also conducted a metaanalysis with the data generated from the previous two studies (Burnik et al.,
2015a, Grondahl et al., 2012) and collectively found 3156 genes differentially
expressed. The later study identified two unique genes that were not previously
reported in human follicular cells:

prokineticin 2 (PROK2) and pregnancy

upregulated nonubiquitous CaM kinase (PNCK). Further, validation of microarray
results by qRT-PCR showed mRNA levels increased for angiotensin I converting
enzyme 2 (ACE2), HtrA serine peptidase 1 (HTRA1), PNCK, and RYR2, while they
decreased for DUSP6, FGG, interleukin 1 beta (IL1B), and PROK2 when
comparing CCs to MGCs. These three studies showed clear differences between
the two distinct granulosa cell types however, the differential mRNA gene
expression (DRGE) among the studies could be due to pooling or not pooling cells
of different oocyte maturational status, different samples sizes in the number of
oocytes per patient used and number of individual patients, stimulation types
between studies, freezing and handling of cells, and varying infertility diagnoses.
Regardless, these studies demonstrate that the different expression profiles of the
MGC and CC populations should be taken into consideration when examining
possible pregnancy and live birth biomarkers.
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1.5

The Menstrual Cycle
The reproductive cycle is a repetitive cyclical process. During the cycle,

several events will occur, including follicular growth, oocyte development,
ovulation, alterations of the endometrial lining of the uterus, and maintenance of
pregnancy or menstruation. This process is governed by modulations of the
hormones of hypothalamic/pituitary/gonadal (HPG) axis (Figure 1.5) which include
pituitary gonadotropins, follicle stimulating hormone and luteinizing hormone, and
ovarian steroids, estradiol and progesterone. The hormones of the HPG axis act
upon a variety of tissues in a concerted manner through an elaborate feedback
system. The actions of FSH are initiated by binding to specific membrane receptors
which cause the GC population to proliferate, E2 production to increase, and also
promote LH/chorionic gonadotropin receptor (LHR or LHCGR) expression. The
actions of LH on the TCs serve to stimulate steroidogenesis by increasing the
production of androgens which are used by GCs to produce E2. LH is also
responsible for ovulation of the mature oocyte and after the CL forms, LH
stimulates luteal P4 production.
Both FSH and LH are heterodimeric glycoproteins. They both, along with
chorionic gonadotropin (CG) and thyroid stimulating hormone share a common subunit while retaining their own unique -subunits (Richards et al., 2002). Each
receptor is a G-protein-coupled transmembrane receptor. When the ligands bind
to their respective receptors, they generate a second messenger in the form of
cAMP via the PKA pathway. The levels of cAMP are vital during folliculogenesis
and oocyte maturation.

FSH sustains higher cAMP levels and modulates gap
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junctions by enhancing permeability and altering the gap-junction alpha-1 gene
(GJA1) within the oocyte (Burghardt et al., 1995). It has also been demonstrated
that GC signaling also involves other signaling pathways, including RAS and
MAPKs (Fan et al., 2012).
In primates, the reproductive cycle is termed the menstrual cycle (Figure
1.6). The HPG axis is a finely tuned feedback loop. The menstrual cycle begins
with menstruation when the levels of E2 and P4 are low. Lack of circulating E2
prompts the hypothalamus to commence pulsatile secretion of gonadotropin
releasing hormone (GnRH).

Gonadotropin releasing hormone acts upon the

anterior pituitary to release the pituitary hormones, FSH and LH.

Follicle

stimulating hormone and LH are the principal drivers of female follicular and oocyte
development (Richards, 1994).

Follicle stimulating hormone and LH, in turn,

stimulate the ovaries. As E2 increases, a negative feedback signal is received by
the hypothalamus which will pause GnRH secretion until the E2 levels drop so the
cycle can start again (Emanuele et al., 2002). Additionally, GCs and TCs produce
inhibins, which have also been shown to inhibit FSH secretion by the pituitary
(Knight and Glister, 2006).
The menstrual cycle consists of a follicular phase and a luteal phase. The
number of primary follicles that mature each cycle is related to a female’s age and
to the number of oocytes within the ovary. Cohort growth is initiated by stimulation
from the hormones produced by the pituitary gland and paracrine factors
generated by the ovary (Hsueh et al., 2000). During the follicular phase, secondary
follicles grow and differentiate while the oocyte matures. FSH levels are highest
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on days 2-5 during the middle of the cycle. During the follicular phase, GCs have
FSH receptors (FSHRs) and the TCs have LHCGRs and produce androstenedione
(Hillier, 2001). FSHR mRNA levels are most abundant in human GCs in small
antral (~6 mm) follicles in the early follicular phase and then decrease, whereas,
LHCGR mRNA levels in human GCs increase starting during the mid-follicular
phase and peak in preovulatory follicles (~15 mm) (Richards, 1994, Jeppesen et
al., 2012). Granulosa cell E2 expression increases in response to androstenedione
produced by the TCs, which is generated from cholesterol through the
steroidogenic pathway as described below. Androstenedione disseminates from
the TCs via the basal lamina to the GCs. Follicle stimulating hormone then acts,
by way of a cAMP signaling pathway, to induce aromatase (CYP19A1) to convert
androstenedione to E2 augmenting overall E2 production (Magoffin, 2005).
As the follicular phase progresses and GC FSHRs decrease and LHCGRs
increase, GCs are now able to respond to LH. The LH surge causes the follicle to
rupture, the oocyte to resume meiosis, and the CCs to radiate outward from the
oocyte. It also causes luteinization of GCs and TCs which form the CL. The
follicular phase culminates, and the luteal phase commences with the ovulation of
the oocyte from the pre-ovulatory, or Graafian follicle, in response to the LH surge
(Jeppesen et al., 2012). Near mid-cycle, the negative feedback generated by E2
switches to positive feedback causing the LH surge with E2 levels exceeded 150200 pg/mL for 36 hrs in humans. Increased E2 levels suppress pituitary FSH
secretion but promote LH secretion. However, there is also a small surge of FSH
at this time, which may signal a new set of follicles to begin recruitment for the next
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cycle. Luteinizing hormone is also necessary for completion of steroidogenesis as
the surge stimulates the formation of the cells of the CL. Amphiregulin (AREG),
an epidermal growth factor-like growth factor found in CCs and MGCs, is induced
by the LH surge and causes expansion of the CCs and mediates oocyte
maturation. Reduced AREG mRNA levels in CCs of oocytes have been shown to
be associated with high-quality blastocysts derived from IVF (Feuerstein et al.,
2007). Additionally, higher AREG mRNA levels in pooled human IVF derived CCs
and MGCs have been shown to be associated with pregnancy (Huang and Wells,
2010).
The luteal phase is notable due to heightened P4 produced from the CL and
modest E2 levels that prepare the uterine environment to be highly receptive to
embryo implantation and the continuation of an ongoing pregnancy. The LH surge
causes TCs to proliferate, luteinize, and secrete increased amounts of
androstenedione and promotes P4 secretion from the CL. GCs transform into
large luteal cells and TCs transform into small luteal cells of the CL (Devoto et al.,
2009, Niswender et al., 1994). The gonadotropin surge has been shown to alter
the gene expression in the CCs and MGCs in humans (Borgbo et al., 2013).
When an embryo implants initiating a pregnancy, the menstrual cycle
temporarily pauses until the pregnancy is complete. In response to an embryo
failing to implant, or when the pregnancy is concluding, GnRH secretion will
increase as P4 levels decline. In either case, the luteal cells of the CL will regress
and develop into scar tissue known as the corpus albicans.
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1.6

Steroidogenesis
Granulosa cells and TCs produce androgens, estrogens, and/or progestins

for use during the reproductive cycle. The collaborative relationship exhibited by
the GCs and TCs is termed the two-cell, two-gonadotropin theory (Figure 1.7).
The reproductive steroids are all derived from their common precursor, cholesterol.
Cholesterol in the body originates from low- or high-density lipoproteins or
hydrolysis of cholesterol esters. Free cholesterol arrives at the mitochondria with
the aid of the cytoskeletal system within the cell (Niswender et al., 2000).
Steroidogenic acute regulatory protein (StAR) shuttles cholesterol into the
mitochondria (Manna et al., 2001). Cholesterol will be modified to pregnenolone
by cytochrome P450 family 11 subfamily A member 1 (CYP11A1), also known as
the cholesterol side-chain cleavage enzyme, irrespective of the final steroid
generated. CYP11A1, ferredoxin 1 (FDX1), and ferrodoxin reductase (FDXR) are
all members of the cholesterol side-chain cleavage complex (CSCC) located on
matrix portion of the inner mitochondrial membrane (Hanukoglu et al., 1990, Miller,
2005). The components of the CSCC serve as an oxidation/reduction system as
part of the process of steroidogenesis. FDX1 and FDXR act as acceptors for
electrons from nicotinamide adenine dinucleotide phosphate hydride (NADPH)
(Hanukoglu and Jefcoate, 1980). They hydrolyze the cholesterol side-chain two
times cleaving the bonds of carbons 20 and 22 forming pregnenolone and
isocaproic acid. Next, cytochrome P450 family 17 subfamily A member 1
(CYP17A1) transforms pregnenolone to dehydroepiandrosterone (DHEA) (Edson
et al., 2009). The final step before leaving the TCs, is the conversion of DHEA to
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androstenedione by hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid
delta-isomerase 1 (HSD3B1).

Androstenedione passes across the basement

membrane to GCs. Follicle stimulating hormone stimulates GC expression of
CYP19A1 and 17-beta hydroxysteroid dehydrogenase (HSD17B) to convert
androstenedione into E2.

Aromatase mRNA levels in human GCs increase

starting during the mid-follicular phase and peak in preovulatory follicles (~15 mm)
(Jeppesen et al., 2012). DNA microarray studies in human CCs and GCs have
shown that HSD3B1, CYP11A1, and StAR mRNA are upregulated in response to
human chorionic gonadotropin (hCG) (Assou et al., 2006).
In addition to the TCs and the MGCs, the COCs coordinate metabolic
processes necessary for the energy requirements of the oocyte needed for
fertilization and early development (Figure 1.8). This means that mitochondrial
functions within the CCs are intimately related to the overall developmental
competence of the oocyte (Dumesic et al., 2016). Therefore, mitochondria within
the CCs and or MGCs may be a viable indirect biomarker to assess oocyte
developmental competence.
Mitochondria are abundant in the oocyte and GCs, with each mature human
oocyte containing approximately 100,000-250,000 mtDNA copies. Mitochondria
are small double-membrane organelles transmitted to offspring through maternal
inheritance, with infrequent rare exceptions (Cummins, 2000, Song et al., 2014).
While spermatozoa do possess mitochondria, once an oocyte has been fertilized
and the subsequent embryo progresses through development, animal and human
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studies have shown that the paternal mitochondria are not present when the
embryo surpasses the 4-cell stage (Cummins, 2000, Sutovsky et al., 2000).
Mitochondria are unique because they contain their own genome. mtDNA
contains 16.6 kb of circular double-stranded DNA with 37 genes encoding for 13
proteins, two ribosomal RNAs, and 22 transfer RNAs (Benkhalifa et al., 2014).
The proteins and RNAs are necessary for OXPHOS and constituents of the
electron transport chain (ETC) with nuclear DNA (nDNA) providing the other
components needed for proper mitochondrial function.
Oxidative phosphorylation accounts for about 88% percent of a cell’s ATP
production with the remainder of the ATP is produced via glycolysis and the
tricarboxylic acid cycle (Seyfried and Shelton, 2010). OXPHOS takes place across
the inner membrane of the mitochondria and is the result of the transfer of electrons
through the linked protein complexes of the ETC (Figure 1.9) which generate
mitochondrial membrane potential by transporting protons across the membrane
(Veatch et al., 2009). Electrons are transferred from electron donors, nicotinamide
adenine dinucleotide hydride (NADH), NADPH, and flavin adenine dinucleotide
hydride (FADH2) to electron acceptors (i.e. O2) during redox reactions. The flow
of electrons in turn transports protons across the inner mitochondrial membrane.
Both the pH gradient and the electrical potential generated through this process
generate potential energy, which converts adenosine diphosphate (ADP) to ATP,
as protons flow through the ATP synthase enzyme.
Cumulus cells have high glycolytic activity and provide oocytes with
pyruvate via gap junctions (Collado-Fernandez et al., 2012). Oocytes exhibit
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minimal glycolytic capacity due to low phosphofructokinase activity and rely upon
pyruvate utilization for proper maturation (Barbehenn et al., 1974, Biggers et al.,
1967). Oocytes overcome this energy deficiency due to low glycolytic activity by
receiving ATP and other energy precursors including amino acids, pyruvate,
nucleotides, and cholesterol from the highly glycolytic CCs through shared gap
junctions (Figure 1.8) (Anderson and Albertini, 1976, Downs, 1995, Downs and
Utecht, 1999, Johnson et al., 2007, Su et al., 2009). The association of the oocyte
and the CCs may be beneficial for better embryo development. Human oocytes
maintained within CCs in culture exhibit higher levels of ATP and improved embryo
development (Van Blerkom et al., 1995).
1.7

In Vitro Fertilization
In vitro fertilization is a type of ART for humans where both the oocytes from

the female and spermatozoa from the male are collected and combined in the
laboratory as opposed to within the female’s body. Once inseminated, the oocyte
will fertilize and develop into a pre-embryo. Fertilization is confirmed with the
presence of both the male and female pronuclei and two polar bodies. This first
stage of development before syngamy, or fusion of the two pronuclei, is termed a
pre-zygote (Braude and Rowell, 2003).

The fused pronuclei will undergo

pronuclear breakdown before the first cleavage division. The fertilized oocyte is
called a zygote from the time immediately after syngamy until the first cell division.
From that point forward through day 14, the conceptus is referred to as a preembryo,

although many use

embryo

and

pre-embryo

interchangeably.

Somewhere between 72 to 96 hrs post insemination, the pre-embryo will undergo
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compaction and progress from 16 cells to the blastocyst stage. The cells of the
blastocyst will differentiate into an inner cell mass (ICM), which ultimately forms
the fetus and the trophectoderm, which gives rise to the placenta. When the
primitive streak develops on day 14, the conceptus will be considered an embryo.
From the end of the 8th-week post-ovulation until birth, the human conceptus is
considered a fetus. In the context of IVF, pre-embryos will be transferred to the
uterus on day 3 (at the cleavage stage) or more commonly on day 5 or day 6 (at
the blastocyst stage). Untransferred supernumerary pre-embryos will be frozen
for use in subsequent FET cycles. Women undergo IVF for many different types
of female infertility including but not limited to age, ovulation disorders, tubal
disease, uterine factors, polycystic ovarian syndrome (PCOS), endometriosis,
diminished ovarian reserve (DOR), and idiopathic or unexplained infertility.
1.8

Patient Characteristics Influencing In Vitro Fertilization Biomarkers
One of the main difficulties when evaluating microarray and qRT-PCR data

in CCs and MGCs for biomarkers that relate to embryo quality and other
reproductive endpoints used with IVF is the heterogeneous population of patients.
Among the potentially complicating factors are the large variability in patient
characteristics and the multiple stimulation types used during IVF procedures.
Patient characteristics influencing IVF outcome and gene expression include age,
body mass index (BMI), diagnosis, stimulation type, hormonal levels during
stimulation, and oocyte yield (Adriaenssens et al., 2010a). To further complicate
matters, uterine receptivity also influences the interpretation of transcriptomic data
such that a non-receptive uterus will cause implantation failure regardless of the
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quality of the transferred embryo. This will affect the statistical sensitivity (# of true
positives)/ (# of true positives + # of false negatives)) of studies. In light of this fact,
for a small number of cases, ETs resulting in “not pregnant” or “no implantation”
results will actually be false negatives due to poor uterine receptivity rather than
embryo characteristics. This section will review studies that demonstrate how
these variables can impact the transcriptional profile of granulosa cells.
In terms of heterogeneous patient populations, the mixture of multiple
diagnoses and stimulation types will skew many analyses. Andrianenssens and
coworkers (Adriaenssens et al., 2010a) showed that mRNA gene expression
profiles are influenced by a patient’s biological characteristics, type of stimulation
used for the patient’s IVF cycle, and oocyte developmental features. In this study,
CCs of 63 patients were evaluated by qRT-PCR for expression of 10 genes; gene
expression was then related to 13 different IVF cycle characteristics. Thirty-five
patients were stimulated with gonadotropin releasing hormone agonist with highpurity-human menopausal gonadotropin (HP-hMG) and 28 patients were
stimulated with GnRH-agonist with recombinant follicle stimulating hormone
(rFSH).

Patient characteristics, biological variables and embryo development

were similar between the two treatment groups. Most of the patients had male
factor infertility (MFI) with subsets having female subfertility (<10%), idiopathic
subfertility (<10%), and a combination of male and female subfertility combined
(<15%). These subgroupings may have influenced the outcome of the statistical
analysis of the gene expression. The analyses may have been stronger if only
MFI patients were used, but on the other hand statistical power would be lost by
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reducing sample size. Using a linear regression model, 5 of the 10 genes
examined syndecan 4 (SDC4), versican (VCAN), gremlin 1, DAN family BMP
antagonist (GREM1), sprouty RTK signaling antagonist 4 (SPRY4) and ribosomal
protein S6 kinase A2 (RPS6KA2) showed differential expression based on the type
of stimulation. Patients stimulated with rFSH showed higher SPRY4 and lower
SDC4 mRNA levels when compared with HP-hMG stimulated patients. VCAN was
negatively correlated with oocyte maturity in the rFSH group and RPS6KA2 was
positively correlated with increasing age in the rFSH stimulated group. GREM1
showed a positive correlation with age and embryos having greater than seven
cells and a negative correlation with serum progesterone on day of hCG
administration in rFSH stimulated patients. Interestingly, SDC4, GREM1, SPRY4,
and RPS6KA2 are all involved in signaling TGF-β or epidermal growth factor (EGF)
signaling pathways.

The above study provides evidence that the type of

gonadotropin treatment can affect certain signaling pathways thereby altering
gene expression.
An individual patient’s diagnosis may also influence differential mRNA gene
DRGE in CCs and MGCs. PCOS compared to non-PCOS (Catteau-Jonard et al.,
2008, Wei et al., 2012, Schmidt et al., 2014, Chen et al., 2015b) endometriosis
compared to non-endometriosis (Yanaihara et al., 2005, Allegra et al., 2014,
Barcelos et al., 2015), and DOR compared to normal ovarian reserve (NOR)
(Greenseid et al., 2011, Jindal et al., 2012, May-Panloup et al., 2012, Meng et al.,
2013) have all been shown to alter gene expression. In fact, PCOS patients with
or without insulin resistance were shown to have DRGE compared to non-PCOS
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normal control patients (Kaur et al., 2012). Other pathologies may also alter gene
expression but have not been examined. Including any of these diagnoses in
studies may also alter the actual transcriptional profiles and should be avoided if
possible or analyzed separately.
The major contributing factor to reduced fecundity is advanced maternal
age (AMA), even among females who do not have other infertility problems.
Advanced maternal age is becoming an increasing concern as more and more
women are choosing to delay starting families past the ideal reproductive age.
Reproduction in human females peaks around 25 years old, exhibits a moderate
decline after the age of 30 and drops steeply following 37 years of age (O'Connor
et al., 1998). This decrease in reproductive potential is due to reduced oocyte
quality and production of more aneuploid embryos associated with aging (Hassold
and Hunt, 2001, Hassold et al., 2007, Heffner, 2004). Comprehensive
chromosomal screenings from trophectoderm biopsies of 15,169 human
blastocysts showed the lowest aneuploidy rates of <30% occurred between the
ages of 26 and 30 years of age, rates increased above 40% for patients younger
than 26 and older than 36 years old, and peaked above 80% for patients over 42
years old (Figure 1.10) (Franasiak et al., 2014). Between 70-90% of aneuploidies
occur within the oocytes due to chromosomal nondisjunction at meiosis I during
oogenesis (Capalbo et al., 2017, Nagaoka et al., 2012). This increase in
aneuploidy is partially due to the years human oocytes spend in a prolonged
arrested state in meiosis I when they may incur physiological alterations.
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It has been postulated that developmental abnormalities seen in oocytes
with AMA are directly related the mitochondrial dysfunction owing to increased
point mutations in mtDNA (Barritt et al., 2000, Bentov and Casper, 2013) and
decreased mtDNA content (Chan et al., 2005, Duran et al., 2011, Murakoshi et al.,
2013). mtDNA mutations are about 25-times higher than mutations in (nDNA)
because mtDNA does not have associated histones or effective DNA repair
processes to repair mutations caused from reactive oxygen species (ROS) and
free radicals within the mitochondrial matrix (Lynch et al., 2006).

Since

accumulation of abnormal mitochondria affects overall mitochondrial function, the
investigation of mitochondrial metabolism may provide some insight into oocyte
developmental competence and help to select the best oocyte and embryos for
uterine transfer.
The overall appearance of mitochondria is altered with increased age in
humans as exhibited by cristae malformation, swelling, and vacuolization (MullerHocker et al., 1996, Van Blerkom, 2011). In addition to altered appearance, there
are functional changes in the mitochondria of aging oocytes as well. Mitochondrial
membrane potential, which correlates to mitochondrial activity, is inversely related
to age and reduced embryo development, which may be responsible for declining
fertility with AMA (Wilding et al., 2001). This decrease in mitochondrial membrane
potential corresponds to other studies where ATP production and metabolic activity
decreased with advancing age (Eichenlaub-Ritter et al., 2011, Van Blerkom, 2011).
Oxidative damage due to ROS accumulation has also been implicated in reducing
oocyte competence (Tatone et al., 2008). It has been suggested that impaired
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mitochondria, which typically begin resumption of biogenesis at the blastocyst
stage (Figure 1.3), may begin replicating early to compensate for impaired function
(May-Panloup et al., 2016). This premature replication may account for increased
mtDNA copy numbers seen by Fragouli and colleagues in trophectoderm biopsies
from blastocysts from older patients (Fragouli et al., 2015). These observations,
taken together, may indicate a disruption of the follicular environment
compromising oocyte and GC communication, disruption of the cell cycle, and
altered meiotic spindle assembly and chromosomal segregation (Eichenlaub-Ritter
et al., 2004, Schon et al., 2000).

All these perturbations may contribute to

decreased oocyte competence and result in reduced embryo development and
account for the decline in fertility with AMA.
Patient age has been shown to be associated with DRGE in CCs and MGCs
(Al-Edani et al., 2014, Kedem et al., 2014, Hurwitz et al., 2010, Liu et al., 2010,
McReynolds et al., 2012) as well as oocytes (Grondahl et al., 2010). Patient BMI
alters CC gene expression in both PCOS (Kenigsberg et al., 2009) and non-PCOS
women (Robker et al., 2009). Therefore, studies with a large range of ages or
BMIs may show DRGE profiles that would not exist if the age ranges or BMI were
controlled for in the studies.
Lower mtDNA mRNA transcripts of genes associated with defending
against ROS have been demonstrated to be associated with AMA in human MCGs
(Tatone et al., 2006). Another group demonstrated that mRNA of sirtuin 3 (SIRT3),
which is a mitochondrial protein associated with metabolism and which alters
mitochondrial function, was lower in MGCs from women with AMA and young
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women with DOR compared to younger women with NOR and lower in CCs from
women with AMA compared to younger women (Pacella-Ince 2014). Additionally,
a common mtDNA 4977 base pair deletion was observed at increased levels in
GCs from women with AMA compared to younger women (Seifer et al., 2002).
Furthermore, the 4977 base pair deletion in mtDNA was found to be higher in the
CCs of non-pregnant women than pregnant women, with a higher incidence in
women more than 34 years old (Tsai et al., 2010).

These studies suggest that

women with AMA and DOR have altered mtDNA within their follicular cells, and
this may affect oocyte developmental competence and ability to establish a
pregnancy.
1.9

Stimulation Protocols Influencing In Vitro Fertilization Biomarkers
The goal of IVF is to harvest as many good quality oocytes as possible from

the pool of oocytes ready to begin maturation at the start of the patient’s cycle in
anticipation that one or more will lead to live birth. This process is accomplished
using controlled ovarian stimulation protocols.

The patient’s HPG axis is

stimulated with medications in order to produce many oocytes from multiple
follicles within a single reproductive cycle, as opposed to a single dominant follicle
with a single oocyte typical of unstimulated cycles. The injectable medications
used are called GnRH agonists or GnRH antagonists and are used in combination
with gonadotropins to stimulate follicular growth. The exact protocols used will
vary between IVF clinics.

These protocols suppress the endogenous LH

production from the pituitary and therefore a “trigger” medication, usually hCG or
recombinant luteinizing hormone (rLH), is necessary to induce ovulation.
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The impact of different gonadotropin treatments on gene expression profiles
of GCs has been corroborated by other groups.

Grondahl and coworkers

(Grondahl et al., 2009) published the first study to report DRGE profiles by
microarray in MGCs with GnRH agonist protocols with either rFSH or HP-hMG. In
their study, 85 genes showed DRGE of which LHCGR and genes involved in
cholesterol and steroid synthesis had lower expression in the HP-hMG group
compared to the rFSH group. This DRGE seen between the agonist HP-hMG and
rFSH treatments in MGC was also demonstrated in a subsequent study (Brannian
et al., 2010). Of the 1736 genes exhibiting a ≥ 2-fold expression difference 400
were related to signal transduction. This data was validated by qRT-PCR and
insulin like growth factor binding protein 4 (IGFBP4), insulin like growth factor
binding protein 5 (IGFBP5), and basigin (BSG) mRNA showed at least a 3-fold
increase in mRNA levels when comparing the HP-hMG to rFSH group, whereas
AKAP11: A-kinase anchoring protein 11 (AKAP11), hypoxia inducible factor 1
alpha subunit (HIF1A), and bone morphogenetic protein receptor type 2 (BMPR2)
were decreased.
Gatta and coworkers (Gatta et al., 2013) evaluated different stimulation
protocols comparing rFSH plus rLH or HP-hMG and found DRGE in CCs by
stimulus type. Two main clusters of genes varied with stimulation type with 61
genes being upregulated with HP-hMG and downregulated with rFSH plus rLH,
and 84 genes being upregulated with rFSH plus rLH and downregulated with HPhMG, compared to rFSH alone. The genes identified mediated functions related
to retinoic acid transport, phosphatase enzymes, DNA methylation and
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transcription, and oocyte/follicle development.

An additional 53 genes were

upregulated in both groups compared to rFSH alone.

Assou and coworkers

(Assou et al., 2013) retrospectively examined individual cumulus mass transcripts
by microchip and embryo development using GnRH antagonist protocols with
either HP-hMG or rFSH. In the HP-hMG group 45 genes were significantly
upregulated including those related to cell-cell interaction and lipid metabolism
whereas 49 genes were significantly upregulated in the rFSH group including
extracellular matrix assembly and tumor necrosis factor family members. No
differences were observed between HP-hMG and rFSH treatments in CC mRNA
levels of LHCGR, BMPR2, cytochrome P450 family 19 subfamily A member 1
(CYP19A1), CYP11A1, steroidogenic acute regulatory protein (STARD1),
hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 2
(HSD3B2), activin A receptor type 1 (ACVR1), activin A receptor type 1B
(ACVR1B), inhibin beta C subunit (INHBC), and inhibin beta B subunit (INHBB) or
in fibroblast growth factor (FGF), insulin like growth factor (IGF), EGF, and platelet
derived growth factor (PDGF) pathways. Not only does the type of GnRH-mediated
stimulation alter the gene expression of CCs and MGCs but the “trigger”
medication that induces the final maturation prior to oocyte retrieval modifies gene
expression as well. After GnRH-antagonist priming, hCG and GnRH agonist
“triggers” exhibit differing expression patterns related to steroidogenic pathways in
CCs and angiogenic pathways in the MGCs (Borgbo et al., 2013). The GnRH
agonist “trigger” also showed higher LHCGR mRNA in CCs than the hGC “trigger”.
In another study, patient groups were given 0, 5,000 or 10,000 IUs of hCG (Coskun

34

et al., 2013). The gene expression profiles differed between the hCG groups and
the non-hCG group with approximately 2000 genes up or downregulated in each
hCG group, yet only 15 genes differed significantly between the two hGC doses.
The GnRH “trigger” leads to an endogenous increase in LH, whereas hCG serves
to mimic the LH surge. hCG has a longer half-life and higher affinity than LH for
the LHCGR (Choi and Smitz, 2014), yet LH is more potent at activating
downstream signals such as cAMP accumulation, extracellular signal–regulated
kinases and protein kinase B activation. Another group examined the effects of a
double “trigger” to produce final oocyte maturation using a GnRH agonist at 40 hrs
before oocyte retrieval and hCG 34 hrs before oocyte retrieval. They found that
AREG, epiregulin (EREG), and serpin family f member (SERPINF1), also called
pigment epithelium-derived factor (PEDF), mRNA levels were significantly higher
while GJA1 mRNA levels were significantly lower in MGCs in the double trigger
group (Haas et al., 2019). Finally, a recent study small study examined the effects
for hCG, GnRH agonist, or a double “trigger” using both medications on the CC
transcriptome in a total of 30 poor, normal and high responder patients by nextgeneration sequencing (NGS) (Fuchs Weizman et al., 2019). The CC samples
from patients with higher than average ovarian reserve tended to cluster together
more closely than CC samples from the other groups. mRNA levels differed
between the 3 treatment groups and the 3 trigger types, including genes related to
apoptosis, cell-cycle regulation, oocyte maturation, immune response, and
inflammation. These findings suggest that possible differences in activation of the
LH receptor may account for trigger differences in CC gene profiles. Moreover,
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these studies indicate the type of gonadotropin stimulus should be considered
when interpreting biomarker data, as different stimuli yield different gene
expression profiles.
1.10

Improving IVF Outcomes with Non-Invasive Biomarkers
Even with improvements in ART over the past couple of decades, the

success rates for procedures treating infertility and leading to live births is still less
than optimal.

European data from 2011, as reported by the European IVF-

Monitoring Consortium and the European Society of Human Reproduction and
Embryology showed the non-donor ET rate was 33% with the pregnancy rate per
embryo thaw cycle being 21% (Kupka et al., 2016). Recent national summary data
from 2017, as reported by the Society for Assisted Reproductive Technology
(SART) website (SART, 2019), indicate the cumulative live birth rate per oocyte
retrieval including fresh and subsequent frozen transfers in the United States from
IVF in patients less than 35 years old was approximately 54% and decreased with
increasing maternal age. There is a need to improve outcomes of IVF, which may
require improved stimulation protocols to yield better oocytes/embryos or
identifying new methods for assessing the most viable oocytes/embryos. Several
approaches are being investigated to find reliable and reproducible surrogate
biomarkers for oocyte competence and selection of the embryos with the best
probability of producing live births.
This suboptimal success rate of IVF may be due to the fact that most
embryos selected for uterine transfer are chosen based on the morphological
appearance of the embryos and their cleavage rates.
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In fact, Munne and

coworkers

(Munne et al., 2007b) reported that most morphologically normal

appearing

embryos

(based

on

shape,

size,

blastomere

number,

and

fragmentation) may be aneuploid. In an analysis of 6000 embryos produced from
oocytes of women less than 35 years of age, approximately 56% of embryos with
the best morphology and development rate were actually aneuploid (Munne et al.,
2007a).

Furthermore, morphologically good, aneuploid embryos increased to

nearly 80% for the women age 41 and older. These data indicate the need for
better methodologies to reduce selection of aneuploid embryos.
In a later study, Munne and coworkers (Munne et al., 2009) suggested that
the best way to select euploid embryos for uterine transfer was to use a
combination of both morphological appearance and PGT-A. For PGT-A, 3-10 cells
are biopsied from the trophectoderm of a day 5 or day 6 blastocyst for chromosome
analysis.

This approach has been validated by several groups that have

demonstrated increased ongoing pregnancy, implantation, and delivery rates of
nearly 20% with PGT-A screened versus non-PGT-A screened embryos
(Schoolcraft et al., 2010, Yang et al., 2012, Scott et al., 2013, Forman et al., 2013).
While PGT-A has been shown to increase positive IVF outcomes in several
studies, it requires invasive manipulation which might harm the embryo potentially
decreasing successful outcomes. This idea is supported by a recent report which
reviewed PGT-A embryo data in the United States for 2011 and 2012 and showed
that utilizing PGT-A-screened embryos did not increase IVF success rates. In
actuality, the success rate per uterine transfer was reduced from 46.2% to 39.3%
when PGT-A was utilized (Kushnir et al., 2016).
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The authors of this study

concluded that PGT-A decreases the chance of live birth, and that improvements
previously reported with PGT-A in women over 37 years-old are due to selection
bias.
There are several non-invasive methods for embryo selection that have
been used in conjunction with embryonic morphological appearance and
development rate. Numerous studies have evaluated the characteristics of GCs
which surround the oocyte, follicular fluid contents or the secretions of the embryos
while in culture. Several non-invasive methods for embryo assessment have been
reviewed elsewhere and include the study of epigenomics which consists of
bisulfite sequencing to analyze DNA methylation of the GCs (Egea et al., 2014);
proteomics, including electrophoresis, chromatography, and mass spectrometry of
follicular fluid or oocyte culture media (Nel-Themaat and Nagy, 2011);
metabolomics of spent human embryo culture media by gas chromatography, high
pressure liquid chromatography, or nuclear magnetic resonance (Uyar and Seli,
2014); and time-lapse imaging of embryos (Kirkegaard et al., 2015). A recent
meta-analysis examining studies using time-lapse to select embryos for uterine
transfers has shown improved pregnancy and live birth rates compared to embryo
scoring methods alone (Pribenszky et al., 2017).
The basis for using CCs and MGCs as biomarkers for oocyte health is the
evidence that there is bi-directional signaling shared between the oocytes the
somatic cells of the follicles providing the optimal environment for oocyte
maturation, fertilization, and embryo development (Assou et al., 2008, Dumesic et
al., 2015, Tsai et al., 2010). These somatic cells are a great source of materials
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for the studies of epigenomics (Egea et al., 2014), mitochondrial function and
mtDNA content (Cecchino et al., 2018), and transcriptomics (Kordus and LaVoie,
2017).

Epigenomics uses bisulfite sequencing to examine DNA methylation

patterns. Mitochondrial function examines both ATP production and OXPHOS.
Transcriptomics uses RT-PCR or microarrays to observe differences in gene
expressions patterns.
1.11

mRNA in Cumulus Cells and Mural Granulosa Cells as Non-Invasive
Biomarkers in IVF
The ability of an embryo to develop appropriately and ultimately implant,

grow, and result in a live birth is dependent upon the original oocyte’s
developmental competence. Therefore, any of the methods mentioned above that
can reliably determine which oocytes are the most developmentally competent will
be invaluable to help improve embryo selection before uterine transfer and
increase IVF success. One of the best sources for biomarkers for non-invasive
study for oocyte development competence is the GCs for the reasons described
above (Feuerstein et al., 2012).
Early assessment of RNA transcripts in GCs addressed small numbers of
genes and techniques utilized were less quantifiable. Such reports included semiquantitative analyses of RT-PCR and northern blotting of a single or handful of
expressed genes. The ability to analyze thousands of transcripts simultaneously
was made possible with the availability gene microarrays.

Furthermore, the

application of qRT-PCR allowed more accurate quantification and validation of
transcript changes. A single microarray can exhibit hundreds, if not thousands, of
DRGE patterns. It is important to validate mRNA level changes by qRT-PCR as
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microarray can produce false positive signals (Provenzano and Mocellin, 2007).
Groundbreaking early microarray work, which evaluated the transcriptomes of
human luteinized granulosa cells from IVF patients, showed differences in
thousands of mRNA transcripts between women with NOR and DOR, however
changes were not validated through qRT-PCR thereby limiting the data
interpretation (Chin et al., 2002). RNA-seq is a more recent method that can
replace microarrays; in this technique, RNA is converted to cDNA then undergoes
deep-sequencing to identify transcripts.
An important factor to consider when evaluating DRGE in transcriptomic
studies in whether or not mature and immature oocyte granulosa cells have been
mixed together.

Mature and immature oocyte CCs have differing mRNA

expression patterns (Assou et al., 2006, Gasca et al., 2007, Kwon et al., 2010,
Ouandaogo et al., 2011, Ouandaogo et al., 2012, Devjak et al., 2012, Huang et al.,
2013, Grondahl et al., 2013). A more recent study using ovarian cortical tissue
from patients undergoing oophorectomy before treatment for cancer showed
DRGE between GCs from primordial follicles and primary follicles (Ernst et al.,
2018). This knowledge may help in finding appropriate biomarkers to determine
pregnancy potential as there may be visually mature oocytes that exhibit immature
gene expression profiles. If the mature oocyte expression pattern can be linked to
live birth, the embryos resulting from those oocytes can be preferentially selected
for uterine transfer.
At this time there is no one single gene transcript that appears to be capable
of predicting which embryos produced by IVF will implant and lead to a live birth.
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The gene biomarker studies undertaken have varied among the chosen endpoints
which include oocyte nuclear maturation, fertilization, day 2 and day 3 embryo
morphologies, day 5 and day 6 blastocyst morphologies, implantation, ongoing
pregnancy, and live birth. Appendices A-C summarize the findings of studies that
show genes positively associated with pregnancy or live birth (Appendix A), genes
that have conflicting findings between different studies (Appendix B), and genes
whose data do not support an association with pregnancy or live birth (Appendix
C). While the most desirable endpoint for transcriptomics studies is live birth,
several studies examined the gene expression of CCs in relation to embryo
development (Anderson et al., 2009, Assou et al., 2013, Cillo et al., 2007, Dhali et
al., 2017, Feuerstein et al., 2007, Hammond et al., 2015, Liu et al., 2018,
Hasegawa et al., 2005, McKenzie et al., 2004, Nivet et al., 2016, Scarica et al.,
2019, Zhang et al., 2005). Since embryos with the best morphological appearance
are usually selected for uterine transfer and have been shown to implant at a higher
rate than morphologically low quality embryos (van Loendersloot et al., 2010), the
gene expression profiles of these studies may serve as an indirect marker of
embryo viability and be at least loosely related to live birth rates.
The first retrospective study to look at CC transcripts and pregnancy as the
end point was conducted by Assou and coworkers (Assou et al., 2008). Thirty
patients less than 35 years old with MFI were included in the study. The stimulation
protocols were varied and included GnRH agonist or antagonist with rFSH or hMG.
The data showed that there was DRGE between the pregnant and not pregnant
groups. Out of the 569 upregulated genes in the pregnant group, pathway analysis
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showed enrichment in genes associated with oxidative stress and nuclear factor
kappa-light-chain-enhancer of activated B cells signaling.

Of the 61

downregulated genes associated with pregnancy, pathways included insulin-like
growth factor 1 (IGF1) and Sonic hedgehog signaling. Five CC masses each from
pregnant patients and non-pregnant patients were used to further validate the
microarray data.

BCL2 like 11 (BCL2L11) and phosphoenolpyruvate

carboxykinase 1 (PCK1) were downregulated while nuclear factor I B (NFIB) was
upregulated in pregnant versus non-pregnant samples. There was no analysis
performed for the mixed stimulation protocols, and thus it is difficult to determine
the impact of stimulation type. The qRT-PCR analyses were only performed on 5
samples each, which does not provide much statistical power. The upregulation
of nearly 600 genes in the pregnant group may indicate that the genome of CC
may need to become transcriptionally activated to achieve pregnancy.
As a follow-up to their 2008 study, Assou and coworkers (Assou et al., 2010)
identified 45 genes as CC biomarkers associated with pregnancy. They conducted
a prospective study with patients < 36 years old undergoing IVF with ICSI. The
study was split into two groups where the two day 3 embryos selected for transfer
were chosen either based on the CC mRNA expression profile or embryo
morphology. In the first group, 267 individual CC from 30 patients were analyzed
by qRT-PCR. Ongoing pregnancy rates per retrieval were 70% in the group which
used qRT-PCR versus 47% for the morphology group alone demonstrating the use
of CC mRNA expression as a useful prognostic tool. The authors note a large
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cohort study would be the best way to confirm this data. Unfortunately, the genes
examined in this study were not specified.
A similar study was the first to look at the CC gene expression transcriptome
based on single ET (Hamel et al., 2008). Forty women undergoing IVF with tubal
factor, endometriosis, or idiopathic infertility were part of the study. MGCs and
CCs were pooled into 2 groups for those that formed a positive pregnancy and
embryos that arrested. From the hybridizations of the positive pregnancy and
negative pregnancy MGC forward-subtracted PCR products were used as probes
to hybridize a custom-made microarray.

Following microarray analyses 18

candidate genes were validated by qRT-PCR with the pooled MGC samples. Five
genes showed DRGE in the positive versus negative pregnancy groups with
CYP19A1, cell division cycle 42 (CDC42), serpin family E member 2 (SERPINE2),
HSD3B1 and FDX1 showing a statistically significant increase in the positive
pregnancy groups. Drawbacks of the study are that the methods did not mention
what type of stimulation protocols were used, and the study included endometriosis
and idiopathic infertility patients and did not take these diagnoses into account or
specify the number of each patient with each diagnosis.
In a follow-up study, the MGCs of transferred embryos from 18 patients
were pooled from embryos that formed an ongoing pregnancy at 6-8 weeks or
embryos that failed to implant (Hamel et al., 2010b). The patient population was
mixed with tubal factor, idiopathic infertility, and endometriosis and the stimulation
was unspecified. Microarray analysis showed DRGE preferentially expressed for
25 genes in the pregnancy group and 19 genes in the non-pregnant group.
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Validation of 10 genes was performed using qRT-PCR and showed UDP-glucose
pyrophosphorylase 2 (UGP2) and pleckstrin homology like domain family A
member 1 (PHLDA1) gene expression was significantly higher in the pregnant
group. In addition, the same lab performed a slightly different study and performed
logistical regression analysis to determine which genes would best predict
pregnancy (Hamel et al., 2010a). Included in these analyses were 9 patients for
intra-patient analysis with successful pregnancies versus arrested embryos, and
38 patients for interpatient analysis which included a third group with unsuccessful
pregnancies.

Successful pregnancies were those in which either the single

transfer or one or both of two transferred embryos implanted. With two transferred
embryos resulting in a singleton pregnancy, determining which embryo implanted
is difficult, so the study employed principal component analysis (PCA) to predict
which embryo most likely implanted. PCA is a statistical method whereby the
correlated variables from the embryos known to implant were used to estimate
which one of a pair of embryos implanted when two were transferred but only one
implanted.

Phosphoglycerate kinase 1 (PGK1) and regulator of G-protein

signaling 2 (RGS2) were determined to be the best predictors of pregnancy from
the intrapatient analysis and PGK1 and CDC42 were the best predictors of
pregnancy from the interpatient analysis.
Two separate studies combined traditional embryo morphology and zona
pellucida birefringence (refractive index) to examine gene expression (Assidi et al.,
2011, Assidi et al., 2015). In the first study, CCs from 8 patients having the same
stimulation protocol were divided into two groups base on positive or negative

44

pregnancy results. Day 3 post-insemination embryos for transfer were selected
based on good embryo morphology and high zona pellucida birefringence.
Dipeptidyl peptidase 8 (DPP8), H4 clustered histone 3 (H4C3), ubiquilin 1
(UBQLN1), calmodulin 1 (CALM1), neuropilin 1 (NRP1), and proteasome 26S
subunit, non-ATPase 6 (PSMD6) mRNA levels were all shown to be related to a
positive pregnancy while target of myb1 membrane trafficking protein (TOM1) was
related to a negative pregnancy following ET. In the second study, seven patients
with MFI were stimulated with GnRH agonist with hMG/FSH. The embryos were
divided into CCs with high zona pellucida birefringence and positive pregnancy
and CCs with low zona pellucida birefringence and negative pregnancy and
compared. By microarray analysis, 48 genes were overexpressed and 27 genes
were under expressed. These genes included CALM1, NRP1, and PSMD6 as
seen in the previous study. DPP8 and UBQLN1, as well as the 3 genes listed
previously showed DRGE by qRT-PCR between the two groups, however, no
correlation was seen between oocyte competence and zona pellucida
birefringence, thereby indicating DRGE is a viable option for embryo selection
while refractive index may not be.
Prostaglandin-endoperoxide synthase 2 (PTGS2) and VCAN mRNA
expression were shown to be significantly higher in CCs from oocytes that led to a
live birth, and GREM1 and phosphofructokinase, platelet (PFKP) mRNA
expression was correlated with the baby’s birth weight (Gebhardt et al., 2011).
These results came from a retrospective study evaluating pregnancy resulting from
38 single ETs.

All patients had long down-regulation protocols with rFSH.
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Feuerstein et al. (Feuerstein et al., 2012) performed 96 microarray hybridizations
and qRT-PCR with 197 individual CC masses from oocytes of 106 IVF patients
and compared the results with embryo development and pregnancy. The samples
were separated by oocyte nuclear maturation. RGS2 was shown to be linked to
pregnancy potential while pentraxin 3 (PTX3) showed a significant correlation with
blastocyst development but only showed a positive correlation with pregnancy.
Perilipin 2 (PLIN2) and angiogenin (ANG) were also associated with
developmental competence. Biomarkers related to LH signaling have also been
examined in relation to IVF success.

Papamentzelopoulou and coworkers

(Papamentzelopoulou et al., 2012b) showed that a more robust CC LHCGR mRNA
expression was positively associated with pregnancy. Forty patients with GnRHagonist protocols with rFSH treatment were examined. Medium to high LHCGR
expression was exhibited in 6 out of 7 patients who became pregnant. RUNX
family3K transcription factor 2 (RUNX2) gene expression, which is induced by the
preovulatory LH surge, was examined in CCs (Papamentzelopoulou et al., 2012a).
This study examined 41 ICSI patients between 24 and 45 years old being treated
for MFI and each had at least one prior unsuccessful IVF cycle. All the patients
were treated with a GnRH-agonist protocol. The RUNX2 gene was detected in 12
out of 41 women. Of the 12 expressing RUNX2 in the cumulus mass only 1
became pregnant, while 7 of the remaining 28 patients who did not express the
gene did become pregnant. The presence of RUNX2 in CCs may signify an oocyte
that will likely not yield a pregnancy while the presence of LHCGR mRNA could
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indicate embryos capable of forming a pregnancy and both could be potentially
useful biomarkers for embryo selection.
Increased levels of GDF9 and BMP15 expression have both been
associated with positive pregnancy as well as mature oocytes, fertilization rate,
and embryo quality (Li et al., 2014). This study utilized one of the largest sample
sizes to date, using 2426 CC masses from 196 patients with MFI, normal BMI, age
27 to 37 years old, and stimulated with a GnRH protocols. GDF9 and BMP15
expression was analyzed by qRT-PCR.

Considering that downstream genes

affected by GDF9 and BMP15 such as PTGS2 and GREM1 have been shown to
be related to pregnancy it is not surprising that their own gene expression would
serve as potential biomarkers for IVF success.
In a small retrospective study assessing the CCs from 16 individual
embryos transferred in 16 IVF patients, mRNA levels of 11 out of 92 mRNA
transcripts associated with the phosphoinositol 1,3-kinase/serine/threonine kinase
1 (PI3K/AKT) pathway were lower in CCs from oocytes resulting in implanted
embryos (Artini et al., 2017). The researchers also looked at 4 transcripts from 4
pregnant patients and 4 non-pregnant patients by RT-PCR. Estrogen repector 1
(ESR1) showed lowered mRNA levels in the pregnant group while forkhead box
O4 (FOXO4) showed higher mRNA levels.

Forkhead box O1 (FOXO1) and

forkhead box O3 (FOXO3) did not show a difference. Since this data only used
eight patients total it is difficult to discern the accuracy of this data.

To validate

their array results, the investigators selected three genes out of the 11 showing
DRGE and collected CCs from CD-1 mice at various time points following hCG
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injection.

Lower levels of AKT serine/threonine kinase 1 (Akt1), BCL2-like 2

(Bcl2I2) and SHC adaptor protein 1 (Shc1) mRNAs were noted from oocytes that
fell within the optimal maturation window of 12-15 hrs post-hCG whereas higher
levels were seen in CCs immature and post-mature oocytes. These results indicate
there may be an optimal maturation window which will have a distinct expression
profile that may be able to identify the most competent embryos and the genes of
the PI3K/AKT pathway may play an essential role in that determination.
Another interesting study examined the role genes related to histone
demethylation may have in contributing to oocytes competence. It was noted that
by immunohistochemical staining that lysine demethylase 4A (KDM4A) was
present in oocytes, GCs, and CLs and that lysine demethylase 4B (KDM4B) was
present in oocytes, GCs, TCs, and CLs (Krieg et al., 2018). This observation
prompted the investigators to determine the mRNA expression of the two genes in
the GCs of IVF patients. Examining both CCs and MGCs of 84 women, it was
demonstrated that KDM4A and KDM4B mRNA levels were lower in the CCs and
MGCs from oocytes resulting in embryos that resulted in pregnancies. This data
should be interpreted with caution as there were significant differences in age,
AMH levels, E2 levels, FSH levels, numbers of oocytes retrieved, number of
fertilized oocytes, and there were very diverse reasons for infertility which may
confound the data.

However, this study may provide early evidence that

epigenetics plays a role in modifying GC gene expression in relation to oocyte
developmental competence.
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Another group examined 10 individual CC samples from 10 idiopathic
patients and looked at the differences in 10 microarray expression profiles between
oocytes that resulted in pregnancies versus no-pregnancies and live births versus
no-pregnancies (Demiray et al., 2019). The authors found that in the pregnancy
assessment group that the genes related to circadian entrainment exhibited the
most DRGE while the genes of the apoptosis and the neurotrophin signaling
showed the highest DRGE in the live birth assessment group. They also identified
20 genes presenting the highest DRGE in the two groups; however, they did not
confirm any of the results by RT-PCR. Also, this data should be viewed with
caution as only three patients out of ten became pregnant, and only two patients
gave birth, indicating the power of this study was low.
In the most recent study to date, microarray analysis indicated that DRGE
was present in 165 genes when comparing oocytes resulting in pregnancy and
oocytes that did not implant (Fortin et al., 2019). The study compared gene
expression of MGCs from 16 patients with each group consisting of 4 pools of 4
patients each.

The microarray analyses indicated higher levels of pro-

inflammatory cytokines and other inflammatory genes.

They validated their

microarray data with six genes by RT-PCR using material from the 32 patients
used in the microarray study, and they also performed a second validation adding
12 more patient samples that were not pregnant and 53 patient samples from
patients who became pregnant. In the first analysis, C-X-C motif chemokine ligand
2 (CXCL2) and docking protein 5 (DOK5) mRNA levels significantly decreased in
the pregnant group.

In the second analysis, DOK5 and NTS mRNA levels
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significantly decreased in the pregnant group.

The study may indicate that

overexpression of genes related to inflammation may play a role in interfering with
the ability of an oocyte to lead to a viable pregnancy.
While several studies have shown DRGE between the CCs of embryos
which form viable pregnancy and those that do not, several studies have also
shown no significant DRGE between the groups. For example, Anderson and
coworkers (Anderson et al., 2009) examined the genes hyaluronan synthase 2
(HAS2), brain derived neurotrophic factor (BDNF), GREM1, PTGS2, tumor
necrosis factor alpha induced protein 6 (TNFAIP6) and PTX3 and showed no
correlation between the gene expression and pregnancy. Only GREM1 showed a
higher gene expression trend with pregnancy but it was not statistically significant.
In two recent studies, evaluating CC and MGC gene profiles and implantation
potential or fertilization, no gene differences were found to be significantly
associated with these endpoints (Burnik et al., 2015a, Burnik et al., 2015c). The
authors selected 3 genes from the published literature that were proposed
biomarkers in CCs for pregnancy in at least 2 studies and were validated with qRTPCR. RGS2 and VCAN showed no DRGE between CCs of embryos that formed
a pregnancy or did not, whereas ephrin B2 (EFNB2) showed a trend toward higher
expression in the embryos that failed to form a pregnancy. In contrast to a previous
GC study (Fujino et al., 2008), CC expression of survival factor gene baculoviral
inhibitor of apoptosis repeat containing 5 (BIRC5) showed no correlation with
pregnancy when examined in Greek women (Varras et al., 2012).
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In a study examining ten aquaporin (AQP) subtypes, LHCGR, and STARD1
from GCs of 111 women, no statistical differences were noted between women
who were pregnant and those that were not pregnant (Lee et al., 2016). More
recently a group engaged in a paired prospective study of 34 CCs from euploid
sibling embryos using RNAseq and found no differences in the transcriptome of
those oocytes resulting in embryos that resulted in a live birth and those that did
not (Green et al., 2018). This study differed from all the other studies reviewed so
far because it controlled for the uterine environment. By transferring two embryos
into each patient, the CC transcripts between the two embryos could be assessed
without the false-negative results due to uterine environments in other studies.
Although there were no differences seen, it is important to note that the embryos
transferred were most likely very similar as they had already been tested by PGTA meaning these were blastocysts of high enough quality to undergo biopsy and
were genetically normal. If the entire cohort of embryos was transferred back into
a single patient over time, and many more patients were analyzed, DRGE may
become apparent. Variations in those studies showing DRGE differences and
those with no differences may be due to the more restrictive inclusion criteria in
studies with negative findings such as exclusion of patients with particular
diagnoses such as endometriosis or sample size differences.
To better identify abnormal embryos, Fragouli and coworkers (Fragouli et
al., 2012) used first polar bodies to access oocyte ploidy. Differential mRNA gene
expression between euploid and aneuploid oocytes was evaluated in CCs.
Women (n=28) ranging in age from 23 to 46 with varied ovarian stimulation
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protocols which included GnRH agonist started in the mid-luteal phase of the
previous cycle with rFSH, a combination of either GnRH agonist or an antagonist
with rFSH, with or without hMG participated in the study. Customized TaqMan
low-density arrays (TLDAs) were utilized to evaluate CC transcriptomes and
initially showed 729 potentially altered genes in CCs associated with aneuploid
oocytes. SplA/ryanodine receptor domain and SOCS box containing 2 (SPSB2)
and putative quinone oxidoreductase (TP5313) were significantly downregulated
in CCs of aneuploid oocytes.

SPSB2 showed a positive but non-significant

correlation with live birth. If oocytes that lead to aneuploid embryos could be
identified using CC gene profiles it would be an asset to the embryologist. The
combined use of morphological endpoints with gene expression profiles may lead
to more precise prediction models.
All the previously discussed studies have examined the transcriptomes of
CCs or MGCs based on the various endpoints of interest. However, none of the
studies attempted to generate a predictive model for prospective embryo selection
based upon the gene expression profiles until Wathlet and coworkers (Wathlet et
al., 2011). This study examined 25 patients stimulated with GnRH antagonist with
rFSH and compared them to 20 patients stimulated with GnRH agonist with HPhMG. The causes of infertility were mixed with 10% idiopathic, 55% male factor
only, 19% combined male and female (3% PCOS, tubal 6%, endometriosis 10%),
and 16% endometriosis.

Multivariable stepwise regression analysis was

performed to develop several predictive models of embryo competence and
pregnancy. Better day 3 embryo quality prediction models included transient
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receptor potential cation channel subfamily M member 7 (TRPM7) and inositoltrisphosphate 3-kinase A (ITPKA), while pregnancy prediction models included
VCAN and SDC4. The best pregnancy prediction model had a sensitivity of 74%
and a specificity of 91%. It is worth noting that the strongest prediction models not
only included the CC gene transcription profiles, but also included other
parameters such as the number of COCs retrieved/gonadotropin dose and the
number of cells in day 3 embryos.
Wathlet and coworkers (Wathlet et al., 2012) performed a follow-up study
using a different set of genes. In this study, 11 genes in 99 CC masses from 33
patients were examined. The patient population was again mixed with 55% male
factor only, 9% female factor (endometriosis, ovulation disorder, and myomatosis),
male and female factor 12% (tubal and PCOS), and 24% idiopathic infertility. All
patients were stimulated with GnRH antagonist protocols with rFSH (Gonal-f or
Puregon). For all pregnancy and live birth analyzes only the transferred oocytes
were considered. The best live birth prediction model with gene expression utilized
calcium/calmodulin dependent protein kinase ID (CAMK1D), EFNB2, and
stanniocalcin 2(STC2). The full predictive model for live birth contained the same
genes as well as the days of stimulation. While VCAN was again assessed in this
study its gene expression did not differ between the pregnant and non-pregnant
patients. This may be due to the fact that the patient infertility diagnoses differed
between the two studies with respect to the proportion of each type of infertility as
PCOS and endometriosis have both been shown to alter the transcriptome as
mentioned previously.
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Building upon the two previous studies, a third study was conducted
validating the CAMK1D, EFNB2, and STC2 model and evaluating 9 additional
candidate genes (Wathlet et al., 2013). Also, for the first time, an intra-patient
model in relation to frozen/thawed embryos from the same patient was examined.
CC from 47 patients undergoing single ET and stimulated with GnRH antagonist
protocols were analyzed. Using just CAMK1D, EFNB2, and STC2 in the model,
an accuracy of 72% was obtained. Five of the 12 genes gave the best predictive
model and included EFNB2, glutathione peroxidase 3 (GPX3), glutathione Stransferase alpha 3 (GSTA3), glutathione S-transferase alpha 4 (GSTA4), and
progesterone receptor (PGR). The model gave a positive predictive value of 78%,
a negative predictive value of 83%, and an accuracy of 81%. Adding the days of
stimulation, relative serum estradiol, and age to the model increased all three
model endpoints to 93%. The receiver operating characteristic (ROC) curves for
the two models were 0.93 and 0.95. For intra-patient pregnancy prediction, the 5
gene predictive model was used since the patient characteristics were the same
in each patient. The model was able to correctly rank the embryos in 6 of 7
patients. These three studies taken together represent, as the authors state, a
“cascade” strategy for selecting candidate genes. The genes yielding the best
predictive model from one set of candidate genes are kept and the ones that do
not show any predictive value are discarded, then a new set of genes are tested
along with the predictive set and kept or discarded in the same way in order to
yield the best model.
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Iager and coworkers (Iager et al., 2013) conducted a retrospective study
between 3 different clinical sites to compare a pregnancy prediction model
accounting for patient and clinic variation. The endpoints for this study were
pregnancy and live birth. The training set revealed 1,180 differentially expressed
genes which were narrowed down to 227 genes in the validation set using
weighted voting analysis with a 97% prediction accuracy on the training set and
87% on the validation set. From the 227 predictive genes a custom TLDA with
196 genes was made. This array was used to further narrow the predictive gene
set down to 12 genes fibroblast growth factor 12 (FGF12), G protein-coupled
receptor 137B (GPR137B), solute carrier family 2 member 9 (SLC2A9), AT-rich
interaction domain 1B (ARID1B), nuclear receptor subfamily 2 group F member 6
(NR2F6), zinc finger protein 132 (ZNF132), COX20, cytochrome c oxidase
assembly factor (COX20), zinc finger protein 93 (ZNF93), rhomboid like 2
(RHBDL2), DnaJ heat shock protein family (Hsp40) member C15 (DNAJC15),
microtubule associated tumor suppressor 1 (MTUS1), and nucleoporin 133
(NUP133). This pregnancy prediction model resulted in an accuracy of 78% and
a ROC curve of 0.76.
By examining the previous published literature Ekart and coworkers (Ekart
et al., 2013) developed a ranking system for selection of mature oocytes that would
theoretically lead to pregnancy based on CC gene transcription.

In this

retrospective study, they selected an 8 gene panel, HAS2, follicle stimulating
hormone receptor (FSHR), solute carrier family 2 member 4 (SLC2A4), activated
leukocyte cell adhesion molecule (ALCAM), secreted frizzled related protein 2
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(SFRP2), VCAN, NRP1 and PGR based on prior published studies (McKenzie et
al., 2004, Gebhardt et al., 2011, Wathlet et al., 2011, Fragouli et al., 2012, Iager et
al., 2013) to predict the mature oocytes that would lead to live birth. Based on their
qRT-PCR results, it was determined that HAS2, FSHR, VCAN, and PGR would be
the best genes to rank the oocytes. If embryos had been chosen based on the
model from the four gene transcript levels, a single good blastocyst capable of
implantation for transfer would have been selected 76% of the time. As the authors
acknowledge, the method needs to be validated in a large unselected population
to assess its validity on a larger scale. This implies that an embryologist could
choose which oocytes to inseminate based on the gene expression of the CCs.
The difference in MGC and CC transcriptomes were analyzed to develop a
statistical classification system using a support vector machine algorithm to predict
live birth (Borup et al., 2016). Samples were collected from 60 women stimulated
with long GnRH agonist protocols. Sixteen individual CCs and their paired MGCs
which were associated with a live birth and embryo morphology-matched CCs and
their paired MGCs which failed to form a pregnancy were analyzed. In total 30
genes found in CCs were predictive of live birth with an accuracy of 81%, a positive
predictive value of 77%, a negative predictive value of 86%, and a ROC curve of
0.86. This model was further applied to three other data sets using blastocyst
formation as the endpoint and had a prediction accuracy of 62%, 75%, and 88%,
respectively. The genes included in the model were related to apoptosis and
extracellular matrix formation.
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In a recent study, the creation of a newer model of CC predictive genes was
prospectively analyzed in IVF patients (Adriaenssens et al., 2019).

Further

refining the previous works of Wathlet and colleagues, the researchers used three
genes in their model, EFNB2, CAMK1D, and SAM and SH3 domain containing 1
(SASH1). The researchers termed their model the “Corona Test”. The results of
the Corona Test were given to the embryologists 2 days following oocyte retrieval
and before ET on day 3. Patients with 2 or more high-quality embryos on day 3
had the embryo with the highest Corona Test rank transferred. This group (n=62)
was compared to 2 control groups with a matched single embryo transferred on
day 3 (n=62) and day 5 (n=44) without Corona Test results. The Corona Test
group had a clinical pregnancy rate of 63%, followed by day 5 at 43% and day 3
at 27%. Live birth rates were 55%, 39%, and 23% in each group, respectively.
The ROC analysis had an area under the curve (AUC) of 0.8081, implying it had
very good predictive accuracy. Subsequently, 26 frozen ETs were also analyzed
for those patients who did not get pregnant in the fresh Corona Test group. In that
analysis, the experimental group had a cumulative pregnancy rate (those who
were pregnant following the fresh or subsequent frozen ETs) of 78% in the Corona
Test group compared to 65% and 56% in the day 5 and day 3 controls,
respectively. The time to pregnancy from the first transfer until a successful
pregnancy was established was significantly reduced in the Corona Test group.
Corona Test scores were discordant compared to embryo morphology in 73% of
all embryos, which means that either that best-looking embryo was not the one
with the highest Corona Test score or that the Corona Test score differed between
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at least 2 embryos that were morphologically the same. This study demonstrates
the proposed utility of using CCs as putative biomarkers to select the best embryos
for transfer using non-invasive methods.
These above studies show that the use of several genes can generate
predictive models with good accuracy and ROC curves. It is also apparent that
the models are incomplete and need further testing. The addition of patient
characteristics to the models seems to improve the specificity as well. None of
these models, with the exception of the (Iager et al., 2013) study, have been
validated by an outside group to confirm the accuracy of the models across
different labs.
1.12

Mitochondria as Non-Invasive Biomarkers for IVF
Mitochondrial function and its relationship to human reproductive potential

is poorly understood, and further research needs to be conducted regarding oocyte
developmental competence and embryonic development. Studies have shown that
mature human oocytes contain more mtDNA than immature oocytes and more
mitochondria than other cells types in general. Mitochondria are abundant in GCs
as well (Ramalho-Santos et al., 2009). What differentiates high-quality oocytes
which will form high-quality embryos and lead to a live birth is not well understood,
and the molecular mechanisms remain to be elucidated. One potential explanation
includes deficient mitochondrial function (Bentov et al., 2011).
Embryos require large amounts of energy throughout the cleavage divisions
that occur during early embryogenesis; therefore, embryo viability may be related
to energy production via the mitochondria (May-Panloup et al., 2005a, Reynier et
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al., 2001, Zhao et al., 2010). Van Blerkom and associates demonstrated increased
ATP content in unfertilized oocytes was more likely to be associated with embryos
that displayed good development in the same cohort (Van Blerkom et al., 1995).
Mitochondrial content amplifies significantly within the oocyte during oogenesis
until ovulation (Figure 1.3). As the embryo undergoes cell division, each cell, also
called blastomere, should receive half of the amount of the mitochondria from that
starting pool. This means the number of mitochondria per blastomere decreases
as the amount of energy required by the embryo increases.

This inverse

relationship indicates oocytes with higher ATP production, and by association
higher mitochondrial content or better metabolism, will be more likely to develop
appropriately to the blastocyst stage when the mtDNA starts to replicate again
(May-Panloup et al., 2016, Chappel, 2013). This observation shows that mtDNA
copy number may be a good surrogate biomarker for embryo development (de Los
Santos et al., 2018, Diez-Juan et al., 2015, Fragouli et al., 2017, Fragouli et al.,
2015, Ravichandran et al., 2017). However, mtDNA copy number alone does not
account for how efficiently the mitochondria function.
Early mitochondrial studies in IVF examined mtDNA content in oocytes.
The average mtDNA content between individual oocytes varies in humans even
within the same patient (Reynier et al., 2001). However, it appears there are some
consistent observations, including lower mtDNA levels associated with oocytes
that fail to fertilize, AMA, and aneuploidy. Studies have demonstrated higher mean
mtDNA levels in fertilized human oocytes compared to both unfertilized oocytes
and degenerated oocytes (Reynier et al., 2001, Santos et al., 2006), although large
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variations were seen between individual oocytes and no threshold had been
established. Higher mtDNA levels were again seen in unfertilized oocytes and
embryos that failed to cleave in patients older than 40 years old (Murakoshi et al.,
2013).
Recent mitochondrial research in IVF has focused mtDNA content in
trophectoderm cells related to blastocyst development. In an elegant study by
Fragouli and colleagues, 379 trophectoderm biopsies from blastocysts were
examined by array comparative genomic hybridization (aCGH), RT-PCR, and NGS
(Fragouli et al., 2015). Euploid blastocysts compared to aneuploid blastocysts,
embryos from younger women compared to older women, and blastocysts that
implanted compared to blastocysts that did not implant all exhibited lower mtDNA
levels in trophectoderm cells. Additionally, the researchers established a predictive
threshold value and found that 30% of the euploid embryos that did not implant
were above the threshold value. Blastocysts which failed to implant, having higher
mtDNA levels in trophectoderm cells, were corroborated in a separate study (DiezJuan et al., 2015). In another retrospective study examining 1641 trophectoderm
biopsies from 402 patients, mtDNA levels in the trophectoderm biopsies were
higher in aneuploid embryos, embryos from patients with higher BMIs, lower P4
levels, and poor grade trophectoderm (de Los Santos et al., 2018). In another
blinded

retrospective

study

282

euploid

blastocysts

were

transferred

(Ravichandran et al., 2017). A total of 185 embryos with lower relative mtDNA
levels in trophectoderm cells resulted in pregnancies while 0 out of 33 embryos
with elevated mtDNA above the predicted threshold value failed to implant. This
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100% negative predictive value may indicate that mtDNA copy number in
trophectoderm cells may be a possible method to improve the odds of selecting
the most viable embryos. Finally, in a prospective blinded non-selection study,
199 euploid blastocysts were transferred, and mtDNA levels in trophectoderm cells
were analyzed. This study also showed a 100% negative predictive value with the
nine embryos with mtDNA content above the threshold level failing to produce a
pregnancy (Fragouli et al., 2017).
Other groups have refuted these observations.

Victor and associates

postulate the data of the above studies may be biased due to a lack of
mathematical corrections necessary to appropriately determine mtDNA copy
number in trophectoderm cells (Victor et al., 2017). When they retrospectively
analyzed 1396 trophectoderm biopsies, they found no difference in mtDNA
trophectoderm copy numbers based on age, ploidy status, or implantation.
Another retrospective study where PGT-A tested blastocysts were transferred in
pairs, showed no predictive value of mtDNA trophectoderm copy number indicating
the need for further analysis before being applied to make clinical decisions about
which embryos to transfer (Treff et al., 2017). In a retrospective study of 1510
trophectoderm biopsies from patients between 31 and 38 years old, poor quality
embryos exhibited higher mtDNA trophectoderm content overall, but when
reanalyzed only assessing euploid embryos, this predictive trend was abolished.
Additionally, mtDNA trophectoderm levels did not show differences in terms of
pregnancy or implantation (Klimczak et al., 2018). Most recently, a prospective
study of 109 trophectoderm biopsies from 100 IVF patients showed no differences
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in mtDNA levels between embryos that implanted and those that did not (Victor et
al., 2019).
It has been hypothesized that the mtDNA pool in CCs and MGCs are
responsible for proper oocyte maturation and that the mtDNA originating in oocytes
supports the early embryonic cleavage divisions making both key players in
ultimate embryo viability.

Evidence for this hypothesis has been shown with

correlations between oocyte and CC mtDNA content in IVF patients (Boucret et
al., 2015). Additionally, the presence of the mtDNA 4977 base pair deletion in
human CCs is associated with lower pregnancy rate (Tsai et al., 2010).
While lower mtDNA copy numbers were associated with better blastocyst
development and implantation as described above, in three separate studies,
increased mtDNA copy numbers in CCs have been shown to be associated with
embryos that developed into high- versus low-quality embryos and embryos more
likely to implant than those that did not implant.

Ogino and colleagues first

proposed using mtDNA in CCs as a biomarker and were also the first to
demonstrate increased mtDNA copy number in CCs using RT-PCR to determine
copy number in humans. In this prospective study, 60 individual COCs were
collected from women undergoing IVF.

They used a mtDNA copy number

threshold value of 86 to distinguish between good- and poor-quality embryos with
a positive predictive value of 84.4 and a negative predictive value of 82.1. The
mean values of good- and poor-quality embryos were 140 (25–75% quartile, 97–
264) and 57 (25–75% quartile, 34–74), respectively. In this study, there was no
difference in good and poor embryo development based on maternal age (Ogino
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et al., 2016). A larger study examined the mtDNA content in CCs by RT-PCR from
452 COCs from 62 patients undergoing IVF (Desquiret-Dumas et al., 2017).
Increased mtDNA copy number in CCs was associated with good- and poor-quality
embryos although there was a much larger interquartile range 738 (25-75%
quartile, 250–1228) and 342 (25-75%, quartile, 159–818) between this study and
the first study. Additionally, the patient’s with lower BMIs and those that were
smokers had higher CC mtDNA copy numbers. The third study from the same
group as the previous study, focused on mtDNA copy number in CCs relating to
implantation and ongoing pregnancy. 84 COCs were analyzed with RT-PCR from
71 patients undergoing IVF. Those embryos that implanted showed a significantly
higher mtDNA copy number in CCs than those that did not implant, independently
of other patient variables with means of 215 [sd 375] and 59 [sd 72], respectively
(Taugourdeau et al., 2019). Interestingly, while increased mtDNA copy numbers
in CCs have been associated with better embryo development and implantation
the inverse was seen in trophectoderm cells. It has been postulated that increased
mitochondria within a blastocyst may serve to compensate for reduced
mitochondrial energy dysfunction due to metabolic stress from ROS and free
radicals (Diez-Juan et al., 2015, Fragouli et al., 2015, Grindler and Moley, 2013,
May-Panloup et al., 2016).
1.13

Specific Aims
Infertility affected approximately 1 in 7 couples from 2015-2017 in the United

States, according to the Centers for Disease Control National Survey of Family
Growth (CDC, 2019). Many of these couples turn to IVF to treat this disease. It

63

has been estimated that less than 10% of all oocytes harvested during an IVF cycle
will produce a live a birth (Lemmen et al., 2016) and the odds of taking home a
child in the United States following IVF is only 30% per oocyte retrieval based on
data tracked by the SART (SART, 2019). Additionally, as a woman ages the
probability of taking home a baby from IVF drastically decreases. These statistics
indicate that current approaches of selecting embryos for uterine transfer are
insufficient, and newer methods for embryo selection are required. Since IVF
procedures have high costs, there is a critical need to identify the embryos with the
highest potential of leading to implantation and live birth as quickly as possible to
reduce IVF costs and offset the effects of advancing age with subsequent
procedures.
Our long-term goal is to create a panel of biomarkers that can help
embryologists quickly and easily select an embryo from a patient’s cohort
of embryos that has the best chance of implanting, leading to live birth, and
improving patients’ odds of success using IVF the first time. We hypothesize
that this can be accomplished using the cells which surround the oocytes during
follicular maturation.

Cumulus cells and mural granulosa cells collectively

comprise the granulosa cell pool. Granulosa cells are by-products harvested
during the oocyte retrieval in assisted reproduction procedures, and they closely
reflect the oocyte’s maturational status and developmental potential (Dumesic et
al., 2015).
Our objectives are to determine a set of non-invasive biomarkers in GCs
which identify the oocytes that will result in a live birth within a patient’s cohort of
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oocytes. In Aim 1, we will analyze several carefully selected mRNA biomarkers
in individual CC masses to determine if a single or panel of biomarkers can be
used to predict euploid embryos that will have the best odds of resulting in a live
birth. In Aim 2, we will examine the mitochondrial metabolic substrate utilization in
pooled granulosa cells and compare between patients based on age, serum AMH
levels, BMI, and number of mature oocytes retrieved per cohort, and embryo
cohort development. We will also examine selected mRNA biomarkers of interest
from Aim 1 and compare them within the same Aim 2 groups.
AIM1: To test the hypothesis that out of the group of selected cumulus
cell mRNA biomarkers there will be one or a panel that will allow selection of
the embryo with the highest odds of implanting and leading to live birth.
Levels of 19 mRNA biomarkers will be assessed via qRT-PCR and related to the
development of their corresponding individually cultured oocytes and subsequent
embryos, embryo ploidy status, and live birth outcomes.
AIM2: (A) To determine if mitochondrial function differs between
patients based on age, serum AMH levels, BMI, number of mature oocytes,
and embryo cohort development and (B) to determine of individual
substrates can be used as mitochondrial biomarkers for IVF. The rates of
mitochondrial metabolic substrate utilization by mitochondria in pooled CCs and
MGCs will be assessed and related to patient demographics including age, serum
AMH level, BMI, percent of mature oocytes, fertilization rate, day 3 embryo
development, blastocyst development, mitochondrial content, and mRNA levels of
selected genes.
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Successful identification of non-invasive biomarkers to select the most
competent oocytes will revolutionize the field of IVF. Once a panel is created that
faithfully identifies the oocytes with the best chance of success, an embryologist
would select the embryos with the best probability of resulting in live birth from the
cohort of embryos created.

This procedure would reduce the number of

procedures needed to have a viable pregnancy resulting in a live birth, increasing
the overall success IVF and reduce cost to the patient. In theory, an embryologist
may only need to inseminate a small number of oocytes from the cohort rather
than all of them. This change in procedure would prevent creation of excess
embryos and the moral dilemma of what to do with any extra unused embryos.
1.14

Innovation
Few studies have examined the link between CC mRNA levels and

oocyte/embryo ploidy status (Fragouli et al., 2010, Fragouli et al., 2012, Parks et
al., 2016, Green et al., 2018). Our study will employ a focused set of CC mRNA
biomarkers related to CC expansion and oocyte maturation, steroidogenesis, and
hormone modulation and signaling to determine if specific mRNA levels correlate
with oocyte maturity, abnormal embryo development, embryo ploidy status, and
live birth outcomes. Using data collected, we will create a model of specific CC
mRNA biomarker levels to identify a mature oocyte’s ability to produce euploid
embryos with best live birth potential.
Most studies of GC, oocyte, and embryo mitochondria have exclusively
evaluated mitochondrial copy numbers. These proposed studies will evaluate
GC mitochondrial activity in a novel way. This will be the first examination of a
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new mitochondrial function assay that has not previously been used to assess
mitochondrial substrates in GCs. It measures the rate of electron flow through
the electron transport chain from varying metabolic substrates that produce
NADH or FADH2. The goal will be to see how substrate utilization differs
between various patient groups. Additionally, we will examine fertilization rates,
day three embryo development, blastocyst development, and mRNA levels of
selected genes between the groups to see if one or more substrates can be used
for future individual CC biomarker screening purposes and improve IVF
outcomes.
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Figure 1.1. Midsagittal section of the female reproductive tract. Uterus-poster 3791876: freepik.com. This cover has
been designed using resources form Freepik.com.
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Figure 1.2. The ovary exhibiting different stages of follicular development. A random cross-sectional view as seen
here would exhibit follicles and corpora lutea at various stages from development from primordial follicles through corpus
albicans. Typically Graafian follicles, developing corpus luteum, and corpus luteym are not present in the ovary
concurrently but rather in succession (Marieb, 2016). Reprinted by permission of Pearson Education, Inc., New York,
New York.
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Figure 1.3. Mitochondrial biogenesis during oogenesis, folliculogenesis (F = Follicle, I primary, II pre-antral, III
antral) and early embryonic development in humans. During early maternal embryogenesis, the mtDNA content of
each embryonic cell undergoes a drastic reduction. This is followed, during oogenesis, by a restriction and amplification of
mtDNA content leading to a refreshed and purified mtDNA pool as illustrated in the bottleneck (green), quantitatively
sufficient for allocation among the embryonic blastomeres. The close relationship between the oocyte and the surrounding
cumulus cells appears to be important for the constitution of the oocyte mitochondrial pool (orange). Modified from (MayPanloup et al., 2016). Reprinted with permission.
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Figure 1.4. Follicular development. The diagram summarizes the process of ovarian follicle development and growth,
from oocyte nests present in the fetal ovary through follicle growth, ovulation and corpus luteum formation during
adulthood. Modified from (Hernandez-Ochoa et al., 2009). Reprinted with permission.
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Figure 1.5. The female hypothalamic–pituitary–gonadal axis. The hypothalamus produces and secretes gonadotropin
releasing hormone (GnRH) into a system of blood vessels that link the hypothalamus and the pituitary gland. GnRH
stimulates the pituitary gland by attaching to specific molecules (i.e., receptors). After the coupling of GnRH with these
receptors, a cascade of biochemical events causes the pituitary gland to produce and secrete two hormones, luteinizing
hormone (LH) and follicle–stimulating hormone (FSH). LH and FSH are two of a class of hormones commonly known as
gonadotropins. They are secreted into the general circulation and attach to receptors on the ovary, where they trigger
ovulation and stimulate ovarian production of the hormones estrogen and progesterone. These female hormones cause
monthly menstrual cycling and have multiple effects throughout the body. In particular, estrogen has profound effects on
the skeletal system and is crucial to maintaining normal bone health. Modified from (Emanuele et al., 2002).
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Figure 1.6. The human menstrual cycle. A typical human menstrual cycle lasts 28 days, with ovulation occurring at
midpoint, at day 14. The first day of vaginal bleeding is day 1. The first phase of the cycle is the follicular phase, during
which progesterone levels are very low, and estrogen levels start low and slowly increase. At approximately day 12,
estrogen levels peak, causing increased secretion of pituitary LH and FSH, with levels peaking on day 13-14. The LH
surge results in ovulation, and a transient drop in estrogen, and a new increase in progesterone levels. During the postovulation period, called the luteal phase, estrogen and progesterone levels first rise, then fall back to very low levels, at
which point the next menses starts. The progesterone scale is 1000-fold higher than the estrogen scale. Modified from
(Emanuele et al., 2002).
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Figure 1.7. The two-cell, two-gonadotropin theory of follicular conversion of cholesterol to steroid hormones.
Free cholesterol is deposited into theca cells by low-density lipoprotein (LDL) receptor-mediated LDL endocytosis. The
conversion of cholesterol to pregnenolone by CYP11A1 in the inner membrane of the mitochondria is initiated by the
binding of luteinizing hormone (LH) to the luteinizing hormone receptor (LHR). Pregnenolone is converted to
dehydroepiandrosterone (DHEA) by CYP17A1 in the endoplasmic reticulum (ER). DHEA is converted to androstenedione
by HSD3B1. Androstenedione diffuses across the basement membrane to the granulosa cells (GCs). Finally,
androstenedione is converted to estradiol (E2) by aromatase (CYP19A1) which is initiated by the binding of folliclestimulating hormone (FSH) to the follicle-stimulating hormone receptor (FSHR). (Black solid line arrows: synthesis step;
blue solid line arrow with + symbol: activation; dotted line arrows: transfer step). Modified from (Hebert-Schuster et al.,
2018). Reprinted with permission.
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Figure 1.8. Metabolic cooperativity between oocytes and cumulus cells, and the role of oocyte-derived paracrine
factors in promoting metabolism in cumulus cells. Oocytes are deficient in metabolizing glucose by glycolysis,
synthesizing cholesterol from acetate and taking up alanine directly, as compared with cumulus cells. Oocytes obtain
products of the glycolysis (e.g., pyruvate) and cholesterol biosynthesis (e.g., cholesterol) pathway, as well as alanine from
cumulus cells. Oocytes, via secreting paracrine factors, promote these metabolic processes in cumulus cells by promoting
the expression of transcripts encoding key enzymes in the corresponding pathways, as well as the expression Slc38a3
encoding an amino acid transporter for L-alanine. GDF9 and BMP15 are involved in promoting cholesterol biosynthesis in
cumulus cells, while cooperation between BMP15 and FGFs are required for promoting glycolysis. Which oocyte-derived
paracrine factor(s) participate in the induction of Slc38a3 expression, as well as L-alanine uptake by cumulus cells are
unknown. (Su et al., 2009). Reprinted with permission.
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Figure 1.9. Mitochondrial metabolism. Glucose breakdown through glycolysis and the tricarboxylic acid cycle (dark
blue) generates reduced NADH and FADH2. Fatty acid β-oxidation (FAO, light blue) of fatty acyl-CoA esters is performed
in four enzymatic reactions that also generate NADH and FADH2, as well as acetyl-CoA. Electrons derived from NADH
and FADH2 are utilized by the five OXPHOS complexes (green) to generate ATP. Complex I (CI, NADH: ubiquinone
oxidoreductase), complex III (CIII, ubiquinol: ferricytochrome c oxidoreductase) and complex IV (CIV, cytochrome c
oxidase) pump electrons out of the mitochondrial matrix to generate a membrane potential (Δψm) that drives the synthesis
of ATP by complex V (CV, FoF1-ATP synthetase). CII, complex II (succinate: ubiquinone oxidoreductase). (Nsiah-Sefaa
and McKenzie, 2016). Reprinted with permission.
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Figure 1.10. Prevalence of aneuploidy in human women. The prevalence of aneuploidy relative to the age of the
female partner demonstrates the lowest risk in women from their middle to late twenties, with significantly higher rates in
embryos obtained from both younger and older women (P<1*10−6). The relationship between age and the rate of
aneuploidy is a best fit at the 5th degree polynomial (regression line shown). Modified from (Franasiak et al., 2014).
Reprinted with permission.

CHAPTER 2
Materials and Methods
2.1 Ethical Approval
These studies were approved by the University of South Carolina Institutional
Review Board (IRB registration number: 00000240) and Greenville Health System
Institutional Review Board (IRB number: Pro00072006).
2.2 Patient Controlled Ovarian Stimulation and Granulosa Cell Harvest
Granulosa cells were harvested from patients undergoing infertility treatment
at Advanced Fertility and Reproductive Endocrinology Institute (Columbia, SC,
USA) and Fertility Center of the Carolinas (Greenville, SC, USA).

Patient

demographics, cycle information, pregnancy, and live birth data were collected.
Each patient’s ovaries were stimulated using either a long luteal protocol or an
antagonist controlled ovarian stimulation protocol. In the antagonist cycles, when
one follicle reached at least 13 mm or the patient’s estradiol level reached 300
IU/mL, a GnRH antagonist (Cetrotide, EMD-Serono, Rockland, MA, USA or
Ganirelix, EMD-Serono, Rockland, MA, USA) was administered. In both protocols,
when 2-3 follicles reach >17 mm by ultrasound an ovulatory dose of hCG (Pregnyl,
EMD-Serono, Rockland, MA, USA) or Lupron (Leuprolide Acetate, Sandoz,
Princeton, NJ, USA) was delivered.

Thirty-six hrs later, the patient’s oocyte

retrieval was performed by a physician.

Each CC mass was mechanically

separated from its oocyte and rinsed in sperm wash medium (FUJIFILM Irvine
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Scientific, Santa Ana, CA, USA), a medium containing 21 mM N-2Hydroxyethylpiperazine-N’-2- ethanesulfonic acid (HEPES) and 4 mM sodium
bicarbonate buffered modified human tubal fluid (HTF) and 5 mg/ mL human serum
albumin to remove debris. For the PGT-A related studies, each CC mass and its
associated oocyte/embryo were kept separate throughout the entire process.
Cumulus cell masses were snap-frozen and maintained in liquid nitrogen (LN2)
until they were transported from the clinics to the University of South Carolina
School of Medicine where they were stored in a freezer at -70°C until use. For the
mitochondrial function assay associated RT-PCR, the CCs and MGCs were pooled
together, and an aliquot of GCs were placed in RNAlater solution, (Life
Technologies, Carlsbad, CA, USA) cooled for 24 hrs at 4°C, snap-frozen and
handled as above.
2.3 Embryo culture and ploidy assessment
Mature oocytes were inseminated via ICSI. Fertilization was confirmed by
the presence of two pronuclei and two polar bodies 16-18 hrs after insemination.
Embryos for the PGT-A studies were individually cultured in 20 µL LifeGlobal®
global total media drops (Cooper Surgical, Trumbull, CT, USA) under oil (Ovoil,
Vitrolife, Englewood, CO, USA) at 37°C, 6% CO2, 5% O2, 89% N2 in a humidified
atmosphere until day 5 or day 6 post retrieval. For PGT-A related studies, embryo
morphologies were assessed using Gardner’s blastocyst grading (Gardner et al.,
2000), and 3-7 trophectoderm cells were biopsied and sent to Igenomix (Miami,
FL, USA) for genetic testing using NGS. Frozen embryo transfers were performed
using the highest quality euploid embryos. Live birth outcomes were obtained from
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the patient’s obstetrician, including delivery dates, gender, and if there were any
maternal or neonatal interventions or complications. For mitochondrial related
studies, embryos were group cultured in 50 µL LifeGlobal® global total media
drops (Cooper Surgical) under oil (Vitrolife) at 37°C, 6% CO2, 5% O2, 89% N2 in a
humidified atmosphere until day 5 or day 6 post retrieval. Embryo morphologies
were assessed using the American Society for Reproductive Medicine (ASRM)
(Racowsky et al., 2010) criteria for day 3 embryos and day 5/6 blastocysts.
2.4 RNA Isolation and cDNA synthesis
RNA was isolated from each CC sample or pooled CC/MGC samples using
the Direct-zol MiniPrep Kit with DNase treatment (Zymo Research, Irvine, CA,
USA) following the manufacturer’s instructions. Samples were removed from
storage at -70°C and Ribozol (600-1000 μL) was added to each sample and
incubated 5 min at room temperature (RT) to lyse cells. Lysates were transferred
to clean RNase/DNase free microcentrifuge tubes. A 1:1 volume of 95-100%
ethanol was added to tubes containing the Ribozol lysates and vortexed. Samples
were loaded into Directzol spin columns and centrifuged at 15,000xg for 1 min in
a refrigerated microfuge (Eppendorf, Hauppauge, NY, USA).

Each spin was

performed at 15,000xg in the same microfuge throughout this protocol. The flowthrough was discarded. Each spin column was placed into a clean RNase/DNase
free tube and 400 μL of RNA wash buffer was added into each column and
centrifuged for 1 min. The flow-through was discarded. An 80 μL DNase mixture
containing DNase, 1X DNase reaction buffer, and kit water was added into each
column and incubated 15 min at room temperature. The columns were centrifuged
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for 30 seconds and 400 μL RNA pre-wash buffer was added to the columns and
they were centrifuged for an additional 1 min. The flow-through was discarded.
Another 400 μL RNA pre-wash buffer was added and then centrifuged again, and
the flow-through was discarded. A total of 700 μL RNA wash buffer was added to
each column, centrifuged for 1 min, and the flow-through was discarded. Columns
were centrifuged for another 2 min in order to dry the columns. Each column was
transferred to a new RNase/DNase-free tube. 50μL RNase/DNase-free kit water
was added to the columns for the pooled samples and 30 μL were added for the
individual samples, and incubated at RT for 5 min. The columns were centrifuged
for 2 min to elute RNA, and then kept on ice for immediate use or stored at -70°C.
The RNA concentration and purity of individual CC masses was assessed at the
wavelengths of 260 and 280 nm using a spectrophotometer with a 2 mm lid
(NanoDrop 2000C, Thermo Scientific, Waltham, MA, USA). RNA concentration
and purity for pooled samples were assessed at the wavelengths of 260 and 280
nm using a Biophotometer 6131 spectrophotometer (Eppendorf).
2.5 DNA Isolation
DNA was isolated from pooled GCs using the Direct-zol MiniPrep Kit as
described above but omitting the DNase treatment step (Zymo Research). DNA
concentration and purity were assessed at the wavelengths of 260 and 280 nm
using a Biophotometer 6131 (Eppendorf).
2.6 cDNA synthesis
Each sample was reverse transcribed into cDNA using the iScript kit (BioRad Laboratories, Hercules, CA, USA). RNA (15 μL), 4 μL of 5X iScript reaction
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mix, and 1 μL of iScript Reverse Transcriptase enzyme were combined on ice,
vortexed and pulsed down. Samples were allowed to sit for 2 min at RT before
starting the program. The reverse transcription reaction was carried out in a
thermocycler (Eppendorf), for 5 min at 25°C, 30 min at 42°C, and 5 min at 85°C.
After cDNA synthesis, each sample of the cDNA was diluted with DNase/RNasefree water and stored at -20°C for subsequent qRT-PCR.
2.7 Quantitative Real-Time PCR
Synthesized primers were cartridge purified (Life Technologies). Primers
included: AMH, AREG, CALM1, CYP11A1, CYP19A1, FSHR, GJA4, GREM1,
HSD3B1, insulin-like growth factor 2 (IGF2), IGFBP5, inhibitor of growth protein 1
(ING1), inhibin beta A subunit (INHBA), LHCGR, mitochondrially encoded ATP
synthase 8 (MT-ATP8), pappalysin-1 (PAPPA), PGR, PGRMC1, PTGS2,
steroidogenic acute regulatory protein (STARD1), and VCAN. Primer sets may be
found in Tables 3.2 and 4.3. Real-time PCR reactions were run with 2 or more
wells per sample for 40-45 cycles and threshold cycle (Ct) values were averaged.
The reactions included between 5-27 ng starting cDNA, 300 nM of each upstream
and downstream primer, and 10 µL 2X SsoAdvanced Universal SYBR Green
Supermix (Bio-Rad Laboratories) and sterilized PCR-grade water to a final volume
to 20 µL per well. PCR-grade water was substituted for the cDNA as a negative
control. PCR amplification was performed using the iCycler iQ Real-Time PCR
Detection System (Bio-Rad Laboratories). TATA-box binding protein (TBP) mRNA
was used as an internal control for cDNA samples (Nelson-Degrave et al., 2005)
and actin beta (ACTB) DNA was used as an internal control for nuclear DNA
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(nDNA) samples (Diez-Juan et al., 2015).

Primer efficiency curves were

determined on all amplicons. Single amplicons of the correct size were verified
using agarose gels and by the presence of single melt-curve peaks. All primers
not previously reported in the literature had their amplicons sequenced. mRNA
and nDNA quantities were derived from a standard curve for each transcript using
serial dilutions of its purified amplicon. TBP has extensively been tested as a
control gene in our laboratory with human GCs under multiple conditions and
treatments and has not been found to be regulated under any circumstances.
Target mRNA values were expressed relative to values of the TBP mRNA control.
2.8 Quantification of mtDNA
Relative amounts of mtDNA and nDNA and were determined by qRT-PCR.
The nuclear gene ACTB was selected as a reference gene to calculate mDNA
content and the mtDNA gene MT-ATP-8 was used to quantify mitochondrial
genome content. The ratio of mtDNA:(2x nDNA) was used to determine mtDNA
content.
2.9 Analysis of Mitochondrial Metabolic Substrates
Cumulus cells from each patient were rinsed in sperm washing medium
(FUJIFILM Irvine Scientific) following oocyte retrieval and placed in a 5 mL tube.
Follicular fluid containing MGCs from each patient was split between 50 mL tubes
and centrifuged for 15 min at 300xg. Each spin was performed at 300xg in the
same centrifuge throughout this protocol. Follicular fluid was decanted from the
tubes and a filtered solution of hyaluronidase (50 mg/mL) from bovine testes
(Sigma, Raleigh, NC, USA) was added to each MGC pellet and the CC tube and

89

incubated at 37°C for 10 min to remove cell clumps. Calcium/magnesium-free
phosphate-buffered saline (PBS) (Gibco, Gaithersburg, MD, USA) was added to
bring the pellet to ≥4 mL. Mural granulosa cells were layered on top of 35% over
70% Percoll solutions in 15 mL tubes and centrifuged for 30 min. A 30 µL assay
mix containing 2x Biolog Mitochondrial Assay Solution (MAS) (Biolog, Hayward,
CA, USA), 6x Redox Dye (Biolog), 24x saponin (90 µg/mL) for permeabilization
(Alfa Aesar, Ward Hill, MA, USA), and sterile water was added to each well of the
96-well MitoPlate S-1 plates (Biolog) to incubate for 1 hour. Mural granulosa cells
were partitioned into 1 or 2 bands with the blood pelleting to the bottom of the
tubes.

The upper band containing purified MGCs was removed, 25 mL of

calcium/magnesium-free PBS (Gibco) and the CCs were combined. The mixture
was poured through a 70-micron strainer. Pooled GCs were centrifuged for 20
min. The supernatant was decanted, and the pellet was resuspended in 1x MAS
buffer (Biolog) to 2 mL. The GC/MAS mixture (0.5 mL) was removed and a 10 µL
sample was counted on a hemocytometer. The remaining aliquot was centrifuged
for 5 min. The supernatant was decanted and the pellet was placed in 0.5 mL
RNAlater solution (Life Technologies), stored at 4°C for 24 hrs, and snap-frozen in
LN2 until it was transported to the University of South Carolina School of Medicine
for further processing. The remaining 1.5 mL GC/MAS mixture was diluted to 3.0
mL with 1x Biolog MAS and a 10 µL sample was counted with a hemocytometer
and averaged with the first cell count to determine the total cells in each sample.
After 1 hr incubation, 30 µL of the GC/MAS suspension was added to each well of
the MitoPlate S-1 plate.

Permeabilized cells were assayed in triplicate for
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mitochondrial activity using MitoPlate S-1 plates. The plates contained 31
cytoplasmic and mitochondrial metabolic substrates. Metabolism of substrates
was assessed by a colorimetric change of a terminal electron acceptor tetrazolium
redox dye at a wavelength of 590 nm read every 2.5 min for 50 cycles on a kinetic
plate reader. Results were normalized to mtDNA copy number per sample and
the negative control wells containing GC/MAS and assay mix without any
additional substrates and positive control wells containing GC/MAS and assay mix
with succinic acid.

Slope ratio = [Slope (sample) – Slope (negative control)] /

[Slope (positive control) – Slope (negative control)].
2.9 Statistics
Real-time PCR reactions were run with 2 or more wells per sample for 40-45 cycles
and threshold cycle (Ct) values were averaged. The mRNAs were normalized
against internal controls as described above. Statistical analysis of the results was
performed using generalized linear mixed models (GLMMs) fitted by maximum
likelihood using the R package lme4 (Bates et al., 2015). Substrates on in the
mitochondrial function assay were run in triplicate on the same plate along with a
negative control and a positive control. The slopes of the kinetic curves were
averaged.

Multiple linear regression models were estimated to predict the

normalized average rate of each substrate’s metabolism and mitochondrial
metabolic score using Box-Cox transformation for normality (Box and Cox, 1964).
Statistical analysis was performed using the statistical analysis environment R
3.6.2 (R Core Team, 2019).
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Chapter 3
Cumulus cell Pappalysin-1, Luteinizing Hormone/ Choriogonadotropin
Receptor, Amphiregulin and Hydroxy-delta-5-steroid dehydrogenase,
3 beta- and steroid delta-isomerase 1 mRNA levels associate with
oocyte developmental competence and embryo outcomes3

________________________________________________________________
3R.J.

Kordus, A. Hossain, M.C. Corso, H. Chakarborty, G.F. Whitman-Elia, and
H.A Lavoie.
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3.1 Abstract
3.1.1 Purpose: To determine whether a selected set of mRNA biomarkers
expressed in individual cumulus granulosa cell (CC) masses show association with
oocyte developmental competence, embryo ploidy status, and embryo outcomes.
3.1.2 Methods: This prospective observational cohort pilot study assessed levels
of mRNA biomarkers in 163 individual CC samples from 15 women stimulated in
antagonist cycles. Nineteen mRNA biomarker levels were measured by real-time
PCR and related to the development of their corresponding individually cultured
oocytes and subsequent embryos, embryo ploidy status, and live birth outcomes.
3.1.3 Results: PAPPA mRNA levels were significantly higher in CC from oocytes
that led to euploid embryos resulting in live births and aneuploid embryos
compared to immature oocytes by ANOVA.

LHCGR mRNA levels were

significantly higher in CC of oocytes resulting in embryos associated with live birth
compared to immature oocytes and oocytes resulting in arrested embryos by
ANOVA. Using a General Linearized Mixed Model to assess ploidy status, CC
HSD3B1 mRNA levels in oocytes producing euploid embryos were significantly
lower than other oocyte outcomes, collectively. When transferred euploid embryos
outcomes were analyzed by ANOVA, AREG mRNA levels were significantly lower
and PAPPA mRNA levels significantly higher in CC from oocytes that produced
live births compared to transferred embryos that did not form a pregnancy.
3.1.4 Conclusions: Collectively, PAPPA, LHCGR, and AREG mRNA levels in CC
may be able to identify oocytes with the best odds of resulting in a live birth, and
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HSD3B1 mRNA levels may be able to identify oocytes capable of producing
euploid embryos.
3.1.5 Key Words: cumulus cells, real-time PCR, mRNA levels, oocyte
developmental competence, euploid embryo
3.2 Introduction
Successful in vitro fertilization (IVF) is highly dependent upon the quality of
the oocytes harvested and the subsequent quality of embryos used for uterine
transfer (Uyar et al., 2013).

Several studies have shown that use of

preimplantation genetic testing for aneuploidy (PGT-A) to select euploid embryos
for uterine transfer increases implantation, ongoing pregnancy, and delivery rates
(Chen et al., 2015a, Yang et al., 2012, Scott et al., 2013), whereas other studies
showed PGT-A decreased pregnancy rates (Kushnir et al., 2016, Chang et al.,
2016).

Conflicting PGT-A findings might indicate that other methods beyond

genetic screening are needed to improve IVF pregnancy rates. The differing PGTA study results may also reflect the invasive methodology of PGT-A, which
requires the removal of 3-10 cells from the trophectoderm. Increased numbers of
trophectoderm cells per biopsy have been correlated with decreased implantation
rates (Zhang et al., 2016). Therefore, a method for identifying oocytes that will
produce euploid embryos with the greatest chances of leading to a live birth that
does not require embryo manipulation would be advantageous.
Some non-invasive methods for assessing oocyte and embryo live birth
potential include preimplantation embryo metabolomics and proteomics of
secreted products (Uyar and Seli, 2014, Nel-Themaat and Nagy, 2011) and
granulosa cell (GC) mRNA biomarkers (Kordus and LaVoie, 2017). The use of
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GC biomarkers is based on knowledge that cumulus granulosa cells (CCs) and
mural granulosa cells (MGCs) interact with oocytes and can reflect the health and
maturational status of the oocyte (Tanghe et al., 2002, Uyar et al., 2013). GCs are
obtained as a by-product of oocyte retrieval and can be rapidly assessed for mRNA
levels by reverse transcription and quantitative polymerase chain reaction (PCR).
Several studies suggest that CC biomarker mRNA levels from individual oocytes
can be used to generate models capable of predicting pregnancy and live birth
(Ekart et al., 2013, Iager et al., 2013, Wathlet et al., 2011).
Approaches to evaluate differentially expressed genes in CCs have
employed large-scale microarray, transcriptome deep sequencing, PCR arrays
and quantitative PCR (Kordus and LaVoie, 2017). In most cases the ploidy status
of the embryos was not known, which could have altered the study outcomes. Only
a handful of studies have examined CC mRNA levels in conjunction with oocyte or
embryo ploidy status (Fragouli et al., 2012, Parks et al., 2016, Green et al., 2018).
Taken together, a focused quantitative PCR analysis of CC target genes selected
from prior studies combined with the ploidy status of the embryos should yield
valuable information regarding mRNA biomarker usefulness in predicting live birth.
Many oocytes fail to fertilize, or when fertilized, arrest before reaching the
blastocyst stage, or fail to develop into euploid blastocysts. We hypothesize that
while many mature oocytes appear morphologically normal, the actual
developmental competence of those oocytes is variable, and will be reflected by
varying mRNA levels of specific biomarkers in their associated CCs. Furthermore,
we propose that a CC mRNA biomarker model could potentially indicate whether
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a mature oocyte, when fertilized, will result in a euploid embryo. In addition, we
hypothesize that certain CC mRNA biomarkers and their levels will associate with
oocytes that are capable of producing viable embryos which result in live births.
A comprehensive review of the human literature for potential CC candidate
mRNA biomarkers was performed (Kordus and LaVoie, 2017), and genes were
selected based on their functions. In some cases, the genes selected were based
on data in non-human animals (Christenson et al., 2013, Vigone et al., 2013, Assidi
et al., 2008, Blaha et al., 2015, Nivet et al., 2013, Saini et al., 2015, Glister et al.,
2010). Gene products associated with oocyte maturation included calmodulin 1
(CALM1), gap junction alpha-4 protein (GJA4), gremlin (GREM1), and inhibitor of
growth protein 1 (ING1).

Genes associated with cumulus mass expansion

included amphiregulin (AREG), prostaglandin-endoperoxide synthase 2 (PTGS2),
and versican (VCAN).

Genes encoding proteins mediating de novo

steroidogenesis, estrogen, and progesterone production included aromatase
(CYP19A1), cholesterol side-chain cleavage enzyme (CYP11A1), hydroxy-delta5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 1 (HSD3B1), and
steroidogenic acute regulatory protein (STARD1). Genes related to hormone
modulation included insulin-like growth factor 2 (IGF2), insulin-like growth factorbinding protein 5 (IGFBP5), and inhibin beta A subunit (INHBA), and pappalysin-1
(PAPPA).

Gene encoding hormone receptors included follicle-stimulating

hormone receptor (FSHR), luteinizing hormone/choriogonadotropin receptor
(LHCGR), progesterone receptor (PGR), and progesterone receptor, membrane
component 1 (PGRMC1). The primary goal of this study was to determine if a
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model of specific CC mRNA biomarker levels could identify a mature oocyte’s
ability to produce euploid embryos. The secondary goal of this study was to
determine if specific CC mRNA biomarker levels could indicate oocytes capable of
leading to euploid embryos with live birth outcomes.
3.3 Materials and methods
3.3.1 Study population, participants, and CC isolation
This study is a prospective observational cohort pilot study. In total, 164
individual CC masses were harvested from their corresponding oocytes from 15
patients undergoing infertility treatment with PGT-A at Advanced Fertility and
Reproductive Endocrinology Institute (Columbia, SC, USA) from February 2015
through June 2016.

Patient’s either electively desired PGT-A or it was

recommended based on the patient’s diagnosis (Table 3.1).

Patients with

endometriosis or diminished ovarian reserve (DOR) were not included as prior
work indicates these conditions alter GC gene expression (Greenseid et al., 2011,
May-Panloup et al., 2012, Allegra et al., 2014, Barcelos et al., 2015). Patient
demographics and cycle information (Table 3.1), blastocyst development, PGT-A
results, and live birth data (Supplemental Table 3.1), as well as CC mRNA levels
were collected.

Each patient’s ovaries were stimulated using an antagonist

protocol until at least one follicle at 15 mm was present when a GnRH antagonist
(Cetrotide, EMD-Serono, USA or Ganirelix, EMD-Serono, USA) was administered.
When two follicles reached 18 mm or 50% of the follicles were ≥ 15 mm by
ultrasound, an ovulatory dose of human chorionic gonadotropin (hCG) (Pregnyl,
EMD-Serono, USA) or Lupron (Leuprolide Acetate, Sandoz, USA) was delivered.
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Thirty-six hrs later patients underwent oocyte retrieval.

Each CC mass was

mechanically separated from its oocyte and rinsed in HTF-HEPES, medium (Irvine,
USA) to remove debris. Each CC mass and its associated oocyte/embryo were
kept separate throughout the entire process. A summary flowchart of the fate of
the collected oocytes is shown in Figure 3.1. CC masses were snap frozen and
maintained in LN2 until they were transported to the University of South Carolina
School of Medicine for further processing.
3.3.2 Embryo culture and ploidy assessment
Mature oocytes were inseminated via intracytoplasmic sperm injection.
Fertilization was confirmed by the presence of two pronuclei and two polar bodies
16-18 h after insemination. Oocytes and embryos were individually cultured in 20
µL media drops (Global total, Global, USA) under oil (Ovoil, Vitrolife, USA) at 37°C,
6% CO2, 5% O2, 89% N2 in a humidified atmosphere until day 5 or day 6 post
retrieval. Blastocyst morphologies were assessed using Gardner’s blastocyst
grading scale (Gardner et al., 2000), and 3-7 trophectoderm cells were biopsied
and sent to Igenomix (Miami, FL, USA) for PGT-A using NGS. Fifteen FETs were
performed using the highest quality euploid embryos (19 embryos total) for each
patient. Live birth outcomes were obtained from the patient’s obstetrician including
delivery dates and if there were any maternal or neonatal interventions or
complications.
3.3.3 RNA Isolation and cDNA synthesis
RNA was isolated from each CC mass using the Direct-zol MiniPrep Kit with
DNase treatment (Zymo Research, Irvine, CA, USA). RNA concentration and
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purity were assessed at the wavelengths of 260 and 280 nm using a
spectrophotometer with a 2 mm lid (NanoDrop 2000C, Thermo Scientific, USA).
Sample amounts varied between 80 and 360 ng RNA per individual sample. Each
sample was reverse transcribed into cDNA using the Bio-Rad iScript kit (Hercules,
CA, USA). The reverse transcription reaction was carried out in an Eppendorf
thermocycler, for 5 min at 25C, 30 min at 42C, and 5 min at 85C.
3.3.4 Quantitative Real-Time PCR
Gene primer sequences, annealing temperatures, and amplicon sizes can
be found in Table 3.2.

Synthesized primers were cartridge purified (Life

Technologies, Carlsbad, CA, USA). PCR reactions were run with two or more
wells per sample for 45 cycles and threshold cycle (Ct) values were averaged. The
reaction included 2 µL of cDNA (6-27 ng starting RNA), 300 nM of each upstream
and downstream primer, and 10 µL 2X SsoAdvanced Universal SYBR Green
Supermix (Bio-Rad Laboratories, Hercules, CA, USA) and sterilized PCR-grade
water to a final volume to 20 L per well. PCR-grade water was substituted for the
cDNA as a negative control. PCR amplification was performed using the iCycler
iQ Real-Time PCR Detection System (Bio-Rad, USA). TATA-box binding protein
(TBP) mRNA was used as an internal control (Nelson-Degrave et al., 2005).
Single amplicons of correct size were verified using agarose gels and by the
presence of single melt-curve peaks.

mRNA quantities were derived from a

standard curve for each mRNA made using serial dilutions of its purified amplicon.
TBP has extensively been tested as a control gene in our laboratory with human
granulosa cells under multiple conditions or treatments and has been found not to
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be regulated under any circumstances. Target mRNA values were expressed
relative to values of the TBP mRNA control.
3.3.5 Statistical analysis
The mRNA levels were normalized using log2 transformation. Principal
Component Analysis (PCA) was conducted to explore the mRNA level correlation
patterns between the CC samples. CC mRNA levels were compared between
different oocyte and subsequent embryo developmental outcomes using repeated
measures analysis of variance (ANOVA) to accommodate for the variable number
of oocytes per patient followed by Tukey’s post hoc tests for pairwise comparisons.
The CC samples used for these studies were divided into the following categories:
Immature oocytes, mature oocytes that failed fertilization, oocytes that produced
embryos that arrested and were not appropriate for biopsy, oocytes that produced
biopsied blastocysts that were aneuploid, and oocytes that produced biopsied
blastocysts that were euploid.

Oocytes that produced euploid embryos were

further subdivided into embryos that resulted in live birth, embryos that resulted in
a negative pregnancy, and embryos that were vitrified and not transferred. Each
figure states which categories were used for the specific statistical analysis.
3.3.6 Statistical models
Models

were

estimated

to

predict

multiple

dichotomous

oocyte

developmental outcomes using generalized linear mixed models (GLMMs) fitted
by maximum likelihood using the R package lme4 (Bates et al., 2015). The
GLMMs included the normalized gene expressions as variables and used patients’
demographics (age and body mass index (BMI) as controlling factors and adjusted
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for two ovulation induction or trigger medications).

Unstructured correlation

patterns were used in fitted GLMMs to capture the correlation among the repeated
observations from same individual. The statistical models aimed to include as
many patients as possible. However, some of the genes had high proportion of
missing values for some patients because of limited RNA amounts that were
obtained from CC masses. To ensure maximum utilization of the data we started
the modeling by including all the genes and proceeded backward dropping the
genes one-by-one with highest proportion of missing observations until the fitted
mixed-effects model attained computational convergence successfully. Since
different patients had missing observations on different genes, exclusion of the
missing values eventually reduced the number of patients and number of
observations in the sample used to fit the model. The analysis sample size differed
from model-to-model (for different response variables) as the maximum possible
data points were used for a model to converge. Statistical significance in all
analyses was determined at a 0.05 significance level. All the inference P-values
were reported after adjusting for multiple comparisons (Hothorn et al., 2008). The
predictive performances of the fitted models were assessed using Receiver
Operating Characteristics (ROC) curves and Area Under ROC Curves (AUC). The
AUC values of the models used in this study ranged from 0.75 to 1.00 implying the
models exhibited good/very good to excellent predictive accuracy.

Statistical

analysis

R

was

performed

using

the

(http://www.r.project.org/).
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statistical

software

3.4.4

3.4 Results
In total, 164 CCs were harvested from 15 patients undergoing infertility
treatment with PGT-A. Fifteen FETs were performed after PGT-A results were
obtained.

Eleven patients had single embryo transfers and four had double

embryo transfers. In the four cases where two embryos were selected, one embryo
of each gender was transferred. Eight patients gave birth to nine healthy children
with no complications. 163 of 164 CC samples (n=15 patients) analyzed contained
a sufficient amount of RNA to detect the endogenous control house-keeping gene,
TBP. Due to limited starting sample RNA amounts, not all samples were able to
be tested for each biomarker and the variations in sample size are noted in figures.
PCA was utilized to test the hypothesis that several of the CC genes we
examined would be correlated with one another. The correlations of the CC mRNA
levels of 151 observations from 14 patients were examined by creating a biplot
within the multivariable dataset that contained the most biomarkers and individual
patient observations that fit the model (Figure 3.2). The biplot is based on the first
and second principal components (PC1 and PC2) of the log2-transformed mRNA
levels of each individual CC mass. PC1 and PC2 explain 35.7% and 22.9% of the
variability of the model, respectively. All genes shown were positively correlated
to PC1. HSD3B1, IGFBP5, PAPPA, and PGR were all positively correlated with
PC2 while CYP11A1, CYP19A1, and INHBA are negatively correlated with PC2.
In addition, a significant (P < 0.001) strong positive correlation was observed
between CYP19A1 and CYP11A1 (r = .68), and significant (P < 0.001) moderate
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positive correlations were observed for PGR and HSD3B (r = .59), CYP11A1 and
INHBA (r = .50), PGR and IGFBP5 (r = .41), and PAPPA and INHBA (r = .41).
We next wanted to test the hypothesis that the CC mRNA levels of the
selected genes would vary by oocyte developmental competence and resulting
embryo endpoint. To test this hypothesis, we analyzed all the CC mRNA level
data by the resulting developmental outcome for each group of oocytes by
repeated measures ANOVA followed by Tukey’s post hoc test (adjusted P-values).
PAPPA mRNA levels in CCs were higher in oocytes that resulted in euploid
embryos that led to a live birth compared to immature oocytes and in oocytes that
resulted in aneuploid embryos compared to immature oocytes, when comparing
all groups (P < 0.05) (Figure 3.3). LHCGR mRNA levels in CCs were higher for
oocytes that resulted in embryos which led to a live birth compared to immature
oocytes and oocytes that resulted in arrested embryos compared to immature
oocytes, when comparing all groups (P < 0.05). Other CC biomarkers showed no
statistical differences between groups and their expression profiles are shown in
Supplemental figure 3.1.
We also wanted to test the hypothesis that certain CC biomarker mRNA
levels associated with oocytes giving rise to euploid embryos would be distinct
from those giving rise to aneuploid embryos and those oocytes that resulted in
arrested embryos or those that failed fertilization. Using a GLMM, the best fitting
model examining whether CC biomarker mRNA expression associated with
oocytes that became euploid embryos included 11 patients (n=78 CC masses) and
CYP11A1, CYP19A1, HSD3B1, IGFBP5, PAPPA, PGR, PGRMC1, ING1,
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LHCGR, and STARD1 (Figure 3.4). CCs associated with oocytes that produced
euploid embryos exhibited significantly (P < 0.05) lower CC HSD3B1 mRNA levels
than those oocytes that led to mature oocytes resulting in aneuploid blastocysts,
oocytes producing embryos that arrested and did not reach the blastocyst stage,
and mature oocytes that failed to fertilize, collectively (abnormal group). CC ING1
mRNA levels associated with oocytes that produced euploid embryos trended
toward being lower than CCs from oocytes that gave rise to the abnormal
outcomes, collectively (P = 0.061).
A critical hypothesis we tested was that certain CC mRNA biomarker levels
of oocytes giving rise to euploid embryos would be associated with live birth
outcomes. CC mRNA levels from all 15 patients (n = 19 CC masses) were
assessed for differences between oocytes yielding transferred embryos that
resulted in a live birth and those that did not form a pregnancy, using repeated
measures ANOVA followed by Tukey’s post hoc test (adjusted P-values). AREG
mRNA levels were significantly lower in CCs from oocytes that resulted in live
births (n = 8 from 8 patients) compared to the no pregnancy group (n = 7 from 5
patients) (P < 0.05) (Figure 3.5). PAPPA mRNA levels were higher in CCs from
oocytes producing euploid embryos that resulted in live births (n = 9 from 8
patients) compared to those that produced no pregnancy (n = 10 from 7 patients)
(P < 0.05).

The other biomarkers showed no statistical differences between

groups.
Using a GLMM, we also compared the CC mRNA biomarkers associated
with oocytes that resulted in euploid embryos producing a live birth compared to
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oocyte outcomes not producing a live birth (non-viable group), collectively. The
non-viable group included immature oocytes, mature oocytes resulting in
aneuploid blastocysts, oocytes producing embryos that did not reach the
blastocyst stage, and mature oocytes that failed to fertilize. The best fitting model
for this comparison included 110 CC samples from 14 patients and included mRNA
levels for CYP11A, CYP19A1, IGFBP5, PAPPA, PGRMC1, and STARD1
(Supplemental Figure 3.2). As revealed in the fitted model higher CC PAPPA
mRNA levels (P < 0.05) significantly increased the odds of an oocyte producing an
embryo that resulted in a live birth (OR = 4.591, 95% CI: 1.098 to 19.201). The
other five CC mRNA biomarkers did not significantly associate with live births.
3.5 Discussion
The key findings of this research were that higher PAPPA, higher LHCGR,
and lower AREG mRNA levels in CCs were associated with oocytes that produced
embryos capable of yielding live birth outcomes. In addition, lower CC HSD3B1
mRNA was associated with oocytes that resulted in euploid embryos compared to
other outcomes. Our premise was that although many retrieved oocytes in our
study appeared mature, several oocytes would have mRNA expression profiles
that were similar to those of immature oocytes. Aberrant mRNA levels would cause
them to be incapable of forming euploid embryos and leading to live births.
Therefore, an individual oocyte’s developmental competence would be reflected in
specific mRNA levels of their CC masses. For example, we predicted that an
immature oocyte CC profile would differ from that of a mature oocyte CC profile
capable of giving rise to a euploid embryo resulting in a successful pregnancy.
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This was partly the case for CC PAPPA and LHCGR mRNA levels which were
higher in CCs surrounding mature oocytes that gave rise to embryos resulting in
live birth than immature oocytes (by ANOVA). However, by ANOVA the levels of
CC PAPPA and LHCGR could not distinguish between oocytes giving rise to
morphologically normal embryos that were aneuploid and transferred euploid
embryos that resulted in live birth or no pregnancy. When utilizing the best fit
GLMM, higher CC PAPPA levels continued to associate with oocytes giving rise
to embryos with live birth compared to transferred embryos that did not result in
pregnancies as well as other oocyte outcomes, collectively.

In transferred

embryos, lower CC AREG associated with oocytes giving rise to embryos with live
birth outcomes by ANOVA analysis.

Combining these data with that for CC

HSD3B1, where lower levels were associated with euploid embryos, one can
envision using these findings to create a future practical model where the CC levels
of all four mRNA biomarkers could be used to predict which of a patient’s cohort
of oocytes and embryos will most likely be euploid and give rise to a live birth
outcome. Although four biomarkers of the selected group exhibited significant
differences in statistical models, this was a small pilot study and the data is limited
by the small sample numbers for FETs. However, these results provide a starting
point for a larger prospective future study.
Several of our analyses indicated PAPPA may be a reliable novel biomarker
in CCs for identifying oocytes capable of leading to a live birth. PAPPA encodes
a metalloproteinase that cleaves insulin like growth factor binding protein 4
(IGFBP4) and IGFBP5 (Laursen et al., 2001). Increased levels of PAPPA mRNA
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and protein in peri-ovulatory follicles may be necessary to increase intrafollicular
free IGFs through enhanced cleavage of IGFBPs (Firth and Baxter, 2002). IGFs
are known to enhance gonadotropin signaling and FSH-induced LHCGR
abundance (Wang and Chard, 1999). We also found that immature oocytes
possessed lower CC LHCGR mRNA levels compared to all the other groups
except oocytes that resulted in arrested embryos. Similarly, others have shown
that CC LHCGR mRNA levels were higher in mature compared to immature
oocytes (Maman et al., 2012). In addition, the ratio of CC LHCGR mRNA splice
variants was previously reported to be higher in pregnant compared to nonpregnant patients (Papamentzelopoulou et al., 2012b).
Differential mRNA levels of steroidogenic genes in CCs may impact the fate
of their associated oocytes. A previous study utilizing GCs pooled from multiple
patients and follicles showed increased CYP19A1 and HSD3B1 mRNA levels in
GCs from oocytes producing embryos that resulted in pregnancies compared to
oocytes resulting in embryos that failed to develop (Hamel et al., 2008). In our
study, lower CC HSD3B1 mRNA levels associated significantly with oocytes which
yielded euploid embryos.

Additionally, HSD3B1 and PAPPA both positively

correlated with principal component 1 and 2 in our biplot analysis. The difference
may have become apparent as we evaluated individual CC masses rather than
pooling. Before including the trigger in our best fitting model, lower CC CYP19A1
mRNA level was associated with live birth (P = 0.048, not shown), but showed only
a trend when trigger medication was added to the model (P = 0.052; Supplemental
figure 3.2). Given that different trigger medications can alter steroidogenic gene
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expression (Borgbo et al., 2013), caution must be used in interpreting HSD3B1
and CYP19A1 mRNA data. Like LHCGR, CYP19A1 is induced through FSH
signaling, and CYP19A1 is higher in dominant follicles of monovulatory species
(Hayashi et al., 2010, Sisco et al., 2003, Kristensen et al., 2017).
Huang and colleagues found that higher AREG levels in CCs and MGCs
were more likely to be associated with pregnancy (Huang et al., 2015). This differs
from our study as we saw lower AREG levels in CCs from oocytes associated with
live birth. As above, this discordant finding may be the result of pooling CCs and
MGCs and/or the use four stimulation protocols in the Huang study. Our results
are consistent with Feuerstein and colleagues who showed reduced AREG mRNA
levels for CCs of oocytes that resulted in high-quality blastocysts (Feuerstein et
al., 2007).
Two strengths of our study were that all patients received the same
stimulation regimen, albeit with two differing trigger medications, and we excluded
patients with endometriosis or DOR. Differing stimulation protocols have been
reported to alter mRNA expression and bias results (Adriaenssens et al., 2010a,
Assou et al., 2013, Grondahl et al., 2009). In previous studies, CCs and MGCs of
patients with DOR (Greenseid et al., 2011, May-Panloup et al., 2012) or
endometriosis (Allegra et al., 2014, Barcelos et al., 2015) exhibited altered mRNA
expression relative to their control groups. For these reasons we excluded patients
with these conditions.
As with any patient-driven clinical study, our study had limitations. Patient
heterogeneity (Adriaenssens et al., 2010a, Hurwitz et al., 2010), patient age
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(Hurwitz et al., 2010, Al-Edani et al., 2014) and differing trigger medications have
been previously demonstrated to alter gene expression (Borgbo et al., 2013). A
study design including younger patients with only male factor infertility using the
same trigger medication would be a more ideal group to examine. Additionally,
sample size may have influenced the findings. While we were able to analyze 163
samples, the samples were collected from 15 patients. Additionally, we were not
able to analyze all genes for each of the samples as RNA amounts were a limiting
factor with individual cumulus masses.

With more patients, other mRNA

expression level differences may have been apparent, and a larger prospective
study is necessary to confirm the results we found and determine the predictive
value of the CC mRNA levels for oocyte endpoints such as euploidy and live birth
outcomes. Moreover, an argument can be made that looking at oocyte CC
biomarkers and comparing the ploidy status of embryos disregards the potential
that aneuploidy may have resulted from the paternal contribution to the embryos.
We feel our study is still a valid assessment as aneuploidy is predominantly due to
maternal origins (Rabinowitz et al., 2012). Finally, we cannot overlook the impact
of uterine receptivity. Although we have no evidence of patient uterine receptivity
issues, it is possible some non-implanting embryos were capable of leading to a
live birth but were not able to implant due to a suboptimal uterine environment. A
way to account for this would be to perform double embryo transfers with euploid
embryos and assess CC mRNA expression for those where one implants and one
does not (Green et al., 2018).
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In conclusion, taken together the ideal oocyte developmental competence
needed to produce live birth may be reflected by the interplay between AREG,
HSD3B1, LHCGR, and PAPPA mRNA levels and likely their resulting proteins.
The current data support that CC mRNA levels of these four biomarkers may be
useful in assisted reproduction. A larger prospective study will be needed in to
order to corroborate the results and to determine numerical ranges for levels of
these biomarkers that could potentially have clinical value in selecting oocytes to
fertilize or embryos for uterine transfer that will have the highest odds of yielding
live birth.
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Table 3.1 Patient demographics and cycle information
Pt# Age

1
2
3
4
5

27.8
36.4
39.7
30
32.6

BMI

25.3
26.4
25
25.6
26.4

Diagnosis/
PGT-A
Reason

Cycle
#

Day 3 E2 per
#
#
#
FSH
oocyte Oocytes Mature Fertilized
level (pg/ml)
(IU/ml)
5.4
141.9
8
8
8
7.2
86.6
8
7
6
12
100.4
7
4
3
6
147.4
10
9
7
9.2
131.0
5
5
5

#
Embryos
biopsied

Trigger

112

Sex selection
3
4
hCG
Male factor
1
4
hCG
AMA
1
3
hCG
Donor
1
6
hCG
Translocation
2
5
Lupron
w/PGT-A
6 35.9 21 Idiopathic
1
8.3
163.3
4
4
4
2
Lupron
7 39.7 38.8 AMA
1
11
145.5
9
9
6
5
Lupron
8
40
32 AMA + male
1
12
31.4
7
5
5
4
Lupron
factor
9
33 18.8 Male factor
1
10
194.7
11
10
10
4
Lupron
10
42 20.3 AMA
1
6.6
108.2
5
5
5
3
hCG
11 36.1 29.2 Tubal factor
1
5.2
179.5
23
23
18
12
Lupron
12
37 20.7 AMA
1
11
142.2
16
15
14
8
Lupron
13 33.9 35 Male factor
2
10
183.1
11
10
8
2
hCG
14
28 28.4 PCO
1
5.9
184.2
24
6
5
4
hCG
15 39.7 31 AMA
1
7.5
132.6
16
14
14
7
Lupron
AMA = advanced maternal age, hCG = human chorionic gonadotropin, PGT-A = Pre-genetic testing for aneuploidy, PCO
= polycystic ovaries,

Table 3.2 Primer set information
Gene

Primer sequences
5'--3'
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Annealing
temperature
(°C)
62°

Amplicon size
(base pairs)

Reference or NCBI no.

AREG

For TGGACCTCAATGACACCTACTCTG
Rev GGGCTTAACTACCTGTTCAACTCTG

251

(Feuerstein et al., 2007)

CALM1

For TACTTCGTGTGCTCCGACCCAT
Rev AGTCCACAGCCACAGCCTACTC

62

231

(Assidi et al., 2011)

CYP11A1

For GCAACGTGGAGTCGGTTTATGTC
Rev GTGCAGGACACTGACGAAGTC

60

269

(Tsutsumi et al., 2008)

CYP19A1

For GCACATCCTCAATACCAGGTC
Rev TTTGAGGGATTCAGCACAGAC

60

380

(Hamel et al., 2008)

FSHR

For ACCAAGCTTCGAGTCATCC
Rev CATCTGCCTCTATCACCTCC
For CATCTCCCACATCCGCTACT
Rev GAAGCCTGCCTCTAGCACAC

58

103

(Gonzalez-Fernandez et al., 2011)

58

295

(Wang et al., 2009)

GREM1

For CGCCGCACTGACAGTATGAG
Rev ACCTTGGGACCCTTTCTTTTTC

62

108

NG_013372.7

HSD3B1

For TGTGCCAGTCTTCATCTACAC
Rev TGTTTTCCAGAGGCTCTTCTTC

60

101

(Hamel et al., 2008)

IGF2

For TTCCGCAGCTGTGACCTGGC
Rev CCTCGAGCTCCTTGGCGAGC

62

229

NG_008849.1

IGFBP5

For AAGAAGCTGACCCAGTCCAA
Rev GAATCCTTTGCGGTCACAAT
For GCCTGGTGTGAGGAGGACAA
Rev CCCTATGAAAGGAATGGTTCCTT

60

201

(Walker et al., 2007)

62

124

(He et al., 2004)

GJA4

ING1

Table 3.2 Continued
Gene

Primer sequences
5'--3'

114

Annealing
temperature
(°C)
62

Amplicon size
(base pairs)

Reference or NCBI no.

INHBA

For AAGTCGGGGAGAACGGGTATGTGG
Rev TCTTCCTGGCTGTTCCTGACTCG

123

(Seder et al., 2009)

LHCGR

For TGGAGAAGATGCACAATGGA
Rev GGCAATTAGCCTCTGAATGG

60

122

(Yung et al., 2014)

PAPPA

For GTCATCTTTGCCTGGAAGGGAGAA
Rev AGGGCTGTTCAACATCAGGATGAC

62

129

(Wagner et al., 2011)

PGR

For GTCATAGACCCCCGTTGCTA
Rev GCTAAGCCAGCAAGAAATGG

60

124

(Guzman et al., 2013)

PGRMC1

For TCTGGACTGCACTGTTGTCCTTG
Rev GCAAACACCTGTTCCTATTCTG

60

290

(Zachariades et al., 2011)

PTGS2

For GCTTTATGCTGAAGCCCTATGA
Rev TCCAACTCTGCAGACATTTCC

60

70

(Adriaenssens et al., 2010b)

STARD1

For TACGTGGCTACTCAGCATCG
Rev ACAGCAGGCTGGTCTTCAAC

60

157

(Chen et al., 2009)

TBP

For CACGGCACTGATTTTCAGTTC
Rev TCTTGCTGCCAGTCTGGACT

62

79

(Nelson-Degrave et al., 2004)

VCAN

For GCACCTGTGTGCCAGGATA
Rev CAGGGATTAGAGTGACATTCATCA

60

70

(Adriaenssens et al., 2010b)

Figure 3.1 Flow diagram summarizing the study population from oocyte
retrieval to final outcome. Oocytes (164) were retrieved from 15 patients and
individually cultured. Individual CC masses from each oocyte were collected and
mRNA was harvested from each mass. Of the 164 oocytes, 134 were mature and
30 were immature. All 134 were injected with sperm. Seventy-three of the fertilized
oocytes became blastocysts and were biopsied for PGT-A testing and all were
vitrified. PGT-A results indicated that 39 embryos were euploid and 34 were
aneuploid. Nineteen of the euploid embryos were transferred and 20 remained in
cryostorage. Ten embryos from 7 patients failed to implant while 9 embryos from
8 patients implanted and resulted in live births. *The control TBP mRNA did not
amplify in one CC sample from an oocyte yielding a euploid embryo and was not
included in the data analysis. RNA analyses were performed on n = 163 individual
cumulus masses.
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Figure 3.2 Principal Component Analysis Biplot for CC mRNA expression. Biplot of the log2-transformed mRNA levels
for 7 genes from 14 patients along the first and second principal components (PC1 and PC2). PC1 accounted for 35.7% of
the observed variance while PC2 accounted for 22.9% of the variance. Each data point represents an individual CC mass
mRNA level associated with an individual oocyte (n=151 oocytes). The biplot demonstrates the relationship between
individual CC mRNA level patterns and the correlation between the different genes. The closer the data points are to each
other, the more similar the normalized CC gene expression patterns. The closer the arrows are to each other, the higher
the correlation between the normalized CC gene expressions. Groups represent CC mRNA from oocytes with the following
descriptions: Aneuploid = mature oocytes resulting in aneuploid embryos; Arrested = mature oocytes resulting in embryos
that did not reach the blastocyst stage; Euploid = mature oocytes resulting in euploid blastocysts that were not transferred;
Failed Fert = mature oocytes that did not fertilize; Immature = immature oocytes that were not fertilized; Live Birth = oocytes
that resulted in euploid embryos that resulted in live births; No Pregnancy = oocytes that resulted in euploid embryos that
did not result in a pregnancy
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Figure 3.3 Biomarkers for CC mRNA expression associated with mature oocyte competence and embryo outcomes.
To determine the differences in CC mRNA between groups where oocytes had different developmental and embryo
outcomes, target mRNA levels were compared using repeated measures ANOVA followed by Tukey’s post hoc test
(adjusted P-values) for pairwise comparisons. Groups represent CC mRNA from oocytes with the following descriptions:
Aneuploid = mature oocytes resulting in aneuploid embryos; Arrested = mature oocytes resulting in embryos that did not
reach the blastocyst stage; Failed Fert = mature oocytes that did not fertilize; Immature = immature oocytes that were not
fertilized; Live Birth = oocytes that resulted in transferred euploid embryos that resulted in live births; No Pregnancy =
oocytes that resulted in transferred euploid embryos that did not result in a pregnancy. Data are presented as the median
copy number (line inside box), first and third quartile (bottom and top of box), and highest and lowest data points (top and
bottom of whiskers). Groups with different letters (a and b) exhibit significant differences (P < 0.05)
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Figure 3.3 Continued
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Figure 3.4 Biomarkers from the generalized linear mixed model associated with oocytes producing euploid
embryos versus mature oocytes with other outcomes. To evaluate CC biomarker mRNA level association with oocytes
capable of producing euploid embryos a model was fit with 78 CC samples from 11 patients and included the biomarkers:
CYP11A1, CYP19A1, HSD3B, IGFBP5, PAPPA, PGR, PGRMC1, ING1, LHCGR, and STARD1. Higher HSD3B mRNA
level significantly decreased the odds of an oocyte resulting in a euploid embryo (OR = 0.408, 95% CI: 0.175 to 0.953).
Higher ING1 mRNA levels marginally decreased the odds of an oocyte resulting in a euploid embryo (OR = 0.552, 95% CI:
0.297 to 1.027). Groups represent CC mRNA from oocytes with the following descriptions: Abnormal = mature oocytes
resulting in aneuploid blastocysts, oocytes producing embryos that did not reach the blastocyst stage, and mature oocytes
that failed to fertilize; Euploid = mature oocytes that resulted in euploid embryos regardless of whether they were transferred
or remained vitrified. Data are presented as stated in figure 3.3 legend
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Figure 3.5 CC biomarkers associated with oocytes giving rise to euploid embryos with live birth or no pregnancy.
Transferred embryos (n=19) from all 15 patients were assessed for mRNA level differences between those oocytes yielding
embryos that resulted in a live birth and those that did not form a pregnancy using repeated measures ANOVA followed by
Tukey’s post hoc test (adjusted P-values) for pairwise comparisons. Of the transferred embryos, 9 resulted in live births.
AREG mRNA levels were significantly lower in CCs from oocytes that resulted in live births (n = 8 from 8 patients) compared
to the no pregnancy group (n = 7 from 5 patients) (P < 0.05). PAPPA mRNA expression was significantly increased in CCs
from oocytes producing embryos that resulted in live births (n = 9 from 8 patients) compared to no pregnancy (n = 10 from
7 patients) (P < 0.05). GREM1 mRNA levels (n = 3/group) were not significantly different and not shown. Data are presented
as in figure 3.3 legend
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Table 3.3 Ploidy status and outcomes of biopsied embryos
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Pt #

Embryo #

1
1
1
1
2
2
2
2
3
3
3

8
10
13
14
4
6
7
8
1
3
5

3
4
4
4
4
4

7
2
4
7
8
11

4
5
5

12
3
4

Ploidy
Status
Euploid
Euploid
Euploid
Euploid
Euploid
Monosomy
Monosomy
Monosomy
Euploid
Monosomy
Triple
Trisomy
Euploid
Euploid
Euploid
Monosomy
Trisomy
Complex
Aneuploid
Euploid
Euploid
Complex
Aneuploid

EXP

ICM

TROPH

ET

LB

5
2
5
3
6
5
6
6
5
2
5

A
B
B
B
A
B
A
A
A
B
A

B
B
B
B
B
B
B
B
B
B
B

X

X

5
2
2
2
2
2

A
B
B
B
B
B

B
B
B
B
B
B

X
X

2
5
5

B
A
C

B
B
C

NI

NT

NU

X
X
X
X

X
X
X
X
X
X
X
X
X
X
X
X
X
X

X

X
X

Table 3.3 Continued
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Pt #

Embryo #

5
5

6
8

5

9

6
6
7
7
7
7
7
8
8

2
6
3
6
7
8
11
2
3

8
8
9
9
9

6
7
1
2
10

9

15

Ploidy
Status
Monosomy
Complex
Aneuploid
XXX Super
Female
Trisomy
Euploid
Euploid
Euploid
Trisomy
Euploid
Monosomy
Monosomy
Double
Monosomy
Monosomy
Euploid
Euploid
Euploid
Complex
Aneuploid
Complex
Aneuploid

EXP

ICM

TROPH

ET

LB

5
3

A
B

B
B

X
X

5

A

A

X

5
6
3
5
5
5
2
5
3

A
A
B
B
B
B
B
A
C

B
B
C
B
B
C
B
B
C

X

5
5
4
3
2

A
A
B
A
B

A
B
A
A
B

2

B

B

X
X

NI

NT

NU

X
X
X
X

X

X
X
X
X
X

X
X

X
X
X
X
X
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Pt #

Embryo #

10

1

10

4

10
11
11
11
11
11

5
3
6
7
8
13

11
11
11
11
11
11
11
12
12
12
12
12

14
15
17
18
19
20
22
5
6
7
8
12

Ploidy
Status
Complex
Aneuploid
Complex
Aneuploid
Euploid
Euploid
Euploid
Monosomy
Euploid
Trisomy/Mon
osomy
Monosomy
Monosomy
Euploid
Euploid
Monosomy
Euploid
Euploid
Euploid
Euploid
Trisomy
Trisomy
Euploid

EXP

ICM

TROPH

ET

4

B

C

X

4

B

C

X

4
5
5
5
5
5

B
A
A
B
B
B

C
A
B
B
C
A

5
5
5
5
3
5
5
5
5
5
5
5

A
A
A
A
A
A
B
A
A
A
B
B

B
A
B
A
B
A
B
B
A
A
B
B

X
X

LB

NI

NT

NU

X
X
X
X
X
X
X
X
X
X
X

X

X
X

X

X
X
X
X
X

Table 3.3 Continued
Pt #

Embryo #
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Ploidy
EXP
ICM TROPH
ET
LB
NI
NT
NU
Status
12
14
Euploid
5
A
A
X
12
16
Trisomy
5
A
A
X
12
17
Monosomy
5
A
B
X
13
3
Euploid
4
B
B
X
13
7
Euploid
5
B
B
X
X
14
2
Euploid
4
B
B
X
X
14
4
Euploid
4
B
A
X
X
14
5
Trisomy
4
A
B
X
14
14
Euploid
4
B
C
X
15
3
Trisomy
4
A
A
X
15
4
Euploid
3
B
B
X
X
15
6
Euploid
3
B
B
X
15
8
Euploid
4
A
A
X
15
10
Euploid
4
B
B
X
15
11
Monosomy
4
A
B
X
15
17
Euploid
4
B
B
X
X
EXP = blastocyst expansion grade; ICM = inner cell mass grade; Troph = trophectoderm grade; ET = transferred embryo;
LB = live birth; NI = no implantation;
NT = not transferred (cryopreserved); NU = not used
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Figure 3.6 Biomarkers for CC mRNA expression not associated with mature oocyte competence and embryo
outcomes. To determine the differences in CC mRNA between groups where oocytes had different developmental and
embryo outcomes target mRNA levels were compared using repeated measures ANOVA followed by Tukey’s post hoc test
(adjusted P-values) for pairwise comparisons. Groups represent CC mRNA from oocytes with the following descriptions:
Aneuploid = mature oocytes resulting in aneuploid embryos; Arrested = mature oocytes resulting in embryos that did not
reach the blastocyst stage; Failed Fert = mature oocytes that did not fertilize; Immature = immature oocytes that were not
fertilized; Live Birth = oocytes that resulted in transferred euploid embryos that resulted in live births; No Pregnancy =
oocytes that resulted in transferred euploid embryos that did not result in a pregnancy. No differences were seen in these
biomarkers (P > 0.05). Data are presented as stated in figure 3 legend
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Figure 3.7 Generalized linear mixed model distinguishing CC from oocytes
giving rise to live births and oocytes with outcomes not resulting in live birth,
collectively. To evaluate the potential of CC biomarker mRNA levels to identify
oocytes capable of producing euploid embryos resulting in a live birth versus
groups not producing live births, the best fitting model included 110 CC samples
from 14 patients and included biomarkers: CYP11A1, CYP19A1, IGFBP5, PAPPA,
PGRMC1, and STARD1. Increased PAPPA mRNA expression (P < 0.05)
significantly increased the odds of an oocytes producing an embryo resulting in a
live birth (OR = 4.591, 95% CI: 1.098, to 19.201). All previously stated categories
were included in this model except oocytes yielding euploid embryos that were not
transferred. Groups represent CC mRNA from oocytes with the following
descriptions: Live Birth = mature oocytes that resulted in euploid embryos that
lead to live births; Non-Viable = immature oocytes, mature oocytes resulting in
aneuploid blastocysts, oocytes producing embryos that did not reach the
blastocyst stage, and mature oocytes that failed to fertilize, collectively. Data are
presented as in figure 3 legend
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Chapter 4
Mitochondrial Metabolic Substrate Utilization in Granulosa Cells
Reflects Body Mass Index and Total Follicle Stimulating Hormone
Dosage in In Vitro Fertilization Patients4

_______________________________________________________________
4R.J.

Kordus, A. Hossain, H.E. Malter, and H.A Lavoie. Submitted to Journal of
Assisted Reproduction and Genetics
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4.1 Abstract
4.1.1 Purpose: To utilize a novel mitochondrial function assay with pooled
granulosa cells to determine whether mitochondrial function would differ by
patient demographics and embryo development.
4.1.2 Methods: Prospective pilot study in a hospital based assisted reproductive
program and public university. The study assessed mitochondrial metabolic
substrate utilization and mRNA levels in pooled granulosa cells from 40 women
undergoing in vitro fertilization during 2018 and 2019.
4.1.3 Results: In pooled granulosa cells, mitochondrial utilization of citric acid (P
< 0.01), L-malic acid (P < 0.05), and octanoyl-L-carnitine (P < 0.01) were
significantly lower with lower body mass index. Citric acid (P < 0.05), cis-acontic
acid (P < 0.01), D-alpha-keto-glutaric acid (P < 0.05), L-glutamine (P < 0.05), and
alanine-glycine (P < 0.05) were significantly lower with increasing FSH
administered. Utilization of glycogen (P < 0.05) was significantly lower with lower
fertilization rates and D-alpha-keto-glutaric acid (P < 0.05) was significantly lower
in good 8-cell embryos. L-glutamine (P < 0.05) was significantly higher with
lower blastocyst formation. Mitochondrial metabolic scores, which reflect overall
mitochondrial activity of granulosa, were significantly higher with increased
numbers of zygotes formed (P < 0.05), higher BMI (P < 0.05), less FSH
administered (P < 0.01), and with greater numbers of mature oocytes (P < 0.05).
4.1.4 Conclusions: Body mass index and FSH dose administered were
associated with mitochondrial utilization of citric acid, L-malic acid, octanoyl-Lcarnitine, cis-acontic acid, D-alpha-keto-glutaric acid, L-glutamine, and alanine-
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glycine. Glycogen, D-alpha-keto-glutaric acid, and L-glutamine may be possible
biomarkers for embryo development.
4.1.5 Key Words: granulosa cells, in vitro fertilization, mitochondrial function
assay, mitochondrial metabolic score, mitochondrial utilization
4.2 Introduction
Mitochondria are double-membrane organelles, which are believed to
have originated from a symbiotic relationship between bacteria and host cells
(Margulis, 1996). They are involved in apoptosis, calcium homeostasis, fatty acid
oxidation, and metabolism. Mitochondria, the key source of power within
eukaryotic cells, are responsible for generating 88% of a cell’s total energy in the
form of adenosine triphosphate (ATP) created during oxidative phosphorylation
via mitochondrial membrane potential (Seyfried and Shelton, 2010). The
remaining ATP required by the cell is produced from the processes of glycolysis
and the tricarboxylic acid cycle through substrate-level phosphorylation.
Oxidative phosphorylation is modulated by the cellular demand for ATP and the
substrates available for processing within the cytoplasm. Glucose is the main
substrate that will produce ATP via the intermediates of glycolysis. Pyruvate and
other substrates of the glycolytic process will generate reducing equivalents,
nicotinamide adenine dinucleotide hydride (NADH) and flavin adenine
dinucleotide hydride (FADH2), which will transfer electrons to the electron
transport chain (ETC). The flow of electrons through the ETC will provide
mitochondrial membrane potential ultimately producing ATP (Veatch et al.,
2009).
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Successful embryo development relies upon energy metabolism
generated by ATP processed through the mitochondria to drive the cleavage of
blastomeres and other cellular processes during early embryo development.
While human oocytes contain the most mitochondrial of all cell types within the
body, it is problematic to relate mitochondrial DNA (mtDNA) copy number and
function to oocyte developmental competence; since the oocytes, and
subsequent embryos, are required for clinical use. However, parallels between
mtDNA content in human oocytes and granulosa cells (GCs), including both
cumulus cells (CCs) and mural granulosa cells (MGCs), have been demonstrated
(Boucret et al., 2015, Pawlak et al., 2016). Additionally, the metabolism of CCs
directly affects their enclosed oocytes by providing the proper energy substrates
required to complete meiosis and fertilization. Cumulus cells produce ATP and
augment oocyte ATP supply during follicular growth. The CCs also provide
pyruvate, generated from glycolysis, to their enclosed oocytes via gap junctions
(Su et al., 2009, Sutton-McDowall et al., 2010). Further, mitochondrial function,
measured by ATP production in CCs, has been shown to relate to proper human
oocyte maturation and in vitro fertilization (IVF) outcomes (Dalton et al., 2014,
Huang and Wells, 2010, Tsai et al., 2010).
Assessing mitochondrial substrate metabolism in GCs may allow for a
non-invasive method for investigating oocyte competence and embryo
development. Several studies have evaluated CCs, MGCs, and trophectoderm
cells from blastocysts; and it appears there is a high correlation between the
mtDNA content found in oocytes and CCs indicating that GC mtDNA might serve
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as a biomarker for oocyte competence (Desquiret-Dumas et al., 2017, Diez-Juan
et al., 2015, Fragouli and Wells, 2015, Ogino et al., 2016, Boucret et al., 2015).
Furthermore, increased mtDNA GC copy numbers are associated with good
quality embryos (Ogino et al., 2016, Desquiret-Dumas et al., 2017). Therefore,
we hypothesized mitochondrial substrate utilization in pooled GCs, measured
using a novel mitochondrial function assay, will also show correlations between
various demographic and embryo endpoints.
The goal of this study was to see how individual substrates and total
substrate utilization differed between patients based on age, serum anti-Mullerian
hormone (AMH) level, body mass index (BMI), and number of mature oocytes
retrieved per cohort. We also related individual and total substrate utilization to
fertilization rates, day 3 embryo development, blastocyst development, and
mRNA levels of selected genes to determine if one or more substrates can be
used as a biomarker for IVF. In a recent investigation by our laboratory, several
candidate mRNA transcripts in individual cumulus masses showed associations
with viable embryos capable of leading to live births (Kordus et al., 2019), and
these mRNAs were also investigated in this study. Genes of interest included,
amphiregulin (AREG), which is associated with cumulus mass expansion;
inhibitor of growth protein 1 (ING1), which is associated with oocyte maturation;
aromatase (CYP19A1), cytochrome p450 family 11 subfamily A member 1
(CYP11A1), and hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid
delta-isomerase 1 (HSD3B1), which are associated with mediating de novo
steroidogenesis, estrogen, and progesterone production; pappalysin-1 (PAPPA),
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which is related to hormone modulation; and luteinizing
hormone/choriogonadotropin receptor (LHCGR), which encodes for it’s
associated hormone receptor. We also examined AMH mRNA due to the
relationship of serum AMH with ovarian reserve.
To our knowledge, this is the first study to examine a novel mitochondrial
function assay to assess the metabolism of mitochondrial substrates in pooled
GCs. The assay measures the rate of electron flow through the electron
transport chain from 31 metabolic substrates that, when metabolized by cell
preparations, produce NADH or FADH2 using a tetrazolium dye (Bochner et al.,
2001). The primary goal of this study was to determine if metabolic substrate
utilization differed between patient groups and embryo cohorts. We also wanted
to determine if a mitochondrial metabolic score could be generated from the
overall metabolic rate of the substrates combined, that would be related to
patient groups and primary embryo developmental endpoints.
4.3 Materials and methods
4.3.1 Study Population, Participants, and GC isolation
This study was a prospective cohort pilot study. In total, 817 pooled CCs
and MGCs from 40 patients undergoing infertility treatment at Fertility Center of
the Carolinas (Greenville, SC, USA) were analyzed (Figure 4.1). Of 58 starting
patients, those with total GC numbers <650,000 per sample were excluded from
the study (n=14), as well as patients with appropriate GC numbers where the
positive assay control did not exhibit color change (n=4). Patient demographics
and cycle information were collected for each cycle (Table 4.1). The patients’
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assay data were compared based on age, serum AMH levels, BMI, and number
of mature oocytes retrieved per cohort. Each patient’s ovaries were stimulated
using a long luteal protocol or an antagonist protocol. In the antagonist cycles,
when one follicle reached 13 or 14 mm or the patient’s estradiol level reached
300 IU/mL a GnRH antagonist (Cetrotide, EMD-Serono, USA or Ganirelix, EMDSerono, USA) was administered. In both protocols, when 3 follicles reach >17
mm by ultrasound an ovulatory dose of human chorionic gonadotropin (hCG)
(Pregnyl, EMD-Serono, USA) was delivered. Thirty-six hrs later patients
underwent oocyte retrieval. Each CC mass was mechanically separated from it’s
oocyte and rinsed in medium (Sperm Wash Medium, Irvine, USA) to remove
blood and debris and all CC masses per retrieval were combined in a single tube.
The CCs and MGCs from each patient were taken to the research lab on ice for
immediate processing.
4.3.2 Embryo culture and ploidy assessment
Mature oocytes were inseminated via intra-cytoplasmic sperm injection.
Fertilization was confirmed by the presence of two pronuclei and two polar bodies
16-18 hrs after insemination. Embryos were group cultured in 50 µL LifeGlobal®
global total media drops (Cooper Surgical, Trumbull, CT, USA) under oil (Ovoil,
Vitrolife, Englewood, CO, USA) at 37°C, 6% CO2, 5% O2, 89% N2 in a humidified
atmosphere until day 5 or day 6 post retrieval.

Embryo morphologies were

assessed using the American Society for Reproductive Medicine (ASRM)
(Racowsky et al., 2010) criteria for day 3 embryos and day 5/6 blastocysts.
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4.3.3 Analysis of Mitochondrial Metabolic Substrates
Follicular fluid, containing MGCs from each patient, was split between 2 or
more 50 mL tubes and centrifuged for 15 min at 300xg. A filtered solution of
hyaluronidase (50 mg/mL) from bovine testes (Sigma, Raleigh, NC, USA) in media
was added to each MGC pellet and the CC tube and incubated at 37°C for 10 min
to dissociate cell clumps. Calcium/magnesium-free phosphate-buffered saline
(PBS) (Gibco, Gaithersburg, MD, USA) was added to bring the pellet to
approximately 4 mL. MGCs were purified by 35%-70% discontinuous Percoll
gradient in 15 mL tubes and spun in a swinging bucket centrifuge for 30 min at
300xg. Assay mix (30 µL) containing 2x Biolog Mitochondrial Assay Solution
(MAS) (Biolog, Hayward, CA, USA), 6x Redox Dye (Biolog), 24x saponin (90
µg/mL) for permeabilization (Alfa Aesar, Ward Hill, MA, USA), and sterile water
were added to each well of the 96-well MitoPlate S-1 plates (Biolog) and incubated
for 1 hr per manufacturer’s instructions. Mural granulosa cells (the uppermost
band in the gradient) were removed and combined with CCs in 25 mL of
calcium/magnesium-free PBS (Gibco). The mixture was poured through a 70micron strainer to remove any remaining cell clumps.

Pooled GCs were

centrifuged for 20 min, and the pellet was resuspended in 1x MAS (Biolog) to a
volume of 2 mL. A 0.5 mL aliquot of the GC/MAS mixture was removed and a 10
µL sample was counted using a hemocytometer. This remainder of the aliquot
was centrifuged for 5 min, and the pellet was placed in 0.5 mL RNAlater solution
(Life Technologies), stored at 4°C for 24 hrs, and snap-frozen in LN2 and stored
until it was transported to the University of South Carolina School of Medicine and
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stored at -70°C until processed. The remaining 1.5 mL GC/MAS mixture was
diluted to 3.0 mL with 1x Biolog MAS and a 10 µL sample was counted with a
hemocytometer. After 1 hr incubation at 37°C to allow all substrates to dissolve,
30 µL of the GC/MAS suspension was added to each well of the MitoPlate S-1
plate. Permeabilized cells were assayed in triplicate for metabolism of individual
substrates (Table 4.2) using MitoPlate S-1 plates. Metabolism of substrates was
assessed by a colorimetric change of a terminal electron acceptor tetrazolium
redox dye at an optical density of 590 nm read every 2.5 min for 50 cycles on a
kinetic plate reader (Figure 4.2). The slopes of the optical density absorbance
readings were normalized to mtDNA copy number per sample (as described
below) and the relative absorbance of the negative control wells containing
GC/MAS without any additional substrates.

To quantitatively compare the

metabolism of each patient we developed a scoring system based on the
aggregate slope ratios of all substrates normalized to the negative control and
positive control wells. The mitochondrial metabolic score was the total of all the
slope ratios of each substrate for each individual patient.

Slope ratio = [Slope

(sample) – Slope (negative control)] / [Slope (positive control) – Slope (negative
control)] (Vanderstichel et al., 2015).
4.3.4 RNA Isolation and cDNA synthesis
RNA was isolated from each pooled CC/MCG sample per patient using the
Direct-zol MiniPrep Kit with DNase treatment (Zymo Research, Irvine, CA, USA)
following the manufacturer’s instructions. RNA concentration and purity for pooled
samples were assessed at the wavelengths of 260 and 280 nm using a
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biophotometer 6131 spectrophotometer (Eppendorf). Each sample was reverse
transcribed into cDNA using the iScript kit (Bio-Rad Laboratories, Hercules, CA,
USA) following the manufacturer’s instructions. The reverse transcription reaction
was carried out in a thermocycler (Eppendorf), for 5 min at 25°C, 30 min at 42°C,
and 5 min at 85°C.
4.3.5 DNA Isolation and Quantification
DNA was isolated from pooled GCs using the Direct-zol MiniPrep Kit (Zymo
Research) as described above, omitting the DNase treatment step.

DNA

concentration and purity were assessed at the wavelengths of 260 and 280 nm
using a biophotometer 6131 (Eppendorf). Relative amounts of mtDNA and nuclear
DNA content (nDNA) and were determined by qRT-PCR (described below). The
ratio of mtDNA:(2x nDNA) was used to determine mtDNA content.
4.3.6 Quantitative Real-Time PCR
Synthesized primers were cartridge purified (Life Technologies). Primers
to amplify cDNA included: AMH, AREG, CYP19A1, HSD3B1, ING1, LHCGR,
PAPPA, and TATA-box binding protein (TBP) (Table 4.3). The nuclear gene ACTB
(beta-actin) was selected as a reference gene to calculate nDNA and the mtDNA
gene mitochondrially encoded ATP synthase 8 (MT-ATP-8) was used to quantify
mitochondrial genome content. Real-time PCR reactions were run with 2 or more
wells per sample for 40-45 cycles and threshold cycle (Ct) values were averaged.
The reactions included 5 ng starting cDNA, 300 nM of each upstream and
downstream primer, and 10 µL 2X SsoAdvanced Universal SYBR Green Supermix
(Bio-Rad Laboratories) and sterilized PCR-grade water to a final volume to 20 µL
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per well. PCR-grade water was substituted for the cDNA as a negative control.
PCR amplification was performed using the iCycler iQ Real-Time PCR Detection
System (Bio-Rad Laboratories). TBP mRNA was used as an internal control for
cDNA samples (Kordus et al., 2019) and actin beta (ACTB) DNA was used as an
internal control for nuclear DNA (nDNA) samples (Diez-Juan et al., 2015). Target
RNA and DNA quantities were derived from a standard curve made using serial
dilutions of its purified amplicon. TBP has extensively been tested as a control
gene in our laboratory with human GCs under multiple conditions and treatments
and has not been found to be regulated under any circumstances. Target mRNA
values were expressed relative to values of the TBP mRNA control.
4.3.7 Statistical analysis
Multiple linear regression models were estimated to predict the normalized
average rate of each substrate’s metabolism and mitochondrial metabolic score
using Box-Cox transformation for normality (Box and Cox, 1964). Each substrate
was assessed separately, and a mitochondrial metabolic score was created based
on the slopes of the normalized absorbance readings of all substrates combined.
The mitochondrial metabolic scores were normalized against the mtDNA content
in each sample. The individual substrate rates and the mitochondrial metabolic
scores were related to patient demographics. To determine the relationship
between mitochondrial metabolic score and mRNA levels, Pearson’s correlation
analysis was used with both variables being Box-Cox transformed. We determined
statistical significance of findings by P < 0.05 and considered the findings with 0.05
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< P < 0.10 to be borderline significant. Statistical analysis was performed using the
statistical analysis environment R 3.6.2 (R Core Team, 2019).
4.4 Results
In total, 817 oocytes and associated GCs were harvested from 40 patients
undergoing fertility treatment. The CCs were combined with the MGCs from each
patient. Thirty-seven out of 40 patients had at least one fresh or frozen embryo
transfer (FET) and currently 49% of patients who did receive an ET either have
ongoing pregnancies or have delivered a child.
We examined the mitochondrial metabolic profile of IVF patients using a
novel mitochondrial function assay, Mitoplate S-1 which examined 31 different
substrates. In hypothesis one, we tested whether individual substrate utilization
by pooled granulosa mitochondria would differ according to age, serum AMH
levels, BMI, and total number of mature oocytes retrieved per patient cohort.
Absorbance readings in the assay reflected metabolism of utilization of substrates.
To test this hypothesis, we analyzed the averaged normalized absorbance
readings of each metabolic substrate within the comparison groups using a
multiple linear regression model using Box-Cox transformation examining the
independent variables of age, BMI, serum AMH, mature oocytes per cohort, antral
follicle count, stimulation type, amount a HMG given, and amount of FSH
administered. Age, BMI, serum AMH were divided into higher and lower groups
as follows: Older age ≥ 34 years old and younger age < 34 years old; high BMI ≥
26 kg/m2 and low BMI < 26 kg/m2; and higher serum AMH ≥ 3.5 ng/mL and lower
serum AMH < 3.5 ng/ml. Based on the estimated multiple linear regression model
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using observed data, patient mitochondrial utilization of citric acid (P < 0.01), Lmalic acid (P < 0.05), and octanoyl-L-carnitine (P < 0.01) were found to be
significantly lower (Figure 4.3), and mitochondrial utilization of cis-acontic acid (P
< 0.10), D,L-beta-hydroxy-butyric acid (P < 0.10), and pyruvic acid/L-malic acid
100 µM (P < 0.10) were found to be borderline lower in patients with lower BMI in
pooled GCs, while no other substrates demonstrated utilization differences by BMI
in the model, after adjusting for the other factors in the model (Figure 4.4).
Individuals with a greater number of mature oocytes were found to have a
significant increase for alpha-keto-isocaproic acid mitochondrial utilization by
pooled granulosa (P < 0.01) (Figure 4.5). No other substrates demonstrated
utilization differences in the model (Figure 4.6). Additionally, patient mitochondrial
utilization for citric acid (P < 0.05), cis-acontic acid (P < 0.01), D-alpha-ketoglutaric acid (P < 0.05), L-glutamine (P < 0.05), and alanine-glycine (P < 0.05) were
found to be significantly lower (Figure 4.7), and mitochondrial utilization of D,Lisocitric acid (P < 0.10), D,L-beta-hydroxy-butyric acid (P < 0.10), L-glutamic acid
(P < 0.10), acetyl-L-carnitine (P < 0.10), pyruvic acid/L-malic acid 100 µM (P <
0.10) were found to be borderline lower in pooled GCs of patients with higher
administered FSH dosages, after adjusting for the other factors in the model while
no other substrates demonstrated mitochondrial utilization differences for the
number of mature oocytes in the model (Figure 4.8).
The second hypothesis tested was that a mitochondrial metabolic score
generated from the aggregate metabolism of the pooled GCs would differ
according to age, serum AMH levels, BMI, and total number of mature oocytes
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retrieved per patient cohort. To test this, we analyzed the mitochondrial metabolic
scores using a multiple linear regression model using Box-Cox transformation
examining the independent variables of age, BMI, serum AMH level, number of
mature oocytes, zygote fertilization, good 8-cell embryo development, and overall
blastocyst formation per patient cohort. Based on the estimated multiple linear
regression model using observed data, mitochondrial metabolic scores were found
to be significantly higher in granulosa of patients with higher numbers of mature
oocytes retrieved (P < 0.05), after adjusting for the other factors in the model
(Figure 4.9). In a backward selected best fit model using only the BMI and total
FSH dosage administered, mitochondrial metabolic scores were found to be
significantly lower in pooled GCs of patients with a lower BMI (P < 0.05) (Figure
4.9), and significantly lower as the patient’s FSH dose administered increased (P
< 0.01) (Figure 4.9).
Our third hypothesis predicted that individual substrates metabolized by
mitochondria in GCs of patients would differ by overall embryo cohort
development. We created a multiple linear regression model using Box-Cox
transformation looking at fertilization percentage, percentage good 8-cell embryo
development on day 3, and percentage of blastocyst development by day 6. The
3 groups were divided into higher and lower groups as follows: higher fertilization
percentage ≥ 80%, and lower fertilization percentage < 80%; higher good 8-cell
development

> 55% and lower good 8-cell development ≤ 55%; and higher

percentage of blastocyst formation > 55% and lower percentage of blastocyst
formation ≤ 55%. One patient was excluded from the blastocyst formation data as
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she had an embryo transfer on day 3 with no additional embryos available for
extended culture. Based on the estimated multiple linear regression model using
observed data, mitochondrial utilization of glycogen (P < 0.05) was found to be
significantly lower in pooled GCs of patients with lower fertilization percentage
(Figure 4.10). No other substrates demonstrated utilization differences for
fertilization in the model (Figure 4.11). In contrast, patient mitochondrial utilization
of D-alpha-keto-glutaric acid (P < 0.05) was found to be significantly higher (Figure
4.10), and L-serine (P < 0.10) was found to be borderline higher in granulosa of
patients with a lower percentage of good quality 8-cell embryos (Figure 4.12). In
addition, patient mitochondrial utilization of D-gluconate-6-phosphate (P < 0.10),
and D,L-isocitric acid (P < 0.10) was found to be borderline higher in patients with
a lower percentage of blastocyst formation in pooled GCs, after adjusting for the
other factors in the model (Figure 4.13). In a backward selected best fit model
using only the percentage of good 8-cell embryos and percentage of blastocysts,
GC mitochondrial utilization of L-glutamine (P < 0.05) was found to be significantly
higher in patients with a lower percentage of blastocyst formation (Figure 4.10)
and L-glutamine (P < 0.10) was found to be borderline higher in patients with a
lower percentage of good quality 8-cell embryos in pooled GCs(Figure 4.12).
A fourth critical hypothesis we wanted to test was that a mitochondrial
metabolic score generated from the aggregate metabolism of the pooled GCs
would be associated with better overall embryo development.

To test this

hypothesis, we analyzed the patient mitochondrial metabolic score using a multiple
linear regression model using Box-Cox transformation examining the independent
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variables of age, BMI, AMH level, mature oocytes per cohort, zygote fertilization,
good 8-cell embryo development, and overall blastocyst formation. Based on the
estimated multiple linear regression model using observed data, mitochondrial
metabolic scores were found to be significantly higher in granulosa cells of patients
with higher overall number of fertilized zygotes (P < 0.05) in pooled GCs, after
adjusting for the other factors in the model (Figure 4.14).
Finally, we wanted to test the hypothesis that the mitochondrial metabolic
score would be differ with mRNA levels of the genes: AMH, AREG, CYP19A1,
CYP11A1, HSD3B1, ING1, LHCGR, and PAPPA. In order to test this hypothesis,
we used Pearson’s correlation analysis with both variables being Box-Cox
transformed, which demonstrated that HSD3B levels we borderline lower (P <
0.10) as the mitochondrial metabolic score decreased (Figure 4.13). No other
mRNA levels varied.
4.5 Discussion
To our knowledge this is the first use of this mitochondrial function assay to
investigate mitochondrial metabolic substrate utilization in the pooled GCs of IVF
patients. The mitochondrial function assay plates utilized in our study contained
31 cytoplasmic and mitochondrial metabolic substrates to profile the metabolic
capabilities of mitochondria in pooled GC from individual patients. Each well in the
plate contained an individual chemical as the sole energy source. The substrates
were metabolized through different biochemical pathways by entering the
mitochondria through different transporters and they were then modified by various
enzymes and dehydrogenases to produce NADH or FADH2 (Figure 4.16).
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Deviations in the mitochondrial metabolism of the substrates were detected by
chemometric alterations in the energy-rich redox dye. As the cells metabolized the
energy source, tetrazolium dye in the media was reduced, generating a purple
color according to the amount of NADH or FADH2 reducing equivalents generated
and reflected the biochemical reactome of the substrates by the mitochondria
(Bochner et al., 2001).
Our main goal was to determine if mitochondrial metabolic substrates in
pooled GCs of IVF patients were significantly associated with patient age, serum
AMH levels, BMI, or the number of mature oocytes retrieved per cohort. Secondly,
we wanted to determine if mitochondrial substrate utilization was related to embryo
cohort development. We hypothesized that mitochondria would metabolize the
individual substrates at differing rates based on patient demographics and embryo
cohort development.

We also hypothesized that the overall mitochondrial

metabolic utilization of all the substrates in the plate, combined, would allow us to
score each patient’s overall GC mitochondrial function and perhaps be used as a
prediction tool for embryo development.
The key findings of our research were that GC mitochondrial utilization of
the assay’s metabolic substrates citric acid, L-malic acid, and octanoyl-L-carnitine
were found to be significantly lower in patients with lower BMI indicating a potential
increase in oxidative phosphorylation and perhaps reactive oxygen species
production in overweight patients.

Citric acid and L-malic acid are both

components of the tricarboxylic acid cycle. The conversion of L-malic acid to
oxaloacetate by malate dehydrogenase produces NADH which is processed
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through the ETC.

Octanoyl-L-carnitine is a medium chain fatty acid that

catabolizes to several acetyl-CoA molecules and feeds into the tricarboxylic acid
cycle.

Granulosa cell utilization of citric acid, cis-acontic acid, D-alpha-keto-

glutaric acid, L-glutamine, and alanine-glycine in the assay were found to be
significantly lower in patients with higher administered FSH dosages using a
multiple linear regression model. This indicates that the total FSH dose required
to produce follicle maturation is associated with suppressed mitochondrial activity
by the pool of granulosa. Cis-acontic acid and D-alpha-keto-glutaric acid are both
components of the tricarboxylic acid cycle.

The conversion of D-alpha-keto-

glutaric acid by alpha-ketoglutarate dehydrogenase produces NADH which is
processed through the ETC.

L-glutamine, converted to alpha-ketoglutarate

through glutamate dehydrogenase, enters the tricarboxylic acid cycle at that
juncture.

Alanine-gflycine will be converted into pyruvic acid and enters the

tricarboxylic acid cycle after pyruvic acid is converted to acetyl-CoA. Four out the
7 substrates altered by either BMI and/or FSH were substrates directly involved in
the citric acid cycle. Octanoyl-L-carnitine, modified by BMI, is involved in fatty acid
metabolism. There is a commonality between the BMI and FSH dose-altered
substrates. Both citric and cis-aconitic acid are modified by the enzyme aconitase
in a reversible isomerization reaction. L-malic acid and alpha-keto-glutaric acid
are both modified by dehydrogenases and undergo oxidation.

The changes

observed in the mitochondrial substrate utilization by GCs may indicate that
dehydrogenase activity and oxidation reactions are altered by BMI and total FSH
dosage administered.
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Patients who fall within the obese range (>30 kg/m 2) of BMI have been
shown to have almost 70% lower odds of becoming pregnant in their first IVF cycle
compared to women who have lower BMI (Moragianni et al., 2012). Furthermore,
high BMI and diabetes have both been shown to be related to alteration of
mitochondrial function in mouse oocytes (Igosheva et al., 2010, Ou et al., 2012).
In human GCs, mitochondrial membrane potential is decreased with higher BMI
levels (Gorshinova et al., 2017), and gene expression has also been shown to be
modified by BMI (Adriaenssens et al., 2010a, Kenigsberg et al., 2009, Robker et
al., 2009).

In our study BMI and FSH both altered the utilization of several

mitochondrial metabolic substrates related to the tricarboxylic acid cycle. The
findings that BMI and the total FSH dose administered alter mitochondrial
metabolism in granulosa may be explained by the tendency of patients with higher
BMI to receive higher doses of FSH during an IVF stimulation cycle (Fedorcsak et
al., 2004). Interestingly, total FSH dosage was previously shown to have no impact
on mitochondrial expression of a polycistronic RNA transcript in GCs of IVF
patients (Saito et al., 2013), Citric acid and ATP levels have been shown to be
reduced in diabetic mice suggesting reduced mitochondrial function due to
increasing BMI (Wang et al., 2010). We found that the mitochondrial metabolic
scores were significantly reduced when BMI was lower and total FSH dose
administered was higher, when only BMI and FSH were in the backward selected
models. Our results may indicate that increasing BMI causes an increase in
oxidative phosphorylation and reactive oxygen species. This may or may not
translate into an increase in ATP production. A recent study by Abraham and
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colleagues demonstrated that fibroblasts from infants born to overweight mothers
(compared to lean mothers) had significantly higher mitochondrial oxygen
consumption rates and increased ATP production indicating mitochondrial
inefficiency; cells also exhibited elevated ROS and oxidative stress (Abraham et
al., 2018). One may expect that higher doses of FSH administered would show a
similar increase in metabolic utilization since higher doses of FSH are associated
with higher BMIs, however, we found the opposite effect in this study. This may
indicate that GC from patients receiving higher FSH dose indeed suppress
mitochondrial substrate utilization.

Unfortunately, we did not assess ATP

production in this study, but a future study may be able to assess the effect of BMI
and FSH dose administered on substrate utilization and ATP production to see if
BMI and FSH affect mitochondrial function independent of ATP production.
One of the key pathways for energy production is fatty acid oxidation.
Lipotoxicity caused by excessive lipid accumulation and increased intracellular
free fatty acid content leads to mitochondrial dysfunction which can compromise
mitochondrial function through free fatty acid beta-oxidation and oxidative stress
(Hauck and Bernlohr, 2016). Gorshinova and colleagues demonstrated reduced
mitochondrial membrane potential in CCs with increasing BMI (Gorshinova et al.,
2017). Surprisingly, octanoyl-L-carnitine is an interesting metabolite whose usage
was altered in our experiments. Pyruvate, derived from the CCs surround the
oocyte, and free fatty acid oxidization are the major sources of ATP production by
oocyte mitochondria (Simerman et al., 2015).

Octanoyl-L-carnitine has been

shown to increase the respiration rate in saponin-treated heart muscles of rats
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(Toleikis et al., 2001). The modulation of octanoyl-L-carnitine may indicate that
patients with high BMI suffer from compromised mitochondrial function, due to
lipotoxicity, causing the mitochondria to work harder in order to produce the same
amount of ATP as a person with lower BMI.
We additionally hypothesized that oocyte maturity would be associated with
altered mitochondrial metabolic function in granulosa cells as the amount of
mtDNA in an oocyte has been previously shown to be important for oocyte maturity
and fertilization (Reynier et al., 2001). Since mtDNA content in the oocytes has
been shown to be associated with mtDNA content in the GCs (Boucret et al., 2015,
Desquiret-Dumas et al., 2017, Ogino et al., 2016) we hypothesized that the
mitochondrial metabolism of the GCs should reflect the mitochondrial metabolism
of the oocyte and relate to an oocyte’s overall developmental competence. The
amount of mtDNA in oocytes has previously been demonstrated to be reduced in
older patients and those with diminished ovarian reserve and mitochondrial
membrane potential has been shown to decrease with advancing age (de Boer,
1999, Diez-Juan et al., 2015, May-Panloup et al., 2005b). However, mtDNA copy
number alone does not account for how efficiently the mitochondria function. We
observed a significant increase for alpha-keto-isocaproic acid metabolism by GCs
in the assay as the number of mature oocytes increased. Alpha-keto-isocaproic
acid is converted to leucine by way of a transamination reaction. Leucine then is
converted to acetyl-CoA where it enters the tricarboxylic acid cycle. In our study,
the calculated mitochondrial metabolic scores were significantly increased in a
linear relationship with the total number of oocytes retrieved. Mitochondrial ATP
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production and mitochondrial membrane potential in CCs have both been shown
to correlate with the number of mature oocytes retrieved (Dumesic et al., 2016).
Our observations may indicate there is a component of leucine metabolism that is
related to final oocyte maturation.
We did not find any significant differences in mitochondrial metabolism
related to age or serum AMH (Figure 4.17 and 4.18). AMH levels and advanced
maternal age are closely related. Both AMH gene and protein expression are
increased in GCs with advancing age (Kedem et al., 2014) while serum AMH levels
in the blood decrease as the supply of oocytes dwindles with age (Knight and
Glister, 2006). We performed correlation analysis between mtDNA copy number
and patient age, BMI, serum AMH levels, and oocyte maturity and found no
differences (Figure 4.19). The reason we may not have seen differences in these
groups is because were we unable to look at patients with low oocyte yield, which
normally fall in the low AMH and older patient groups. The minimum number of
GCs needed to utilize the mitochondrial function assay required pooled CCs and
MGCs from at least 10 oocytes. Therefore, older women and those with lower
AMH levels in our study were still within a better prognostic group than patients
with low oocyte yield due to age or diminished ovarian reserve. If we had been
able to use fewer GCs for the assay and could have included patients with lower
oocyte yield, we may have observed different results.
A secondary goal of this study was to determine if mitochondrial substrates
in pooled GCs would relate to a patient’s overall cohort development and yield
potential substrate biomarkers to possibly predict embryo development or
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pregnancy/live birth in future studies. The premise of this hypothesis was that one
potential explanation for compromised oocyte, and subsequent embryo quality,
has been postulated to be deficient mitochondrial function (Bentov et al., 2011).
Embryo viability is related to the amount of energy produced by the mitochondria
in the oocyte and surrounding GCs as early embryogenesis demands substantial
amounts of energy produced by the mitochondria to drive the cleavage divisions
(May-Panloup et al., 2005a, Reynier et al., 2001, Zhao et al., 2010). In fact,
mitochondria with metabolic dysfunction may impair oocyte quality, overall embryo
development, and live birth rates (Dumesic et al., 2016).
Glycogen is a cytoplasmic substrate which is converted through several
steps to acetyl-CoA where it enters the tricarboxylic acid cycle. Mitochondrial
utilization of glycogen was found to be significantly lower in patients with lower
fertilization percentage. Mitochondrial metabolic scores significantly increased as
the number of mature oocytes retrieved increased, while the scores decreased as
the number of fertilized oocytes increased. This inverse relationship is likely due
to the fact that GCs surrounding immature oocytes may exhibit increased
mitochondrial activity which drops off as the oocyte matures and prepares for
fertilization.

Prior studies have demonstrated higher mean mtDNA levels in

fertilized human oocytes compared to both unfertilized oocytes and degenerated
oocytes (Reynier et al., 2001, Santos et al., 2006, Murakoshi et al., 2013). Our
data appear to indicate that mitochondria in granulosa of oocytes that are better
positioned to fertilize can utilize glycogen more efficiently to produce ATP than
those granulosa of oocytes less likely to fertilize and perhaps the increase in ATP
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is needed in order to complete fertilization.

This data indicates that the

mitochondrial metabolic score may be able to predict fertilization potential of a
cohort of oocytes.
Mitochondrial utilization significantly increased for D-alpha-keto-glutaric
acid in GCs from patients with lower good quality 8-cell embryos compared to
those with high good quality 8-cell embryos. In addition, mitochondrial utilization
of L-glutamine was found to be significantly higher in pooled GCs in patients with
a lower percentage of blastocyst formation when using a backward selected model
looking only at 8-cell embryos and blastocysts. L-glutamine was likely converted
to alpha-keto-glutaric acid and used the same biochemical pathway in the assay.
Increased mtDNA copy numbers in CCs have been shown to be associated with
embryos that developed into high quality versus low-quality embryos and embryos
more likely to implant than those that did not implant. It has been postulated that
increased mitochondria within a blastocyst may serve to compensate for reduced
mitochondrial energy production due to metabolic stress from reactive oxygen
species and free radicals (Diez-Juan et al., 2015, Fragouli et al., 2015, Grindler
and Moley, 2013, May-Panloup et al., 2016). In future studies use of a single
substrate that showed significant differences based on embryo development could
conceivably be optimized to test individual CC masses to examine the endpoints
of individual embryo development, pregnancy, and live birth.
Finally, we wanted to test the hypothesis that the mitochondrial metabolic
score, which reflects overall mitochondrial activity in the granulosa pool would be
differ between mRNA levels of the selected genes. We selected AMH mRNA,
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based on our original hypothesis that serum AMH levels would alter substrate
utilization. We selected AREG, CYP19A1, CYP11A1, HSD3B1, ING1, LHCGR,
and PAPPA as genes of interest based on a prior study our lab conducted with
individual cumulus masses (Kordus et al., 2019). HSD3B levels were borderline
lower (P < 0.10) as the mitochondrial metabolic score decreased, but none of these
mRNAs showed significant regulation. In our prior study we examined individual
CC masses from oocytes and their individual embryos. We believe we did not see
any significant differences due to the use of pooled GCs in this study.
A strength of this study was that we were able to compare multiple
substrates at once over a specified time course using the mitochondrial function
assay.

Another strength of this study was that we were able to assess

mitochondrial function and not just mtDNA content. This study was limited by the
number of GCs needed to analyze each substrate in triplicate in the mitochondrial
function assay. We found that the threshold concentration of cells needed was
approximately 7000 cells per well or just above 650,000 cells per plate in order to
yield absorbance readings above the negative control values. Therefore, this
necessitated pooling of the MGCs and the CCs to achieve the required number of
cells per patient for the assay plate. Since we pooled the GCs, this caused us to
have to examine at the embryo cohort as a whole, rather than individual embryos,
which reduces the clinical utility of using this particular test to assess embryo
development. Since this was a pilot study, our goal was to narrow the cohort of
substrates down to a few which could be optimized in the future to analyze
individual CC masses and then relate those results to individual oocytes and
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resulting embryos in future studies. Specialized assay plates could be made with
only the substrates of interest in the wells. Another limitation was the use of two
stimulation protocols. A more ideal study would include patients undergoing a
single stimulation protocol, either long luteal stimulation or antagonist stimulation.
Mitochondrial function and its relationship to human reproductive potential
is poorly understood, and further research needs to be conducted regarding oocyte
developmental competence and embryonic development. In this study we found
mitochondrial metabolic function was altered with BMI and FSH dosage. We also
found that there was a subset of mitochondrial metabolic substrates utilized by
GCs that can potentially be used as novel biomarkers related to embryo
development in future studies.
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Supplementary data are available at Journal of Assisted Reproduction and
Genetics online.
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Figure 4.1 Flow diagram summarizing the study population from oocyte
retrieval to final outcome. Oocytes, CC masses, and MGCs were collected from
58 patients (pts). Individual CC masses from each oocyte collected (n=817) were
combined with the MGCs from each patient. Fourteen samples collected had an
insufficient number of cells to visualize an appropriate color change in the wells of
the assay plate and were excluded from the analysis. Four patients did exceed
the minimum number of cells required to run the plate but no color changes were
observed with the control wells and thus were excluded from the analysis, so the
final number of patients analyzed was n = 40.
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Table 4.1 Patient demographics and cycle information
Pt #

Age

BMI

1
2
3
4
5
6
7
8
9

34
24
40
26
32
38
36
36

23.1
19.4
19.9
21.6
19.1
21
29.7
27.9

32

21.7

35
30

25.3
26.7

34
30
29
33
35

36.7
19
26.2
30.3
21.4

37
38

29.4
35.7

33
28
22

28.3
23
19.3

10
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11
12
13
14
15
16
17
18
19
20
21

Diag

AMH

AFC

STIM

MF
MF
MF
PCO
RPL
AMA
RPL
DOR

5.65
2.25
3.86
4.34
1.98
1.52
2.48
0.55

15
27
20
30
11
11
26
7

LL
LL
LL
LL
AN
AN
AN
AN

TUBAL
MF.OD.
PCO
RPL
MF.OD.
PCO
OD
MF
DOR
MF
OD.
AMA
OD
DOR.
OD
MF
IDIO

6.28

9

1.17
3.67

HMG
dose

FSH
dose

# Mat
oocyte

%
Fert

%
Blast

mtDNA
content

77%
89%
90%
67%
86%
82%
92%
67%

%
8-C
Good
71%
25%
61%
33%
58%
55%
78%
83%

300
600
450
750
750
675
750
1200

825
1125
1488
1425
1700
1575
1800
3300

22
9
20
9
14
11
25
9

47%
50%
61%
33%
50%
66%
73%
100%

0.001184
0.001294
0.001562
0.001663
0.000311
0.001355
0.000824
0.000778

LL

525

1525

6

17%

0%

0%

0.000525

11
22

AN
LL

675
825

2025
2250

6
18

67%
67%

0%
50%

50%
58%

0.000621
0.000957

3.02
2.5
1.85
0.78
5.48

25
22
13
13
22

LL
LL
LL
AN
LL

525
675
750
600
750

1050
1425
1500
1800
1875

14
13
10
11
15

36%
85%
60%
82%
73%

0%
55%
67%
67%
55%

0%
54%
50%
33%
64%

0.000592
0.000927
0.001091
0.001265
0.004323

1.14
2.63

12
12

AN
AN

675
825

2250
2475

7
16

86%
94%

50%
87%

50%
47%

0.006901
0.000297

1.75
6.8
5.38

11
18
30

AN
LL
LL

825
600
225

3150
1050
787.5

15
11
25

73%
46%
80%

55%
60%
70%

55%
20%
80%

0.001608
0.000809
0.000432

Table 4.1 Patient demographics and cycle information continued
22
23
24
25
26
27
28
29
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30
31
32
33
34
35
36
37
38
39
40
median
range

32
31
36

21.5
29.7
17.9

ENDO
OD
MF

4.73
5.06
1.26

20
23
23

LL
LL
LL

600
750
825

1275
1500
2475

24
19
12

58%
84%
58%

21%
38%
57%

57%
62%
43%

0.000362
0.001179
0.001328

31
35
36
37

29
31.3
38.3
33.1

PCO
OD
OD
OD

11.5
0.85
1.92
1.94

27
7
9
8

LL
AN
LL
LL

525
750
825
825

1050
2250
3000
3000

10
11
12
10

90%
100%
92%
80%

100%
55%
27%
62%

78%
55%
9%
75%

0.00098
0.000769
0.001229
0.000902

1.61
5.65
9.66
5.13
6.19
1.66
4.68
9.39
5.47
3.15
6.55
9.97
3.41
0.55
11.5

9
15
30
30
27
19
27
30
19
30
30
30
20
7
30

AN
LL
LL
LL
LL
LL
LL
LL
LL
AN
LL
LL

1050
300
600
600
675
675
600
750
750
825
675
675
675
225
1200

3000
775
938
1050
1175
1450
1100
1125
1950
2625
1525
1350
1512
775
3300

6
25
16
22
15
9
26
17
10
22
26
11
19
10
41

100%
84%
88%
68%
73%
89%
42%
100%
70%
82%
100%
73%
81%
17
100

83%
67%
79%
73%
64%
50%
36%
88%
86%
56%
62%
25%
58%
0
100

67%
52%
57%
73%
55%
75%
55%
47%
71%
72%
81%
0%
55%
0
100

0.000570
0.000354
0.000201
0.001147
0.00108
0.000680
0.000739
0.000571
0.001878
0.000675
0.000837
0.000944
0.009145
0.000200
0.006901

37
34
27
33
34
33
31
28
31
38
31
38
33
22
40

26.6
25.8
25.8
23
29.3
28.5
34.4
29.8
20.2
33.1
18.9
23.1
26
17.9
38.3

RPL
BALTRAN
MF
AMEN
RPL
UT
RPL
OD
OD
OD
AMA
OD
OD

Table 4.1 Patient demographics and cycle information continued
_______________________________________________________________________________________________
8-C = 8-cell embryo, AFC = antral follicle count, AMEN = amenorrhea, AMA = advance maternal age, AMH = antiMullerian hormone, AN = antagonist stimulation, BAL-TRAN = balanced translocation, Blast = blastocyst, BMI = body
mass index, Diag = diagnosis, DOR = diminished ovarian reserve, ENDO = endometriosis, FERT = fertilization, FSH =
follicle stimulating hormone, HMG = human menopausal gonadotropin, IDIO = idiopathic, IUs = international units, LL =
long luteal stimulation, MAT = mature, MF = male factor, mtDNA = mitochondrial DNA, PCO = polycystic ovaries, Pt =
patient, OD = ovulatory dysfunction, RPL = recurrent pregnancy loss, STIM = stimulation type, TUBAL = tubal factor, UT =
uterine anomaly
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Table 4.2 List of Substrates on the Mitoplate-S-1 Mitochondrial Function Assay
Cytoplasmic substrates
No substrate control

alpha-D-glucose

glycogen

D-glucose-1-phosphate

D-glucose-6-phosphate

D-gluconate-6-phosphate

L-lactic acid

D,L-alpha-glycerol-phosphate

Tricarboxylic acid cycle substrates
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pyruvic acid

citric acid

D,L-isocitric acid

cis-aconitic acid

D-alpha-keto-glutaric acid

succinic acid

fumaric acid

L-malic acid

alpha-keto-butyric acid

D,L-beta-hydroxy-butyric acid

L-glutamic acid

L-glutamine

alanine-glycine

L-serine

L-ornithine

tryptamine

Other mitochondrial substrates

Other mitochondrial substrates with malic acid 100uM
malic acid 100uM

octanoyl-L-carnitine

acetyl-l-carnitine

palmitoyl-D,L-carnitine

gamma-amino-butyric acid

alpha-keto-isocaproic acid

pyruvic acid

L-leucine

Table 4.3 Primer set information
Gene

Primer sequences
5'--3'

AMH

For GTGCTGCTGCTGAAGATG
Rev CTCCGACAGGCTGATGAG
For TGGACCTCAATGACACCTACTCTG
Rev GGGCTTAACTACCTGTTCAACTCTG

AREG

ACTB

Annealing
Amplicon
temperature size
(°C)
(base
pairs)
60
102
62

251

Reference or NCBI no.

(Detti et al., 2018)
(Feuerstein et al.,
2007)

For AGCGGGAAATCGTGCGTGAC
Rev AGGCAGCTCGTAGCTCTTCTC
For GCACATCCTCAATACCAGGTC
Rev TTTGAGGGATTCAGCACAGAC

60

116

60

380

(Diez-Juan et al.,
2015)
(Hamel et al., 2008)

For TGTGCCAGTCTTCATCTACAC
Rev TGTTTTCCAGAGGCTCTTCTTC
For GCCTGGTGTGAGGAGGACAA
Rev CCCTATGAAAGGAATGGTTCCTT
For TGGAGAAGATGCACAATGGA
Rev GGCAATTAGCCTCTGAATGG

60

101

(Hamel et al., 2008)

62

124

(He et al., 2004)

60

122

(Yung et al., 2014)

For CTAAAATATTAAACACAAACTACCACCTACCTC
Rev GTTCATTTTGGTTCTCAGGGTTTGTT TAA

60

92

(Diez-Juan et al.,

PAPPA

For GTCATCTTTGCCTGGAAGGGAGAA
Rev AGGGCTGTTCAACATCAGGATGAC

62

129

(Wagner et al., 2011)

TBP

For CACGGCACTGATTTTCAGTTC
Rev TCTTGCTGCCAGTCTGGACT

62

79

(Nelson-Degrave et
al., 2004)

CYP19A1
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HSD3B1
ING1
LHCGR
MT-ATP8

2015)

Figure 4.2 Sample mitochondrial functional assay Mitoplate-S-1. The
mitochondrial function assay plates contained 31 cytoplasmic and mitochondrial
metabolic substrates repeated in triplicate. Each well in the plate contained an
individual chemical as the sole energy source. As the cells metabolized the energy
source, tetrazolium dye in the media was reduced, generating a purple color
according to the amount of NADH or FADH2 reducing equivalents generated over
2.0 hrs. Absorbance readings in the assay reflected metabolism or utilization of
substrates

176

177
Figure 4.3 Substrates demonstrating significant mitochondrial utilization differences based on body mass index.
To determine the differences in mitochondrial utilization, substrates were compared using a multiple linear regression model
using Box-Cox transformation. BMI was divided into 2 groups with the higher group being patients with a BMI of ≥ to 26
kg/m2 (n = 20) and the lower group being patients with a BMI of < 26 kg/m2 (n = 20). Mitochondrial utilization of citric acid
(P < 0.01), L-malic acid (P < 0.05), and octanoyl-L-carnitine (P < 0.01) were found to be significantly lower in pooled GCs
of patients with lower BMI, after adjusting for the other factors in the model. Data are presented as the median (line inside
box), first and third quartile (bottom and top of box), and the whiskers extend to 1.5 times the interquartile range beyond the
first and third quartile.
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Figure 4.4 Substrates demonstrating no significant mitochondrial utilization differences based on body mass
index. To determine the differences in mitochondrial utilization, substrates were compared using a multiple linear
regression model using Box-Cox transformation between BMI groups. BMI was divided into 2 groups with the higher group
being patients with a BMI of ≥ to 26 kg/m 2 (n = 20) and the lower group being patients with a BMI of < 26 kg/m2 (n = 20).
Mitochondrial utilization of cis-acontic acid (P < 0.10), D,L-beta-hydroxy-butyric acid (P < 0.10), and pyruvic acid/L-malic
acid 100 µM (P < 0.10) were found to be borderline lower in pooled GCs of patients with lower BMI, after adjusting for the
other factors in the model. No other substrates showed any mitochondrial utilization differences. Data are presented as
the median (line inside box), first and third quartile (bottom and top of box), and the whiskers extend to 1.5 times the
interquartile range beyond the first and third quartle.
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Figure 4.4 Continued
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Figure 4.4 Continued

Figure 4.5 Substrates demonstrating significant mitochondrial utilization
differences based on number of mature oocytes retrieved. To determine the
differences in mitochondrial utilization, substrates were modeled using multiple
linear regression after Box-Cox transformation for normality. Individuals with
greater numbers of mature oocytes retrieved were found to have a significant
increase in alpha-keto-isocaproic acid mitochondrial utilization (P < 0.01) in pooled
GCs of patients, after adjusting for the other factors in the model. Data are
presented as a scatter plot of the individual patient Box-Cox transformed values
showing the trend line and the 95% confidence region.
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Figure 4.6 Substrates demonstrating no significant mitochondrial utilization differences based on number of
mature oocytes retrieved. To determine the differences in mitochondrial utilization, substrates were modeled using
multiple linear regression after Box-Cox transformation for normality. No substrates in pooled GCs of patients demonstrated
any significant mitochondrial utilization differences, after adjusting for the other factors in the model. Data are presented as
a scatter plot of the individual patient Box-Cox transformed values showing the trend line and the 95% confidence region.
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Figure 4.6 Continued
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Figure 4.6 Continued
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Figure 4.7 Substrates demonstrating significant mitochondrial utilization differences based on total FSH dose
administered. To determine the differences in mitochondrial utilization, substrates were modeled using multiple linear
regression after Box Cox transformation for normality. Mitochondrial utilization for citric acid (P < 0.05), cis-acontic acid (P
< 0.01), D-alpha-keto-glutaric acid (P < 0.05), L-glutamine (P < 0.05), and alanine-glycine (P < 0.05) in pooled GCs of
patients were found to be significantly lower as total FSH dose administered increased, after adjusting for the other factors
in the model. Data are presented as a scatter plot of the individual patient Box-Cox transformed values showing the trend
line and the 95% confidence region.
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Figure 4.8 Substrates demonstrating no significant mitochondrial utilization differences based on total FSH dose
administered. To determine the differences in mitochondrial utilization, substrates were modeled using multiple linear
regression after Box-Cox transformation for normality. Mitochondrial utilization of D,L-isocitric acid (P < 0.10), D,L-betahydroxy-butyric acid (P < 0.10), L-glutamic acid (P < 0.10), acetyl-L-carnitine (P < 0.10), pyruvic acid/L-malic acid 100 µM
(P < 0.10) were found to be borderline lower in pooled GCs of patients with higher administered FSH dosages, after
adjusting for the other factors in the model. No other substrates showed any mitochondrial utilization differences. Data
are presented as a scatter plot of the individual patient Box-Cox transformed values showing the trend line and the 95%
confidence region.
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Figure 4.8 Continued
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Figure 4.8 Continued
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Figure 4.9 Mitochondrial metabolic scores demonstrating significant utilization differences based on BMI, total FSH
dose, and number of mature oocytes retrieved. Mitochondrial metabolic scores were Box-Cox transformed for normality
and modeled using multiple linear regression. A) Mitochondrial metabolic scores were found to be significantly higher in
GCs of patients with higher numbers of mature oocytes retrieved (P < 0.05), after adjusting for the other factors in the model.
In a backward selected best fit model using only the BMI and total FSH dosage administered, B) mitochondrial metabolic
scores were found to be significantly lower in pooled GCs of patients with a lower BMI (P < 0.05). BMI was divided into 2
groups with the higher group being patients with a BMI of ≥ to 26 kg/m 2 (n = 20) and the lower group being patients with a
BMI of < 26 kg/m2 (n = 20). C) Mitochondrial metabolic scores were found to be significantly lower as the patient’s FSH
dose administered increased (P < 0.01). For BMI, transformed mitochondrial metabolic scores are presented as the median
(line inside box), first and third quartile (bottom and top of box), and the whiskers extend to 1.5 times the interquartile range
beyond the first and third quartile. For mature oocytes retrieved and FSH dose administered, the transformed scores are
presented in a scatter plot of the individual patient values showing the trend line and the 95% confidence region.
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Figure 4.10 Substrates demonstrating significant mitochondrial utilization differences based on embryo cohort
development. To determine the differences in mitochondrial utilization, substrates were modeled using multiple linear
regression after Box-Cox transformation for normality. Cohorts were grouped as follows, higher fertilization percentage ≥
80% (n = 22), and lower fertilization percentage < 80% (n = 18); Higher good 8-cell development > 55% (n = 22) and lower
good 8-cell development ≤ 55% (n = 18); and higher percentage of blastocyst formation > 55% (n = 17) and lower percentage
of blastocyst formation ≤ 55% (n = 22). One patient was excluded from the blastocyst formation data as she had an embryo
transfer on day 3 with no additional embryos available for extended culture. A) Mitochondrial utilization of glycogen (P <
0.05) was found to be significantly lower in GCs of patients with lower fertilization percentage, B) mitochondrial utilization
of D-alpha-keto-glutaric acid (P < 0.05) was found to be significantly higher in GCs from patients with a lower percentage
of good quality 8-cell embryos, after adjusting for the other factors in the model. C) In a backward selected best fit model
using only the percentage of good 8-cell embryos and percentage of blastocysts, mitochondrial utilization of L-glutamine (P
< 0.05) was found to be significantly higher in GCs from patients with a lower percentage of blastocyst formation. Data are
presented as the median (line inside box), first and third quartile (bottom and top of box), and the whiskers extend to 1.5
times the interquartile range beyond the first and third quartile.
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Figure 4.11 Substrates demonstrating no significant mitochondrial utilization differences based on fertilization
percentage. To determine the differences in mitochondrial utilization, substrates were compared using a multiple linear
regression model using Box-Cox transformation. The 2 groups were delineated by higher fertilization percentage ≥ 80% (n
= 22), and lower fertilization percentage < 80% (n = 18). Data are presented as the median (line inside box), first and third
quartile (bottom and top of box), and the whiskers extend to 1.5 times the interquartile range beyond the first and third
quartile.
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Figure 4.11 Continued
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Figure 4.11 Continued
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Figure 4.12 Substrates demonstrating no significant mitochondrial utilization differences based on good 8-cell
embryo development. To determine the differences in mitochondrial utilization, substrates were compared using a multiple
linear regression model using Box-Cox transformation. The 2 groups were delineated by higher good 8-cell development
> 55% (n = 22) and lower good 8-cell development ≤ 55% (n = 18). Mitochondrial utilization of L-serine (P < 0.10) was
found to be borderline higher in GCs of patients with a lower percentage of good quality 8-cell embryos. In a backward
selected best fit model using only the percentage of good 8-cell embryos and percentage of blastocysts, L-glutamine (P <
0.10) was found to be borderline higher in in pooled GCs from patients with a lower percentage of good quality 8-cell
embryos. No other substrates showed significant differences. Data are presented as the median (line inside box), first and
third quartile (bottom and top of box), and the whiskers extend to 1.5 times the interquartile range beyond the first and third
quartile.
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Figure 4.12 Continued
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Figure 4.12 Continued
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Figure 4.13 Substrates demonstrating no significant mitochondrial utilization differences based on blastocyst
formation. To determine the differences in mitochondrial utilization, substrates were compared using a multiple linear
regression model using Box-Cox transformation. The 2 groups were delineated by higher percentage of blastocyst formation
> 55% (n = 17) and lower percentage of blastocyst formation ≤ 55% (n = 22). Mitochondrial utilization of D-Gluconate-6phosphate (P < 0.10), and D,L-isocitric acid (P < 0.10) were found to be borderline higher in patients with a lower percentage
of blastocyst formation in pooled GCs, after adjusting for the other factors in the model. No other substrates demonstrated
significant differences. Data are presented as the median (line inside box), first and third quartile (bottom and top of box),
and the whiskers extend to 1.5 times the interquartile range beyond the first and third quartile.
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Figure 4.13 Continued
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Figure 4.13 Continued

Figure 4.14 Mitochondrial metabolic scores demonstrating significant
utilization differences based the total number of fertilized oocytes. Based
on the estimated multiple linear regression model using observed data after BoxCox transformation for normality, mitochondrial metabolic scores were found to be
significantly higher in granulosa cells of patients with higher overall number of
fertilized oocytes (P < 0.05) in pooled GCs, after adjusting for the other factors in
the model, Data are presented as a scatter plot of the individual patient Box-Cox
transformed values showing the trend line and the 95% confidence region.
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Figure 4.15 Mitochondrial metabolic scores based on mRNA levels. Based on Pearson’s correlation analysis using
data after Box-Cox transformation for normality, HSD3B mRNA levels were borderline significantly lower (P < 0.10) as the
mitochondrial metabolic score decreased, Data are presented as a scatter plot of the individual patient Box-Cox transformed
values showing the trend line and the 95% confidence region.
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Figure 4.16 Tricarboxylic acid cycle diagram showing where the substrates of the mitochondrial function assay
enter the cycle. This pathway diagram illustrates the various points where the substrates are converted and enter the
tricarboxylic cycle. The substrates were metabolized through different biochemical pathways by entering the mitochondria
through different transporters and they were then modified by various enzymes and dehydrogenases to produce NADH or
FADH2. Blue = tricarboxylic acid constituents that are not substrates in the assay, Blue boxes = enzymes, Black =
tricarboxylic acid cycle substrates, ETC = electron transport chain, FADH2 = flavin adenine dinucleotide hydride, Green =
other mitochondrial substrates, NADH = nicotinamide adenine dinucleotide hydride, Red = cystolic substrates.
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Figure 4.17 Substrates demonstrating no significant mitochondrial utilization differences based on age. To
determine the differences in mitochondrial utilization, substrates were modeled using multiple linear regression after BoxCox transformation for normality. Age was divided into 2 groups with the older age being ≥ 34 years old (n = 19) and
younger age being < 34 years old (n = 21). No substrates showed any statistically significant difference in mitochondrial
utilization. Box-Cox transformed data are presented as the median (line inside box), first and third quartile (bottom and top
of box), and the whiskers extend to 1.5 times the interquartile range beyond the first and third quartile.
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Figure 4.17 Continued
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Figure 4.17 Continued
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Figure 4.18 Substrates demonstrating no significant mitochondrial utilization differences based on serum AMH
levels. To determine the differences in mitochondrial utilization, substrates were modeled using multiple linear regression
after Box-Cox transformation for normality. Serum AMH was divided into 2 groups with higher serum AMH being ≥ 3.5
ng/mL (n = 20) and lower serum AMH being < 3.5 ng/ml (n = 20). No substrates showed any statistically significant
difference in mitochondrial utilization. Box-Cox transformed data are presented as the median (line inside box), first and
third quartile (bottom and top of box), and the whiskers extend to 1.5 times the interquartile range beyond the first and third
quartile.
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Figure 4.18 Continued
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Figure 4.18 Continued
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Figure 4.19 Pooled granulosa cell mtDNA content had no significant association with patient demographics nor
oocyte outcomes. For categorical groups, Box-Cox transformed mtDNA values are presented as the median (line inside
box), first and third quartile (bottom and top of box), and the whiskers extend to 1.5 times the interquartile range beyond
the first and third quartile. Averages were compared using independent samples t-tests. For continuous variables, data
are presented as a scatter plot of the individual patient Box-Cox transformed values showing the trend line and the 95%
confidence region. Pearson’s correlation coefficients were estimated and tested for statistical significance. 8-cells = 8-cell
embryos, AFC = antral follicle count, AMH = anti-Mullerian hormone, ANT = antagonist stimulation, BMI = body mass
index, FSH = follicle stimulating hormone, HMG = human menopausal gonadotropin, LL = long luteal stimulation, mtDNA
= mitochondrial DNA, STIM = stimulation type
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Mature oocytes

Figure 4.19 Continued

221

Chapter 5
General Discussion5

________________________________________________________________
5R.J.

Kordus and H.A. LaVoie. Granulosa cell biomarkers to predict pregnancy in
ART: pieces to solve the puzzle. 2017. Reproduction. 153(2):R69-R83.
Epub 2016 Nov 4. Review. Portions adapted from and reprinted here with
permission of publisher
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Granulosa cells within each follicle are composed of both the CCs and the
MCGs that surround the individual oocytes. The fact that granulosa are easily
collected as a by-product of the IVF process, and the fact that GCs are intimately
related to oocyte maturation and developmental potential (Dumesic et al., 2015),
make them ideal non-invasive materials to investigate various biomarkers to
improve IVF outcomes. Multiple oocytes and their corresponding cumulus and
mural granulosa cells are retrieved during assisted reproduction. As it is possible
to isolate the CCs and MGCs associated with an individual oocyte from each
retrieval, analyses of these cells may be valuable for screening biomarkers
identifying embryos capable of producing a live birth. Appendices A-C summarize
biomarker studies and indicate that CCs more often than MGCs exhibit biomarkers
associated pregnancy and live birth outcomes (Kordus and LaVoie, 2017). Greater
reliability of biomarkers being present in CCs seems logical as they are in direct
contact with the oocyte at the time of retrieval from the ovary. Data from these
studies suggest that the likelihood of a single expressed gene as a predictor of
pregnancy is low, and that multiple genes and cycle characteristics are needed to
create the best predictive models. Patient diagnoses, age, BMI, and IVF
stimulation protocols; among other factors, can alter study outcomes.

A

homogeneous patient study population is critical in identifying GC biomarkers for
predictive models. In addition, the paternal contributions to fertilization, embryo
quality, and live birth outcomes is rarely addressed in studies, but should be
considered. Stepwise multivariate analysis where multiple variables include levels
of several of the most predictive mRNA biomarkers corrected for variations in
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specific patient characteristics, may yield a reliable approach for selecting the best
embryos with potential for live birth (Adriaenssens et al., 2010a).

Predictive

models that can be tested in multiple clinics will allow large scale validation of
biomarkers and possibly transform procedures used for the selection of embryos
for uterine transfer and improve assisted reproduction success rates.
Our long-term goal is to create a panel of granulosa biomarkers that can
help improve a patient’s odds of success using IVF on their first attempt.
Ultimately, our objective is to obtain a biomarker panel that can help embryologists
quickly and easily select an embryo, from a patient’s cohort of embryos, which has
the best chance of implanting in the uterus and leading to a heathy child. In our
first set of aims, we prospectively examined mRNA transcripts in individual CC
masses and related those biomarkers to individual oocyte, and subsequent
embryo genetic status, oocyte developmental competence, and live birth
outcomes. In this series of experiments, we contributed several important and
original contributions to the field of IVF:
•

We revealed for the first time that higher mRNA levels of a novel biomarker,
PAPPA, may be a trustworthy biomarker in individual CCs associated with
identifying oocytes capable of leading to a live birth.

•

We confirmed that higher mRNA levels LHCGR and lower mRNA levels of
AREG in CCs were associated with oocytes that formed embryos capable
of leading to live birth.
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•

We concluded that collectively, CC PAPPA, LHCGR, and AREG mRNA
may be able to be employed as a biomarker panel to identify oocytes with
the best odds of resulting in a live birth.

•

We indicated that lower CC mRNA levels of HSD3B1 were associated with
oocytes that developed into euploid embryos.

Since several studies previously investigated mRNA transcript biomarkers, we
carefully selected transcripts that were potential biomarkers from several previous
studies to validate and we also examined some novel transcripts. Our study was
slightly different than other prior studies as we chose to examine mRNA transcripts
levels in relation to oocyte maturity, abnormal embryo development, embryo ploidy
status, and live birth outcomes. Relatively few studies have examined mRNA
levels as related to ploidy status and IVF outcomes (Fragouli et al., 2010, Fragouli
et al., 2012, Parks et al., 2016, Green et al., 2018).
We hypothesized that certain mRNA transcripts in individual CCs could be used
to select individual oocytes, and their subsequent embryos, with the highest
probability of leading to viable pregnancies and resulting in live births. We found
that increased PAPPA and LHCGR mRNA levels were associated CCs
surrounding mature oocytes that resulted in live births. Differences were also
observed between immature oocytes compared to aneuploid embryos and
immature oocytes compared to arrested embryos, respectively.

This data

indicates that embryos with increased CC mRNA levels of PAPPA and LHCGR
should be preferentially selected first for uterine transfer, using these models, as
they have been shown to be more likely to yield a live birth. This differential mRNA

225

expression between immature oocytes and mature oocytes leading live birth
provides evidence for a potential optimal maturation window.
When comparing only transferred embryos within the entire biomarker
panel, oocytes with decreased AREG and increased PAPPA mRNA levels in their
CCs were more likely to produce a live birth. When applied to the best fitting live
birth prediction model, which included a smaller subset of the biomarker panel,
PAPPA and CYP19A1 mRNA predicted live birth. This could indicate that PAPPA
mRNA may be a reliable biomarker for identifying oocytes capable of leading to a
live birth. PAPPA mRNA encodes a metalloproteinase that cleaves insulin-like
growth factor binding protein 4 (IGFBP4) and IGFBP5 proteins and is found in
follicular fluid (Conover et al., 1999, Laursen et al., 2001, Mazerbourg et al., 2001).
It is a novel biomarker we chose to examine. PAPPA mRNA is present in antral
follicles >5 mm through the pre-ovulatory stage and corpora lutea, but absent in
pre-antral, small antral (1-2 mm), and atretic follicles (Hourvitz et al., 2000).
Furthermore, PAPPA mRNA is present in cultured GCs from human follicles >8
mm (Conover et al., 2001) which coincides temporally with selection of the
dominant follicle during the reproductive cycle (Baerwald et al., 2012). Increased
levels of PAPPA mRNA and its resulting protein in GCs of peri-ovulatory follicles
may be necessary to increase intrafollicular IGF availability. Cleavage of IGFBPs
by PAPPA protein would release IGFs and result in an increase in free IGF
available for signaling (Firth and Baxter, 2002). IGFs are known to enhance FSH
and LH signaling and increase LHCGR abundance (Wang and Chard, 1999).
Increased free IGF could potentially augment FSH and LH action on follicular cells
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during oocyte maturation leading to an optimized follicular environment, and thus
enhance the chances of falling within the optimal maturation window at the time of
oocyte retrieval. Oocytes at optimal maturity would more likely yield euploid
embryos and ultimately improve the chances of live birth.
FSHR and LHCGR are both G-coupled protein receptors. FSHR mRNA
has previously been linked to good quality blastocyst development (Ekart et al.,
2013). Papamentzelopoulou and colleagues demonstrated a relationship between
LHCGR mRNA and pregnancy with the ratio of LH splice variants being higher in
pregnant patients compared to non-pregnant patients (Papamentzelopoulou et al.,
2012b). Webb and Campbell hypothesized that individual follicles have different
sensitivities to FSH (Webb and Campbell, 2007); therefore, because FSH is known
to induce the expression of LH receptors in GCs with follicular maturation, one
might postulate that LHCGR expression is variable between individual follicles.
Interestingly, others have shown that LHCGR mRNA expression in CCs was
higher in mature, as opposed to immature oocytes, yet higher LHCGR mRNA
expression resulted in lower fertilization rates (Maman et al., 2012). Consistent
with these prior studies, we also found that immature oocytes had lower CC
LHCGR mRNA levels compared to all the other groups, with the exception of
arrested embryos. Haouzi and colleagues demonstrated that CC LHCGR mRNA
expression varied between and within individual patient cohorts of mature oocytes
(Haouzi et al., 2009). Measuring individual CCs LHCGR mRNA levels may also
have allowed us to show a difference between oocytes that led to a live birth and
those that did not.
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Genes related to CC expansion and oocyte maturation may show altered
mRNA levels when comparing mature and immature oocytes.

AREG is an

epidermal growth factor (EGF)-like family member previously shown to positively
correlate with embryo quality as well as oocyte maturation and CC expansion in
response to the LH surge (Freimann et al., 2004, Park et al., 2004, Zhang et al.,
2005). AREG protein has shown correlations with good oocyte quality with in vitro
matured porcine embryos (Sugimura et al., 2015) and human IVF derived good
quality oocytes (Zamah et al., 2010).

Huang and colleagues showed that

increased AREG mRNA levels in CCs and MGCs were more likely to be associated
with pregnancy (Huang et al., 2015). This differs from our study, as we saw
decreased AREG mRNA levels in CCs from oocytes resulting in live birth. This
discordant finding may be due to multiple reasons. In the Huang et al. study CCs
and MGCs were pooled together. In addition, the participants were more diverse
in terms of diagnoses than our study, and four different stimulation protocols were
used. While the overall AREG mRNA levels per patient may have been increased,
it is possible that the individual CC level for each oocyte leading to live birth was
decreased. Our results are consistent with a study by Feuerstein and colleagues
who showed reduced AREG mRNA levels for CCs of oocytes that resulted in highquality blastocysts (Feuerstein et al., 2007).
Steroidogenesis is a major function of developing follicles. Granulosa cells
and theca cells collectively produce androgens, estrogens, and progestins.
Differential mRNA levels of steroidogenic genes in CCs may impact the fate of
their associated oocytes.

Previously both CYP19A1 and HSD3B1 showed
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increased mRNA levels between pooled GCs from embryos that resulted in
pregnancies compared to embryos that failed to develop (Hamel et al., 2008). In
our study, decreased CC HSD3B1 levels significantly increased the odds of an
oocyte resulting in a euploid embryo. Additionally, CYP19A1 mRNA was one of
the biomarkers that borderline predicted live birth in our best fitting model.
CYP19A1 mRNA encodes aromatase, which converts androstenedione to estrone
and testosterone to estradiol (Conley and Hinshelwood, 2001). HSD3B1 protein
converts pregnenolone to progesterone (Simard et al., 2005).

Like LHCGR,

CYP19A1 mRNA is induced through FSH signaling, and CYP19A1 mRNA is more
prevalent in dominant follicles of monovulatory species (Hayashi et al., 2010,
Kristensen et al., 2017, Sisco et al., 2003). The optimal maturation window needed
to produce live birth may be reflected by the interplay between these genes as
seen in our study.
We also found decreased ING1 levels showed a borderline increase in the
odds of an oocyte resulting in a euploid embryo. ING1 mRNA is a novel biomarker
we examined. It encodes a tumor suppressor nuclear protein involved in both cell
growth and apoptosis and is a member of the p53 signaling pathway (Garkavtsev
et al., 1998). ING1 protein is known to modulate androgen receptor (AR) signaling
(Esmaeili et al., 2016b, Esmaeili et al., 2016a, Tallen et al., 2009) and suppress
angiogenesis (Tallen et al., 2009). We did not examine the mRNA expression of
AR as Assidi and colleagues found no difference between AR mRNA expression
of oocytes that formed a pregnancy and those that did not (Assidi et al., 2011).
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There are multiple oocytes retrieved during an IVF cycle that would normally
regress in a natural reproductive cycle and not ovulate. Although many of these
supernumerary oocytes will reach the MII stage of development morphologically,
the reason IVF cycles may yield lower percentages of oocytes leading to live birth
is because they fall outside the optimal maturation window. We hypothesize that
many mature appearing oocytes actually exhibit underlying pre- or post-mature
biomarker expression patterns in their CCs and MGCs indicating those oocytes
are incapable of producing high quality embryos that ultimately lead to live births.
Our study only evaluated what we believe to be immature versus mature
oocyte mRNA expression. Evaluation of post-maturity may be more difficult in a
clinical IVF setting. However, in vitro maturation studies in humans or in vivo
studies in lower mammals may help examine the post-mature aspect of oocyte
development. This concept has been recently demonstrated in CCs of CD-1 mice
examined at various time points following hCG injection. Artini and colleagues
demonstrated how the concept of the optimal maturation widow could be
investigated (Artini et al., 2017). Oocytes that fell within the optimal maturation
window exhibited lower levels of AKT serine/threonine kinase 1 (Akt1), BCL2-like
2 (Bcl2I2) and SHC adaptor protein 1 (Shc1) mRNAs (Figure 5.1).
Our second series of aims focused on identifying metabolic substrates
utilized by mitochondria in pooled GCs to determine if any of the substrates were
modulated in relation to patient age, serum AMH levels, BMI, percentage of mature
oocytes within a patient cohort, and embryo developmental endpoints. Since the
literature on mitochondria related to IVF outcomes is sparse and has focused
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mainly on mtDNA content, we wanted to quantify mitochondrial activity and see if
we could identify a group of metabolic substrates differentially utilized by
mitochondria that could be used as biomarkers for IVF.

In this series of

experiments, we contributed several important and original contributions to the
field of IVF:
•

We were the first to demonstrate that a novel mitochondrial function assay
using tetrazolium dye measuring NADH or FADH2 reducing equivalents of
individual substrates could be used to as a tool to investigate granulosa cell
mitochondrial function.

•

We showed that BMI, FSH dosage administered, and the number of mature
oocytes retrieved per cohort associate with how mitochondria utilize certain
substrates in pooled GCs including citric acid, L-malic acid, octanoyl-Lcarnitine, cis-acontic acid, D-alpha-keto-glutaric acid, L-glutamine, and
alanine-glycine.

•

We established that there were individual mitochondrial substrates
including, glycogen, D-alpha-keto-glutaric acid, and L-glutamine that were
altered in relation to oocyte fertilization, embryo development on day 3, and
embryo development to the blastocyst stage.

•

We presented a mitochondrial metabolic scoring system, based on the
mitochondrial function assay results, to interrogate different patient
demographic groups and differences between embryo cohorts.

We discovered that citric acid, L-malic acid, and octanoyl-L-carnitine utillzation by
mitochondria were significantly lower in patients with lower BMI. We expected to
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find some differences in this patient demographic because impaired mitochondrial
function including decreased mitochondrial membrane potential, lower ATP levels,
and lower citric acid levels have been demonstrated to be associated with
increasing BMI in mice (Wang et al., 2010, Igosheva et al., 2010, Ou et al., 2012).
Further, obese patients have been shown to have reduced pregnancy and live birth
rates (Koning et al., 2012, Petersen et al., 2013, Pinborg et al., 2013, Rittenberg
et al., 2011).

Additionally, we found increasing dosages of FSH lowered

mitochondrial utilization of citric acid, cis-acontic acid, D-alpha-keto-glutaric acid,
L-glutamine, and alanine-glycine.

FSH dosage administered was previously

shown to have no impact mitochondrial mRNA expression in GCs of IVF patients
(Saito et al., 2013). However, our data may indicate there is a physiological
metabolic effect in the mitochondria related to FSH dosage. We found that the
mitochondrial metabolic scores were significantly reduced when BMI was lower
and total FSH administered was higher. FSH and BMI are linked during IVF
stimulation as patients with lower BMI tend to require lower doses of FSH than
patients with higher BMI (Fedorcsak et al., 2004). These results seem to indicate
that higher BMI increases, while increased dosages of FSH suppress,
mitochondrial utilization of substrates related to dehydrogenase activity and
oxidation reactions of the tricarboxylic acid cycle.
Alpha-keto-isocaproic acid mitochondrial utilization significantly increased
as the number of mature oocytes increased.

A prior study by Duran and

colleagues demonstrated that ATP levels increase as oocytes mature from GVs to
MII oocytes indicating an increase in mitochondrial metabolism as oocytes mature
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(Duran et al., 2011). We calculated that the mitochondrial metabolic scores were
significantly increased in a linear relationship with the total number of oocytes
retrieved. Mitochondrial ATP production and mitochondrial membrane potential in
CCs have both been shown to correlate with the number of mature oocytes
retrieved (Dumesic et al., 2016). The data from all these studies seem to coincide
as overall metabolism appears to increase with larger numbers of mature oocytes
harvested, potentially indicating a need for higher ATP requirements as GCs help
prepare the oocytes for fertilization.
The secondary goal of this study was more intimately related to our overall
long-term goal. One hypothesis for poor oocyte quality and compromised embryo
development is deficient mitochondrial function (Bentov et al., 2011). We wanted
to determine if mitochondrial substrates in pooled GCs would relate to a patient’s
overall cohort development.

Mitochondrial utilization of products of glycogen

degradation were found to be significantly lower in patients with lower fertilization
percentage. Mitochondrial metabolism significantly increased for D-alpha-ketoglutaric acid from patients with lower good quality 8-cell embryos and utilization of
L-glutamine was found to be significantly higher in patients with a lower percentage
of blastocyst formation, when using a backward selected model looking only at 8cell embryos and blastocysts. Mitochondrial metabolic scores decreased as the
number of fertilized zygotes increased. This data indicates that the mitochondrial
metabolic score may be able to predict fertilization potential of a cohort of oocytes.
Focusing on the substrates which yielded differential metabolic function, one could
potentially analyze individual CC masses and then relate those results to individual
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oocytes and resulting embryos in future studies. Specialized assay plates could
be made with only the substrates of interest in the wells and optimized for fewer
cells than the current commercial assay used.
Proper meiotic spindle formation and function are essential for proper
oocyte fertilization and embryo development. Mitochondrial dysfunction has been
associated with reduced ATP generation and meiotic spindle abnormalities
(Sutton-McDowall et al., 2010) that may lead to compromised embryo
development including fertilization failure (Reynier et al., 2001), aneuploidy (Schon
et al., 2000), and abnormal cytokinesis and arrested development (Van Blerkom,
2004, Shoubridge and Wai, 2007, Ramalho-Santos et al., 2009). Reduction in
ATP content generated by mitochondria may be a symptom of how substrate
utilization is altered by the mitochondria, as seen in our research.
Finally, we wanted to investigate whether there was a relationship between
the mRNA levels with individual CCs observed in our first aim and the mRNAs of
the pooled GCs from the mitochondrial function assay experiments in our second
aim. Examining the subset of genes from the first study which included AREG,
CYP19A1, CYP11A1, HSD3B1, ING1, LHCGR, and PAPPA, lower HSD3B mRNA
levels approached significance (P < 0.10) as the mitochondrial metabolic score
decreased. A prior study demonstrated HSD3B1 mRNA levels increased between
pooled GCs from embryos that resulted in pregnancies compared to embryos that
failed to develop (Hamel et al., 2008). In our first mRNA biomarker study lower
CC HSD3B1 mRNA levels significantly increased the odds of an oocyte resulting
in a euploid embryo. Perhaps there is a link between HSD3B mRNA levels and
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mitochondrial function relating to euploid embryo development that needs to be
further evaluated.
We hypothesized mitochondrial substrate utilization may be altered based
on studies that had previously shown mtDNA content differed in oocytes based on
oocyte fertilization percentage (Santos et al., 2006, Reynier et al., 2001), mtDNA
content in normal compared to diminished ovarian reserve in oocytes (MayPanloup et al., 2005b), and mtDNA content in trophectoderm biopsies of high
quality embryos and embryos that formed pregnancies (Murakoshi et al., 2013,
Diez-Juan et al., 2015, de Los Santos et al., 2018, Fragouli et al., 2017, Fragouli
et al., 2015, Ravichandran et al., 2017). These prior studies did not look at CC
mtDNA content, however, CC mtDNA content and oocyte mtDNA content have
been shown to be positively correlated and increasing mtDNA content was
demonstrated to be associated with better embryo development (Boucret et al.,
2015, Ogino et al., 2016, Desquiret-Dumas et al., 2017). Specific mitochondrial
substrate utilization may also indicate oocytes within the optimal maturation
window.

Oocytes with proper mitochondrial function capable of leading to

pregnancy and live birth would be reflected in the metabolic utilization of the
substrate biomarkers.

In the same way we examined immature versus mature

oocyte CC mRNA levels in study 1, one could examine mitochondrial function the
same way. Cumulus cells from immature and mature oocytes could be collected
and pooled by maturity. The assays could be performed when there are enough
cells of each type to run a single replicate of the assay with a control in each assay

235

as a reference. The individual assays could then be combined and used to
compare the mature and immature mitochondrial function.
Our studies have added valuable knowledge to the search for non-invasive
biomarkers to help select the most viable embryos for uterine transfer. One could
imagine combining embryo morphology, PGT-A testing, mRNA levels of select
genes, and mitochondrial substrates to create a robust prediction model and
ranking system to select the best embryos for transfer.

Future studies will require

prospective analysis of the models described above to determine the specificity
and sensitivity of the biomarkers and the models and include larger samples sizes.
Ideally, the models will be able to yield a method of ranking embryos from the most
to least likely to lead to live birth. Examination of protein levels in CCs related to
the biomarkers of interest by flow cytometry, enzyme-linked immunosorbent
assay, or radioimmunoassay may be valuable to determine if protein content
corroborates with mRNA levels. Biomarker studies for embryo selection are far
from complete and further studies need to be conducted in order to reach the goal
of being able to select the most viable embryos.
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Figure 5.1. Example of an optimal maturation window in mice. The curve draws an oocyte maturation profile. Hours
0-9 represents immature oocytes, hrs 12-15 represent the optimal maturation window, and hrs 15-24 represent a postmature maturation oocyte. Mouse oocytes that fell within the optimal maturation window exhibited lower levels of AKT
serine/threonine kinase 1 (Akt1), BCL2-like 2 (Bcl2I2) and SHC adaptor protein 1 (Shc1) mRNAs (Artini et al., 2017).
Reprinted with permission.
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APPENDIX A
Human pregnancy or live birth candidate biomarkers
shown to have differential mRNA expression
_________________________________________________________________________________________________________________________________
Gene name
Symbol
Function
Study Population
Samples
Reference____________________

265

Down-regulated biomarkers
Estrogen receptor 1

ESR1

Transcription factor

4 CC, 4 preg pts
4 CC, 4 not preg pts

Pooled

Artini et al. 2017

Nuclear factor I B

NFIB

Transcription factor

5 CC, preg pts
5 CC, not preg pts

Individual

Assou et al. 2008

Docking protein 5

DOK5 *

Signal transduction

MGC, 16 & 28 preg pts
MGC, 16 & 69 not preg

Pooled

Fortin et al. 2019

DnaJ heat shock
protein family (Hsp40)
member C15

DNAJC15

Heat shock protein

101 CC, 58 pts,
multicenter

Individual

Iager et al. 2013

Microtubule associated
tumor suppressor 1

MTUS1

Tumor suppressor

Nucleoporin 133

NUP133

Nucleoporin

Rhomboid like 2

RHBDL2

Serine protease

APPENDIX A continued.
_________________________________________________________________________________________________________________________________
Gene name
Symbol
Function
Study Population
Samples
Reference____________________
Zinc finger protein 93
ZNF93
Zinc finger protein
Lysine demethylase 4A

KDM4A

Demethylase

31 CC, 31 MGC preg pts Pooled
53 CC, 51 MGC not preg

Krieg et al. 2018

Lysine demethylase 4B

KDM4B

Demethylase

Runt related
transcription factor 2

RUNX2

Transcription factor

5 CC each, 41 pts

Pooled

Papamentzelopoulou et al. 2012a

FOXO4

Transcription factor

4 CC, 4 preg pts
4 CC, 4 not preg pts

Pooled

Artini et al. 2017

Chromodomain helicase
DNA binding protein 9

CHD9

Chromatin remodeling

14 CC, 8 pts

Individual

Assidi et al., 2011

Proteasome 26S subunit,
non-ATPase 6

PSMD6

Proteasome subunit

Ubiquilin 1

UBQLN1

Ubiquilin

Dipeptidyl peptidase 8

DPP8

Peptidase

11 CC, 7 pts

Individual

Assidi et al., 2015

Proteasome 26S subunit,
non-ATPase 6

PSMD6

Proteasome subunit

Ubiquilin 1

UBQLN1

Ubiquilin

BCL2 like 11

BCL2L11

Apoptosis regulator

5 CC, preg
5 CC, not preg

Individual

Assou et al. 2008

Phosphoenolpyruvate
carboxykinase 1

PCK1

Gluconeogenic enzyme

Up-regulated biomarkers
Forkhead box O4
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Gene name
Symbol
Function
Study Population
Samples
Reference____________________
Pleckstrin homology like
PHLDA1
Apoptosis regulator
MGC, CC, 18 pts
Pooled
Hamel et al. 2010b
Domain family A member 1
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UDP-glucose
pyrophosphorylase 2

UGP2

Glucogenic enzyme

AT-rich interaction
domain 1B

ARID1B

Chromatin remodeling

COX20, cytochrome c
oxidase assembly factor

COX20

Electron transport chain

Fibroblast growth factor 12

FGF12

Growth factor

G protein-coupled receptor 137B

GPR137B

G protein-coupled receptor

Nuclear receptor subfamily 2
group F
member 6

NR2F6

Transcription factor

Solute carrier family 2
member 9

SLC2A9

Glucose transport

Zinc finger protein 132

ZNF132

Zinc finger protein

Bone morphogenetic
protein 15

BMP15

Paracrine signaling

101 CC, 58 pts,
multicenter

Individual

Iager et al. 2013

101 CC, 58 pts,
multicenter

Individual

Iager et al. 2013

2426 CC, 196 pts

Pooled

Li Y et al., 2014

Growth differentiation factor 9
GDF9
Paracrine signaling
_____________________________________________________________________________________________________________________________

* Two separate analyses were performed in the same study
CC = cumulus cells; MGC = mural granulosa cells; pts = patients; preg = pregnant

APPENDIX B
Human pregnancy or live birth candidate biomarkers
with conflicting differential mRNA expression by qRT-PCR *
_________________________________________________________________________________________________________________________________________________
Gene
Symbol
Function
mRNA expression
Study Population
Samples
Reference_______________
Activated leukocyte
ALCAM
Cell adhesion
Live birth = not preg/loss
270 CC, 25 pts
Individual
Ekart et al. 2013
cell adhesion
Preg > not preg
42 CC, 42 pts
Individual
Wathlet et al. 2011
molecule
BIRC5

Apoptosis
regulator

Preg = not preg
Preg > not preg
Preg = not preg

MGC, CC, 38 pts
MGC, 28 pts
CC, 29 pts

Pooled
Pooled
Pooled

Hamel et al. 2010a
Fujino et al.2008
Varras et al. 2012

Calmodulin 1

CALM1

Calcium binding

Preg > not preg
Preg > not preg
Preg = not preg

14 CC, 8 pts
11 CC, 7 pts
39 CC, 39 pts

Individual
Individual
Individual

Assidi et al. 2011
Assidi et al. 2015
Burnik et al. 2015a

Calcium/calmodulin
dependent
protein kinase
kinase ID

CAMK1D

Serine/threonine

Preg > not preg
Preg > not preg ns trend

99 CC, 33 ICSI pts
47 CC, 47 ICSI pts

Individual
Individual

Wathlet et al. 2012
Wathlet et al. 2013

Cell cycle control

Preg > not preg
Preg > not preg ns trend

30 MGC, CC, 18 pts ea
MGC, CC, 38 pts

Pooled
Pooled

Hamel et al. 2008
Hamel et al. 2010a

Inflammation

Preg < not preg
Preg = not preg

16 MGC, 16 pts ea
28 MGC preg pts
69 MGC not preg pts

Pooled
Pooled

Fortin et al. 2019
Fortin et al. 2019

268

Baculoviral IAP repeat
containing 5

Cell division cycle 42DC42

C-X-C motif ligand 2

CXCL2^

APPENDIX B continued.
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Gene
Symbol
Function
mRNA expression
Study Population
Samples
Reference_______________
Cytochrome P450
CYP19A1
Steroidogenic
Preg > not preg
30 MGC, CC, 18 pts ea
Pooled
Hamel et al. 2008
family 19
enzyme
Preg = not preg
MGC, CC, 38 pts
Pooled
Hamel et al. 2010a
subfamily A
member 1
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Ephrin B2

EFNB2

Ephrin

Preg < not preg
Preg > not Preg
Preg > not preg

43 CC, 43 pts
99 CC, 33 ICSI pts
47 CC, 47 ICSI pts

Individual
Individual
Individual

Burnik et al. 2015c
Wathlet et al. 2012
Wathlet et al. 2013

Ferredoxin 1

FDX1

Steroidogenic
enzyme

Preg > not preg
Preg = not preg

30 MGC, CC, 18 pts ea
MGC, CC, 38 pts

Pooled
Pooled

Hamel et al. 2008
Hamel et al. 2010a

Gremlin 1, DAN
family BMP
antagonist

GREM1

BMP antagonist

Live birth = not preg**
Predicts pregnancy
Preg > not preg

38 CC, 38 pts SET
108 CC, 8 ICSI pts
42 CC, 42 pts

Individual
Pooled
Individual

Gebhardt et al. 2011
Mckenzie et al. 2004
Wathlet et al. 201

Hyaluronan synthase 2

HAS2

Glycosyltransferase

Live birth = not preg/loss
Live birth = not preg
Predicts pregnancy

270 CC, 25 pts
38 CC, 38 pts SET
108 CC, 8 ICSI pts

Individual
Individual
Pooled

Ekart et al. 2013
Gebhardt et al. 2011
Mckenzie et al. 2004

H4 clustered histone 3

H4C3

Histone

Preg > not preg
Preg = not preg

14 CC, 8 pts
11 CC, 7 pts

Individual
Individual

Assidi et al., 2011
Assidi et al., 2015

Hydroxy-delta-5steroid
dehydrogenase,
3 beta-and steroid
delta-isomerase 1

HSD3B1

Steroidogenic
enzyme

Preg > not preg
Preg = not preg

30 MGC, CC, 18 pts ea
MGC, CC, 38 pts

Pooled
Pooled

Hamel et al. 2008
Hamel et al. 2010a

Inositol-trisphosphate
3-kinase A

ITPKA

Kinase

Preg = not preg
Preg > not preg
Preg > not Preg

39 CC, 41 pts
42 CC, 42 pts
99 CC, 33 ICSI pts

Individual
Individual
Individual

Burnik et al. 2015a
Wathlet et al. 2011
Wathlet et al. 2012
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Gene
Symbol
Function
mRNA expression
Study Population
Samples
Reference_______________
Luteinizing hormone/
LHCGR
G protein-coupled See note **
CC, 40 pts
Pooled
Papamentzelopoulou
choriogonadotropin receptor
receptor
et al. 2012b
Preg = not preg
MGC, CC, 111 pts
Pooled
Lee et al. 2016
Preg = not preg
30 MGC, CC, 18 pts ea
Pooled
Hamel et al. 2008
Neuropilin 1
receptor

NRP1

Growth factor

Preg > not preg
Preg > not preg
Live birth = not preg/loss
Preg = not preg

14 CC, 8 pts
11 CC, 7 pts
270 CC, 25 pts
MGC, CC, 38 pts

Individual
Individual
Individual
Pooled

Assidi et al. 2011
Assidi et al., 2015
Ekart et al. 2013
Hamel et al. 2010a

Neurotensin

NTS^

Neurotransmitter

Preg < not preg

Pooled

Fortin et al. 2019

Preg = not preg

28 MGC preg pts
69 MGC not preg pts
16 MGC, 16 pts ea

Pooled

Fortin et al. 2019

270

Phosphoglycerate
kinase 1

PGK1

Kinase

Preg = not preg
Preg > not preg

30 MGC, CC, 18 pts ea
MGC, CC, 38 pts

Pooled
Pooled

Hamel et al. 200
Hamel et al. 2010a

Prostaglandinendoperoxide
synthase 2

PTGS2

Prostaglandin
synthesis

Preg = not preg
Live birth > not preg
Predicts pregnancy
Preg > not preg

39 CC, 41 pts
38 CC, 38 pts SET
108 CC, 8 ICSI pts
42 CC, 42 pts

Individual
Individual
Pooled
Individual

Burnik et al. 2015a
Gebhardt et al. 2011
Mckenzie et al. 2004
Wathlet et al. 2011

Pentraxin 3

PTX3

Immune
response

Preg = not preg
Preg > not preg
Live birth > not preg
ns trend

90 CC, 45 pts
38 CC, 22 pts
38 CC, 38 pts SET

Individual
Individual
Individual

Cillo et al. 2007
Feuerstein et al. 2012
Gebhardt et al. 2011

Regulator of
G-protein signaling 2

RGS2

G protein
signaling

Preg = not preg
Preg > not preg
Preg = not preg
Preg > not preg

43 CC, 43 pts
38 CC, 22 pts
30 MGC, CC, 18 pts
MGC, CC, 38 pts

Individual
Individual
Pooled
Pooled

Burnik et al. 2015c
Feuerstein et al. 2012
Hamel et al. 2008
Hamel et al. 2010a

Syndecan 4

SDC4

Intracellular
signaling

Preg > not preg
Preg = not preg

42 CC, 42 pts
99 CC, 33 ICSI pts

Individual
Individual

Wathlet et al. 2011
Wathlet et al. 2012

Serpin family E
member 2

SERPINE2

Peptidase
inhibitor

Preg > not preg
Preg = not preg

30 MGC, CC, 18 pts
MGC, CC 38 pts

Pooled
Pooled

Hamel et al. 2008
Hamel et al. 2010a
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Gene
Symbol
Function
mRNA expression
Study Population
Samples
Reference_______________
Target of myb1
TOM1
Intracellular
Preg > not preg
14 CC, 8 pts
Individual
Assidi et al. 2011
membrane
trafficking
Preg = not preg
11 CC, 7 pts
Individual
Assidi et al. 2015
trafficking protein
Transient receptor
potential cation
channel subfamily
M member 7

TRPM7

Ion channel

Preg > not preg
Preg = not preg

42 CC, 42 pts
99 CC, 33 ICSI pts

Individual
Individual

Wathlet et al. 2011
Wathlet et al. 2012

Taurine up-regulated 1
(non-protein coding)

TUG1

Long noncoding RNA

Preg = not preg
Preg > not preg

14 CC, 8 pts
11 CC, 7 pts

Individual
Individual

Assidi et al. 2011
Assidi et al. 2015

Versican

VCAN

Cell adhesion
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Preg = not preg
43 CC, 43 pts
Individual
Burnik et al. 2015c
Live birth > not preg/loss
270 CC, 25 pts
Individual
Ekart et al. 2013
Live birth > not preg^^
38 CC, 38 pts SET
Individual
Gebhardt et al. 2011
Preg > not preg
42 CC, 42 pts
Individual
Wathlet et al. 2011
Preg = not preg
99 CC, 33 ICSI pts
Individual
Wathlet et al. 2012
_________________________________________________________________________________________________________________________________

* observed in two or more studies;
**Splice variants were present in greater quantities in pregnant vs not pregnant patients
^ Two separate analyses were performed in the same study
^^positive correlation with birth weight
CC = cumulus cells; MGC = mural granulosa cells; ICSI = intra-cytoplasmic sperm injection
SET = single embryo transfer; pts = patients; ea = each group; preg = pregnant, ns = not significant
Symbols: > greater than; = equivalent to, < less than

APPENDIX C
Human pregnancy or live birth candidate biomarkers
shown not to have differential mRNA expression by qRT-PCR
_________________________________________________________________________________________________________________________________________________
Genes
Symbol
Function
mRNA expression
Study Population
Samples
Reference_______________
Aryl hydrocarbon AHR
Transcription factor
Live birth = not preg
38 CC, 38 pts SET
Individual
Gebhardt et al. 2011
receptor
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Aldolase, fructose- ALDOA
bisphosphate A

Gluconeogenic
enzyme

Live birth = not preg

38 CC, 38 pts SET

Individual

Gebhardt et al. 2011

Aquaporin 1
(Colton blood
group)

AQP1

Passive H2O transport

Preg = not preg

MCG, CC, 111 pts

Pooled

Lee et al. 2016

Aquaporin 2

AQP2

Passive H2O transport

Preg = not preg

MCG, CC, 111 pts

Pooled

Lee et al. 2016

Aquaporin 3
AQP3
(Gill blood group)

Passive H2O transport

Preg = not preg

MCG, CC, 111 pts

Pooled

Lee et al. 2016

Aquaporin 4

AQP4

Passive H2O transport

Preg = not preg

MCG, CC, 111 pts

Pooled

Lee et al. 2016

Aquaporin 5

AQP5

Passive H2O transport

Preg = not preg

MCG, CC, 111 pts

Pooled

Lee et al. 2016

Aquaporin 6

AQP6

Passive H2O transport

Preg = not preg

MCG, CC, 111 pts

Pooled

Lee et al. 2016

Aquaporin 7

AQP7

Passive H2O transport

Preg = not preg

MCG, CC, 111 pts

Pooled

Lee et al. 2016

Aquaporin 9

AQP9

Passive H2O transport

Preg = not preg

MCG, CC, 111 pts

Pooled

Lee et al. 2016

APPENDIX C continued.
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Genes
Symbol
Function
mRNA expression
Study Population
Samples
Reference_______________
Aquaporin 11
AQP11
Passive H2O transport
Preg = not preg
MCG, CC, 111 pts
Pooled
Lee et al. 2016
Aquaporin 12A

AQP12A

Androgen receptor AR

Passive H2O transport

Preg = not preg

MCG, CC, 111 pts

Pooled

Lee et al. 2016

Preg = not preg

14 CC, 8 pts

Individual

Assidi et al., 2011

Preg = not preg

30 MGC, CC, 18 pts ea

Pooled

Hamel et al. 2008
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BTB domain and
CNC homolog 2

BACH2

Nuclear hormone
receptor
Transcription factor

Calmodulin 2

CALM2

Calcium binding

Preg = not preg

42 CC, 42 pts

Individual

Wathlet et al. 2011

Calumenin

CALU

Calcium binding

Preg = not preg

14 CC, 8 pts

Individual

Assidi et al., 2011

Chromogranin B

CHGB

Secretory protein

Preg = not preg

14 CC, 8 pts

Individual

Assidi et al., 2011

C-X-C motif
chemokine
ligand 8

CXCL8^

Inflammation

Preg = not preg

MGC, 16 & 28 preg pts
MGC, 16 & 69 not preg

Pooled

Fortin et al. 2019

Cytochrome P450 CYP11A1
family 11
subfamily A
member 1

Steroidogenic enzyme

Preg = not preg

99 CC, 33 ICSI pts

Individual

Wathlet et al. 2012

Dihydropyrimidinase
like 3

DPYSL3

Enzyme

Preg = not preg
Preg = not preg

30 MGC, CC, 18 pts ea
MGC, CC, 18 pts

Pooled
Pooled

Hamel et al. 2008
Hamel et al. 2010b

Early growth
response 1

EGR1

Transcription factor

Preg = not preg
Preg = not preg

30 MGC, CC, 18 pts ea
MGC, CC, 38 pts

Pooled
Pooled

Hamel et al. 2008
Hamel et al. 2010a

Epiregulin

EREG

EGF ligand

Preg = not preg
Preg = not preg

30 MGC, CC, 18 pts ea
MGC, CC, 18 pts

Pooled
Pooled

Hamel et al. 2008
Hamel et al. 2010b

G protein-coupled
receptor

Live birth = not preg/loss

270 CC, 25 pts

Individual

Ekart et al. 2013

Follicle stimulating FSHR
hormone receptor

APPENDIX C continued.
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Genes
Symbol
Function
mRNA expression
Study Population
Samples
Reference_______________
Forkhead box O1 FOXO1
Transcription factor
Preg = not preg
8 CC, 8 pts
Pooled
Artini et al. 2017
Forkhead box O3

FOXO3
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Transcription factor

Preg = not preg

8 CC, 8 pts

Pooled

Artini et al. 2017

GA binding protein GABPB1
transcription factor
beta subunit 1

Transcription factor

Preg = not preg

MGC, CC, 18 pts

Pooled

Hamel et al. 2010b

Glutathione
peroxidase 3

Glutathione
peroxidase

Preg = not preg

47 CC, 47 ICSI pts

Individual

Wathlet et al. 2013

GlutathioneGSR
disulfide reductase

Enzyme

Preg > not preg ns trend

47 CC, 47 ICSI pts

Individual

Wathlet et al. 2013

Glutathione
S-transferase
alpha 3

GSTA3

Glutathione
peroxidase

Preg = not preg

47 CC, 47 ICSI pts

Individual

Wathlet et al. 2013

Glutathione
S-transferase
alpha 4

GSTA4

Glutathione
peroxidase

Preg > not preg ns trend

47 CC, 47 ICSI pts

Individua l

Wathlet et al. 2013

Homeodomain
HIPK1
interacting protein
kinase 1

Serine/threonine
kinase

Preg = not preg

39 CC, 41 pts

Individual

Burnik et al. 2015a

Homer scaffolding HOMER1
protein 1

Scaffold protein

Preg = not preg

MGC, CC, 18 pts

Pooled

Hamel et al. 2010b

Interleukin 1 beta

Cytokine

Preg = not preg

MGC, 16 & 28 preg pts
MGC, 16 & 69 not preg

Pooled

Fortin et al. 2019

Signal transduction

Preg = not preg

30 MGC, CC, 18 pts ea

Pooled

Hamel et al. 2008

GPX3

IL1B^

Interleukin 6 signal IL6ST
transducer

APPENDIX C continued.
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Genes
Symbol
Function
mRNA expression
Study Population
Samples
Reference_______________
Inhibin beta A
INHBA
FSH secretion
Preg = not preg
30 MGC, CC, 18 pts ea
Pooled
Hamel et al. 2008
subunit
inhibitor
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Integral membrane ITM2A
protein 2A

Membrane protein

Preg = not preg

39 CC, 39 pts

Individual

Burnik et al. 2015a

Inositol 1,4,5trisphosphate
receptor type 1

IP3 receptor

Preg = not preg

47 CC, 47 ICSI pts

Individual

Wathlet et al. 2013

KH RNA binding
KHDRBS3
domain containing,
signal transduction
associated 3

Signal transduction

Preg = not preg

39 CC, 39 pts

Individual

Burnik et al. 2015a

Keratin 6A

Filament protein

Preg = not preg

39 CC, 39 pts

Individua l

Burnik et al. 2015a

Lactate
LDHA
dehydrogenase A

Lactate
dehydrogenase

Live birth = not preg

38 CC, 38 pts SET

Individual

Gebhardt et al. 2011

LDL receptor
related protein 8

LRP8

Apolipoprotein E
and reelin receptor

Preg = not preg

MGC, CC, 18 pts

Pooled

Hamel et al. 2010b

Myristoylated
alanine rich
protein kinase C
substrate

MARCKS

Actin binding

Preg = not preg

MGC, CC, 18 pts

Pooled

Hamel et al. 2010b

Nudix hydrolase 10 NUDT10

Hydrolase

Preg = not preg

39 CC, 39 pts

Individual

Burnik et al. 2015a

Parathyroid
Hormone
like hormone

PTHLH

Hormone

Preg = not preg

99 CC, 33 ICSI pts

Individual

Wathlet et al. 2012

Phospho-,
fructokinase
platelet

PFKP*

Glycolytic enzyme

Live birth = not preg

38 CC, 38 pts SET

Individual

Gebhardt et al. 2011

ITPR1

KRT6A

APPENDIX C continued.
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Genes
Symbol
Function
mRNA expression
Study Population
Samples
Reference_______________
Progesterone
PGR
Nuclear hormone
Preg = not preg
MGC, CC, 18 pts
Pooled
Hamel et al. 2010b
receptor
receptor
Preg = not preg
47 CC, 47 ICSI pts
Individual
Wathlet et al. 2013
Live birth = not preg/loss
270 CC, 25 pts
Individual
Ekart et al. 2013
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Pirin

PIR

Iron-binding protein

Preg = not preg

MGC, CC, 18 pts

Pooled

Hamel et al. 2010b

Pyruvate kinase,
muscle

PKM

Glycolytic enzyme

Live birth = not preg

38 CC, 38 pts SET

Individual

Gebhardt et al. 2011

Protein kinase N2

PKN2

Serine/Threonine
kinase

Preg = not preg

14 CC, 8 pts

Individual

Assidi et al., 2011

Prothymosin alpha PTMA^

Immune response

Preg = not preg

MGC, 16 & 28 preg pts
MGC, 16 & 69 not preg

Pooled

Fortin et al. 2019

Regulator of
G-protein
signaling 3

RGS3

G protein signaling

Preg > not preg ns trend

MGC, CC, 38 pts

Pooled

Hamel et al. 2010a

Ribosomal
protein L9

RPL9

Ribosomal protein

Preg = not preg

14 CC, 8 pts

Individual

Assidi et al., 2011

Scavenger
receptor class
B member 1

SCARB1

Lipoprotein receptor

Preg = not preg

30 MGC, CC, 18 pts ea

Pooled

Hamel et al. 2008

Semaphorin 3A
SEMA3A
membrane protein

Secretion

Preg = not preg

MGC, CC, 18 pts

Pooled

Hamel et al. 2010b

Serpin family A
member 3

SERPINA3

Peptidase inhibitor

Preg = not preg
Preg = not preg

30 MGC, CC, 18 pts ea
MGC and CC

Pooled
Pooled

Hamel et al. 2008
Hamel et al. 2010a

Secreted frizzled
related protein 1

SFRP1

Wnt signaling

Preg = not preg

MGC, CC, 18 pts

Pooled

Hamel et al. 2010b

Secreted frizzled
related protein 2

SFRP2

Wnt signaling

Preg = not preg

270 CC from 25 pts

Individual

Ekart et al. 2013
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Genes
Symbol
Function
mRNA expression
Study Population
Samples
Reference_______________
Solute carrier
SLC2A1
Glucose transport
Preg = not preg
47 CC, 47 ICSI pts
Individual
Wathlet et al. 2013
family 2 member 1
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Solute carrier
SLC2A4
family 2 member 4

Glucose transport

Preg = not preg

270 CC, 25 pts

Individual

Ekart et al. 2013

SPHK1 interactor, SPHKAP
AKAP domain
containing

PKA signaling

Preg = not preg

14 CC, 8 pts

Individual

Assidi et al., 2011

Sprouty RTK
Signaling
antagonist 2

SPRY2

Kinase inhibitor

Preg = not preg

MGC, CC, 18 pts ea

Pooled

Hamel et al. 2008

SplA/ryanodine
receptor domain
and SOCS box
containing 2

SPSB2**

Signal transduction

Preg > not preg ns trend

38 CC, 22 pts

Individual

Fragouli et al., 2012

Steroidogenic
STARD1
Acute Regulatory
Protein

Steroidogenesis

Preg = not preg

MCG, CC, 111 pts

Pooled

Lee et al. 2016

Stanniocalcin 1

STC1

Hormone

Stanniocalcin 2

STC2

Hormone

Preg = not preg
Preg = not preg
Preg = not preg

99 CC, 33 ICSI pts
47 CC, 47 ICSI pts
99 CC, 33 ICSI pts

Individual
Individual
Individual

Wathlet et al. 2012
Wathlet et al. 2013
Wathlet et al. 2012

Steroid sulfatase
(microsomal),
isozyme S

STS

Sulfatase

Live birth = not preg

38 CC, 38 pts SET

Individual

Gebhardt et al. 2011

Synaptotagmin 11 SYT11

Protein trafficking

Preg = not preg

14 CC, 8 pts

Individual

Assidi et al., 2011

T-box 6

Transcription factor

Preg = not preg

39 CC, 41 pts

Individual

Burnik et al. 2015a

TBX6
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Genes
Symbol
Function
mRNA expression
Study Population
Samples
Reference_______________
Transforming
TGFB1
Growth factor
Preg = not preg
47 CC, 47 ICSI pts
Individual
Wathlet et al. 2013
growth factor
beta 1
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Thrombospondin 1 THBS1

Adhesion protein

Preg = not preg

47CC, 47 ICSI pts

Individual

Wathlet et al. 2013

THO complex 2

THOC2

Transcription factor

Preg = not preg

14 CC, 8 pts

Individual

Assidi et al., 2011

Transmembrane
protein 64

TMEM64

Calcium signaling

Preg = not preg

39 CC, 41 pts

Individual

Burnik et al. 2015a

TNF alpha
TNFAIP6
induced protein 6

Hyaluronin binding

Tumor protein p53 TP53I3**
inducible protein 3

Dehydrogenase

Live birth = not preg
Preg = not preg
Preg = not preg
Preg = not preg

38 CC, 38 pts SET
MGC, CC, 18 pts ea
108 CC, 8 ICSI pts
38 CC, 22 pts

Individual
Pooled
Pooled
Individual

Gebhardt et al. 2011
Hamel et al. 2008
Mckenzie et al. 2004
Fragouli et al., 2012

UDP-glucose
Pyrophosphorylase 2

UGP2

Glycogenic enzyme

Preg > not preg

MGC, CC, 18 pts

Pooled

Hamel et al. 2010b

Tryptophan rich
basic protein

WRB

Nuclear protein

Preg = not preg

39 CC, 39 pts

Individual

Burnik et al. 2015a

Signal transduction

Preg = not preg

MGC, CC, 18 pts

Pooled

Hamel et al. 010b

Tyrosine 3YWHAZ
monooxygenase/
tryptophan 5monooxygenase
activation protein zeta

____________________________________________________________________________________________________________________

*positive correlation with birth weight; ** overexpressed in chromosomally normal oocytes
^ Two separate analyses were performed in the same study
CC = cumulus cells; MGC = mural granulosa cells; ICSI = intra-cytoplasmic sperm injection
SET = single embryo transfer; pts = patients; ea = each group; preg = pregnant, ns = not significant
Symbols: > greater than; = equivalent to, < less than
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